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ABSTRACT
Intracellular signalling pathways activated by FcyRI
The high affinity receptor for immunoglobulin G, FcyRI,, plays a central role in 
host immune defence by linking the cellular and humoral arms of the immune 
system. However, the signalling pathways initiated by this receptor are poorly 
understood. In this thesis, the intracellular signalling pathw ays activated by 
im m une complexes were studied using U937 cells as a m odel system  to 
investigate the effect of differentiation on these pathways. Previous work has 
show n that, the nature and duration of the calcium transients initiated by 
immune complexes in these cells changes, as the cells differentiate into cells of a 
m ore m acrophage phenotype. This thesis describes the signalling pathw ays 
underlying this change .
M arked differentiation dependent differences in the signalling pathw ays 
activated by immune complexes were found. Thus, in cells differentiated to a 
more macrophage phenotype with dbcAMP, Fc receptor aggregation resulted in
the activation of PLC. In cells primed with IFN-y, no activation of PLC could be 
detected. In contrast, immune complexes in these cells resulted in the activation 
ofPLD.
The switch in the activation of intracellular signalling pathways was found to
result from a switch in the use of accessory molecules by FcyRI. Thus, in IFN-y
prim ed cells, FcyRI signals through the recruitment of the y chain whereas in
dbcAMP differentiated cells FcyRI appears to recruit FcyRIIa.
A novel signalling pathway responsible for calcium transients and trafficking of 
im m une complexes to lysosomes was identified. This pathw ay involved the 
sequential activation of PLD and sphingosine kinase w ith the generation of 
sphingosine-l-phosphate.
In these cytokine primed cells, immune complexes also resulted in the activation 
of PI3-kinase. However, an unusual pattern of PIP3 production was observed. 
Both forms of Class I PI3-kinase were activated. Thus, the initial peak in PIP3 
resulted from the activation of the tyrosine kinase (p85) dependent form of PI3- 
kinase, whereas the latter, prolonged elevation of PIP3  ^ resulted from the
activation of the py dependent form of PI3-kinase.
The switch in signalling pathway appears to dictate the isoform of PKC activated
by FcyRI. Thus, in cytokine primed cells where PLD is activated and the resultant 
calcium transients are brief, only calcium independent isoforms were activated. 
In dbcAMP differentiated cells, where PLC activation results in prolonged 
calcium signals, only the calcium dependent PKC isoforms were activated.
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Fc RECEPTORS; a case for study.
Perhaps the most im portant function of the immune system in host defence 
is the coordination and in terp lay  betw een hum oral and cell-m ediated 
im m une responses. Some of the proteins that are essential for this feedback 
of responses are the receptors for the Fc dom ain of im m unoglobulins (FcRs). 
These proteins were initially discovered over 30 years ago and were known to 
be w idely distributed on cells of the immune system. However, it is only in 
the last few years that the structure of these proteins and the genes that 
encode them have been elucidated, facilitating their study, and giving birth to 
a great am ount of information.
1.1.1 Classes of Fc receptors
There are five isotypes of immunoglobulins (Igs) in mammals: IgA, IgD, IgE, 
IgG and IgM. There are particular Fc receptors which are usually specific for 
only one or two of the Ig isotypes. One class of Fc receptors transports 
im m unoglobulins across epithelial tissues to their m ain site of action. This 
class includes the neonatal Fc receptor (FcRn) (Mostov & Simister 1985), 
w h ich  tra n sp o rts  im m u n o g lo b u lin  G (IgG), and  th e  po lym eric  
im m unog lobu lin  recep tor (pIgR) w hich recognises d im eric IgA and  
pentameric IgM (Brandtzaeg 1981, reviewed in Mostov 1994). Another class of 
receptors are the lectin-like m olecules that bind to IgE (Conrad 1990). 
H ow ever, the largest and best characterised group are the receptors that 
belong to the im m unoglobulin gene superfamily: these receptors are type I 
glycoproteins present on the surface of effector cells. This group includes
receptors specific for IgG (FcyR), for IgE (FceR), and IgA (FcaR) (Maliszewki 
1990). Furtherm ore Fc receptors specific for IgM (FcpR) (Ohno et al 1990) and 
IgD (FcôR) (Sjoberg 1980) have been found.
The focus of this thesis is the study of the type I glycoprotein receptors present 
on the surface of effector cells that bind the Fc region of IgG (FcyRs).
1.1.2 Different IgG Fc receptors (FcyRs).
Three clones of FcyRs w ere defined by affinity, tissue d istribu tion  and 
m onoclonal antibody recognition. This revealed the existence of three 
distinct, bu t closely related, FcyR classes: FcyRI(CD64), FcyRII (CD32) and 
FcyRIII (CD16). Molecular cloning of the genes encoding these proteins have 
revealed that each subclass contains a variety of isoforms. Thus in m an there 
are three genes for FcyRI, three genes for FcyRII and two genes for FcyRIII 
(reviewed in H ulett & H ogarth 1994, Ravetch & Kinet 1991). All these 
receptors are m em brane glycoproteins com posed of a ligand-binding a  
subunit, com prising highly conserved extracellular Ig-like dom ains, w ith  
iden tity  ranging  from  70%-98%; a po lypeptide or lip id  anchor in the 
m em brane; and a cytosolic dom ain that is not very conserved betw een 
receptors. (Figure 1) (reviewed in Ravetch & Kinet 1991, Burton and Woof 
1992, Hulett & Hogarth 1994).
1.1.3 FcyR; the a subunits
The a  subunits of several FcyRs are found in m ultiple forms (Ravetch et al 
1986, Stuart et al 1989, Qiu et al 1990, Ersnt et al 1992; reviewed in Ravetch & 
Kinet 1991, Friedm ann et al 1992, H ulett & Hogarth 1994). In hum ans, three 
FcyRI, three FcyRII, and two FcyRIII genes have been identified (reviewed in 
Ravetch 1994, Hulett & Hogarth 1994).
1.1.4 Structure of the FcyRs ligand-binding subunit
The Ig-binding subunit of FcyRs are generally thought of as being monomeric 
based on analogy to similar Ig superfamily structures including CD4, CD2, and 
VCAM-1 (Ryu et al 1990, W ang et al 1990, Jones et al 1992 & 1995 ). In 
agreem ent w ith this, it has been show n that FcyRI binds only a single IgG 
m olecule (O 'G rady  et al 1986), a lthough  this does not conclusively 
dem onstrate that it is a monomer.
1.1.5 Proteins required for FcyR assembly and signalling (the y and Ç chains)
The ligand-binding subunits of some FcyRs are associated in the m em brane 
w ith other proteins which are required for receptor signalling. The a  chain of 
FcyRI associates w ith an integral membrane protein called the y chain (Ra et al 
1989, Ernst et al 1993, Scholl & Geha 1993). The y chain is homologous to the Ç 
chain, a pro tein  originally identified as essential for the assem bly and 
signalling of the T-cell receptor-CD3 complex (Weissman et al 1989). Both y 
and Ç chains associate w ith FcyRIII, and expression of the y chain is essential 
to support surface expression of FcyRIII. (Figure 1) (Hibbs et al 1989, Lanier et 
al 1989, Orloff et al 1990).
Figure 1
Fey receptors and the signalling 
moiecules with which they interact
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FcyR la; Ib2; lla1; Ilb1; llb2; llb3; lie; and Ilia are transmembrane 
proteins, whereas FcyR slb1; sic; Ila2 are soluble proteins and 
FcyRI I lb is a GPI-anchored protein.
FcyR I a and Ilia receptors do not contain an ITAM and therefore 
associates with the signalling molecules y and/or Ç chains in order 
to signal.
FcyRllal contains an ITAM of its own, and the FcyR I lb proteins 
contain an inhibitory motif (ITIM).
* denotes Tyr residues within the ITAMs
• denotes Tyr residues within the ITIMs.
1.1.6 ITAMs
The cytoplasm ic dom ains of y and Ç chains share a com m on tyrosine- 
containing sequence m otif called the im m uno-receptor tyrosine activatory 
motif (ITAM) (Cambier 1995), previously variously known as ARAM (Reth 
1989, Weiss & Littman 1994), TAM (Samelson & Klausne 1992), or the ARHl 
motif (Cambier 1992).
The motif consists of six conserved amino acid residues spaced precisely over 
an -26-amino acid sequence (D/EX7 D/EX 2 YX2 LX7YX2 L). This is the case with 
the y chain, and the Ç chain. However, there is one small variation in this 
motif and it is the ITAM for FcyRIIa, which has 12 instead of 7 amino acid 
residues between the YX2 E -  YX2L in the motif (D/EX7D/EX 2 YX2 LX12YX2L).
1.1.7 Signals generated by FcyRs: a receptor activation model
Cross-linking of FcyRs on cells such as macrophages, neutrophils, and NK 
cells results in the transduction of signals leading to: the activation of tyrosine 
kinases; elevation of intracellular calcium; release of inflammatory m ediators 
such as leukotrienes, prostaglandins, and hydrolases; and the transcription of 
genes encoding cytokines (van de Winkel & Capel 1993, Edberg et al 1995, Deo 
et al 1997). These cellular responses are similar to those observed w hen the 
antigen receptors of T cells or B cells are cross-linked. This sim ilarity is 
thought to be due to the homology of the signalling motifs in the cytoplasmic 
dom ain of all these receptors. These motifs are collectively know n as the 
Im m unoreceptor Tyrosine-Based A ctivation Motif (ITAM). The general 
scheme that has been deduced for TCR and BCR signalling turns out to be the 
same for FcR signalling as well (Cambier 1995, Johnson et al 1995, Agarwal et 
al 1993). In the model proposed by Cambier (1995), the ITAM associates w ith 
an inactive tyrosine kinase of the src family: cross-linking of the extracellular 
dom ain  of the receptor resu lts in the activation of the kinase and
p h o spho ry la tion  of two critical tyrosines found in the ITAM. The 
phosphorylated ITAM is then able to interact w ith another class of tyrosine 
kinases, such as syk, (zap-70 in TCR), through SH2 interactions w ith the 
ITAM. The complex thus form ed goes on to phosphorylate intracellular 
substrates, like phospholipase C-yl and Phosphatiydylinositol 3-kinase, and 
initiate effector functions and the subsequent biological responses triggered by 
the cells. (Figure 2 ).
Figure 2 Model for Fo-receptor activation
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1.1.8 Biological responses triggered by FcyRs
Effector responses m ediated by FcyRs include phagocytosis, endocytosis, 
antibody-dependent cell-m ediated cytotoxicity (ADCC), and the release of 
inflam m atory m ediators, (Reviwed in Unkeless et al 1988, van de Winkel & 
Anderson 1991).
1.1.8.1 Phagocytosis
Phagocytosis is the ability to internalise large particules 1 pm  or greater in 
diam eter (Silverstein et al 1977). Uptake is triggered by binding of opsonised 
particles to cell surface receptors capable of transducing a phagocytic stimulus 
to the cytoplasm. This stim ulus results in the localised polym erisation of 
actin at the site of particle attachm ent and subsequent pseudopod extension 
that engulfs the bound particle into a cytoplasmic phagosome (Greenberg et al 
1990, 1991, Allen 1996). In macrophages, the forming pseudopods are directed 
by sequential ligand-receptor interactions, which yield a vacuole custom -fit to 
the internalised particle (Silvertein et al 1977). The phagosom es are able to 
fuse w ith endosomes a n d /o r  lysosomes exposing their contents to lower pH  
and hydrolytic enzymes (Rabinowitz et al 1992, Desjardins et al 1994, Allen 
1996). The degraded product can then be processed and presented on the cell 
surface as degraded product-derived peptides, via class II MHC molecules, to 
antigen-specific T lymphocytes (Harding & Geuze 1992, Pfeifer et al 1993).
1.1.8.2 Endocytosis
Endocytosis is the process of internalising small particles (<0.2 \im  in 
diam eter), such as, im m une complexes (antigen-antibody). Most receptor- 
ligand complexes accumulate at clathrin-coated pits of the plasm a m embrane, 
which bud off to yield clathrin-coated vesicles. The vesicles rapidly lose their 
coats, which facilitates fusion with early endosomes (EEs); a dynamic array of
tubules and vesicles distributed throughout the peripheral and perinuclear 
cytoplasm. Due to a slightly acidic pH  (pH~6.0-6.8) m aintained by an ATP- 
driven  p ro ton  pum p (M ellm an et al 1986, Forgac 1992), EEs host the 
dissociation of m any ligand-receptor complexes. Free receptors selectively 
accum ulate in the early endosom e's tubular extensions, w hich bud  off to 
yield recycling vesicles (RVs) that transport receptors directly or indirectly 
back to the plasm a membrane. Dissociated ligands collect in the vesicular 
portions of the EEs because of their high internal volum e relative to the 
endosom e's tubular extensions. The vesicular structures pinch of or are left 
behind following the budding of RVs traverse to the perinuclear cytoplasm 
on m icrotubule tracks, and fuse w ith late endosomes (EEs) and lysosomes. 
H ere, ligands are degraded by an even lower pH  (pH -5) and the high 
concentration of lysosomal enzymes. Endocytosis is thought of as having two 
different functionally and physically distinct com partam ents (Kornfeld & 
M ellm an 1989, M ellman 1996). Early endosom es are responsible for the 
dissociation and sorting of receptors and ligands in an environm ent that 
m inim izes the risk of dam aging receptors intended for réutilisation. Late 
endosom es and lysosomes are responsible for accum ulating and digesting 
exogenous and endogenous macromolecules (Mellman 1996, Robinson et al 
1996).
1.1.8.3 ADCC
A ntibody-dependent cell-m ediated cytotoxicity (ADCC). FcyRs present on 
cells such as natural killer cells m ediate interactions w ith antibody-coated 
target cells, resulting in the destruction of target cells via NK cells in the 
process known as ADCC (van de Winkel & Anderson 1991)
1.1.9 FcyRI expression and genes
FcyRI is expressed on the surfaces of monocytes, m acrophages and IFN-y 
stim ulated neutrophils (van de Winkel & Anderson 1991, Hullet & H ogarth
1994). Three hum an FcyRI genes have been identified, liFcyRIA, hFcyRIB, 
hFcyRIC (that generate four isoforms; see Figure 1), and m apped to the 
chromosome lq21.1. hFcyRIA encodes a transmembrane receptor w ith three 
Ig-like domains; hFcyRIB and hFcyRIC encode soluble receptors w ith three Ig- 
like dom ains (Figure 1). Alternative splicing of one of the soluble receptor 
genes results in an mRNA for a transm em brane receptor w ith two Ig-like 
domains (Ernst et al 1992).
1.1.9.1 FcyRI; the only FcyR that binds monomeric IgG
This receptor binds m onom eric IgG w ith  high affinity; w ith K a  v a lu e s  
ranging from 2 x 10^ M~^ (for the b inding  of hum an IgG l to hum an 
monocyte-like U937 cells expressing endogenous FcyRI; Shopes et al 1990) to 5 
X 10^ M ”1 (for the binding of hum an IgG l to COS cells transfected w ith 
hum an FcyRI; Allen & Seed 1989). The unique role of FcyRI com pared w ith 
the low-affinity receptors FcyRII and FcyRIII may lie in the capability of FcyRI 
to trigger effector responses at low IgG concentrations, which are typical of 
early im m une responses in vivo (Shen et al 1987). The a  chain of FcyRI 
consists of three extracellular Ig-like domains, a transmembrane region, and a 
cytoplasmic domain (Allen & Seed 1989, Sears et al 1990, Ernst et al 1992). The 
a  chain associates on cell surfaces w ith a y hom odim er p ro tein  (y chain ) 
(Scholl & Geha 1993, Ernst et al 1993). (Figure 1).
1.1.9.2 FcyRI interacts better with IgG because of an extra Ig-like domain
FcyRI has three extracellular Ig-like domains, unlike FcyRII and FcyRIII (lower 
affinity receptors) which possess two domains. Domains 1 and 2 of FcyRI 
share greater sequence similarity w ith the two extracellular domains of FcyRII
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and FcyRIII than does dom ain 3, w hich suggests that the th ird  dom ain is 
responsible for some of the interactions which make FcyRI a high affinity 
receptor for IgG and the only one that binds monomeric IgG at physiological 
concentrations (Allen & Seed 1989). It has been shown that removal of the 
third dom ain of m urine FcyRI abolishes high-affinity b inding to m onomeric 
IgG, although domains 1 and 2  on their own retain a weak affinity for IgG. 
However, linking FcyRI third dom ain to domains 1 and 2 of FcyRII does not 
give high-affinity binding of monomeric IgG to this FcyRII chimera (Hulett et 
al 1991, Harrison & Allen 1988). This is telling us that there m ust be regions 
of FcyRI in addition to the third extracellular domain which are required for 
the high-affinity binding capacity of FcyRI. Use of receptor chimeras between 
FcyRI and FcyRII demonstrate that the second domain of FcyRI is essential for 
high binding binding (Harrison & Allen 1998)
1.1.9.3 Biological functions mediated by FcyRI
FcyRI mediates endocytosis and phagocytosis (Shen et al 1987, CL Anderson et 
al 1990, Davis et al 1995). A lthough FcyRI is capable of binding monomeric 
IgG w ith high affinity, the signals necessary for endocytosis and phagocytosis 
are generated only upon receptor cross-linking (Davis et al 1995). However, 
binding of FcyRI w ith monomeric IgG results in a transient internalisation of 
receptor-IgG complexes, in which the receptor-IgG complexes are rapid ly  
recycled back to the cell surface (Harrison et al 1994). Cross-linking FcyRI at 
the cell surface prom otes internalisation, the receptor-ligand complexes are 
then retained  in in tracellu lar endocytic com partm ents and trafficked to 
lysosom es for degradation (M ellman & Plutner 1984, H arrison et al 1994, 
N orm an et al 1998). Endocytosis of cross-linked FcyRI-im m une-com plexes 
could lead to the enhanced presentation of peptide antigens on class II MHC
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molecules, as described for FcyRIII-immune complex interactions (Amigorena 
et al 1992).
1.1.10 FcyRII expression and genes
FcyRII is widely distributed among cells of the immune system; it is found in 
monocytes, m acrophages, neutrophils, basophils, B cells, Langerhans cells, 
platelets, and endotelial cells (placenta) (van de W inkel & A nderson 1991, 
H ulett & H ogarth 1994). Three FcyRII genes have been identified: hFcyRIIA, 
hFcyRIIB, and hFcyRIIC, located on chromosome lq23-24 (Ravetch et al 1986, 
Brooks et al 1989, Stuart et al 1989, Qiu et al 1990), encoding m ultip le  
transcripts (Figure 1) that differ prim arily in their cytoplasmic tails (Ravetch 
& Kinet 1991) . The a  chains of hum an and m urine FcyRII contain two 
extracellular Ig-like domains connected to a transmembrane and cytoplasmic 
region (Figure 1) (Ravetch et al 1986, Brooks et al 1989, Stuart et al 1989).
1.1.10.1 FcyRII binds IgG with low affinity
FcyRII binds monomeric IgG with low affinity (estimated Ka < 1 x  10  ^M for 
hFcyRII b inding  to IgG; H ulett & H ogarth 1994). U nder physiological 
conditions, the low affinity of FcyRII for monomeric IgG ensures that this 
receptor interacts only w ith IgG that has been aggregated by binding to 
m ultivalent antigens.
1.1.10.2 Biological functions mediated by FcyRII
The FcyRII proteins are an example of how distinct biological responses can be 
elicited by differences in the cytoplasmic dom ains of receptors that have 
com m on extracellular ligand-binding dom ains. H um an FcyRII A p ro tein  
(FcyRIIa) contains an IT AM w ithin their cytoplasmic dom ain which allows 
these cells to m ediate conventional cellular activities (e.g. phagocytosis and
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endocytosis) upon receptor aggregation (van der Herik-Oudijk et al 1995, 
Ravetch 1994, van de W inkel & Capel 1993). However FcyRIIB pro tein  
(FcyRIIb) functions in vivo as an inhibitory receptor for both B and mast cells 
(Takai et al 1996). This FcyRII isoform that has inhibitory effects does not 
contain  an ITAM, instead  it contains an inhibitory  m otif w ith in  its 
cytoplasmic dom ain (ITIM) (Muta et al 1994, Daeron 1995, Takai et al 1996). 
Both in vitro and in vivo studies have shown that FcyRIIb acts as a negative 
regulator of imm une complex-triggered activation (Muta et al 1994, Daeron 
1995, Takai et al 1996).
1.1.11 FcyRIII expression and genes
FcyRIII is expressed on macrophages, neutrophils, mast cells, and is the only 
Fc receptor found on natural killer cells (van de W inkel & Anderson 1991, 
H ulett & H ogarth 1994). Two hum an FcyRIII genes have been identified; 
FcyRIII A and FcyRIIIB, m apped to chrom osome lq23-24. Both encode 
proteins that contain an extracellular portion of 180 amino acids with two Ig- 
like dom ains (Ravetch & Perussia 1989). The most significant difference 
betw een FcyRIII A and FcyRIIIB genes is that the FcyRIIIA gene encodes 
FcyRIIIa, a p ro tein  w ith  a po lypeptide  transm em brane region and a 
cytoplasmic dom ain of 25 amino acids, whereas the FcyRIIIB gene encodes 
FcyRIIIb, a protein that is anchored to the membrane by a glycophosphatidyl 
inositol linkage (Figure 1) (Ravetch & Perussia 1989).
1.1.11.1 Different cellular distribution of FcyRIII proteins
FcyRIIIa and FcyRIIIb have different cellular d istributions; FcyRIIIa is 
expressed on m acrophages, natural killer cells, and m ast cells, w hereas 
FcyRIIIb is expressed m ainly on neutrophils (van de W inkel & A nderson
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1991, Hulett & Hogarth 1994). FcyRIIIa a  chain associates w ith the y as well as 
Ç chains (Hibbs et al 1989, P. Anderson et al 1990).
The y and Ç chains protect the FcyRIII a  chain from degradation  in the 
endoplasmic reticulum, and the absence of associated y or Ç chains results in a 
reduction in cell surface expression of the transm em brane version of FcyRIII 
(Hibbs et al 1989, P. Anderson et al 1990).
1.1.11.2 Biological functions mediated by FcyRIII
FcyRIII m ediates ADCC: the in vivo role of FcyRIII in m ediated ADCC was 
exam ined by studying y-chain-deficient mice. N atural killer cells from y- 
chain-deficient mice cannot m ediate ADCC because of the absence of cell 
surface FcyRIII (Takai et al 1994). In addition to its role in ADCC, FcyRIII 
functions in endocytosis and phagocytosis (van de Winkel & Anderson 1991, 
Am igorena et al 1992b, Daeron et al 1994, Nagarajan et al 1995).
1.2 SIGNALING BY PROTEIN TYROSINE PHOSPHORYLATION
1 .2.1 Protein phosphorylation
Protein phosphorylation is a rapidly reversible reaction that represents a 
general mechanism for the regulation of intracellular events in response to 
environm ental changes (Hunter et al 1985, Cantley 1991, Sonfyang & Cantley
1995). The genes encoding a large num ber of serine/ threonine-specific, 
tyrosine-specific, or dual-specificity protein kinases have been cloned and 
compared (Hanks & H unter 1988, H unter 1995), and it is clear, on the basis of 
sequence conserva tion  at the cataly tic  dom ain , th a t bo th  p ro te in  
serine / threonine kinases and tyrosine kinases evolved from a com m on
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ancestor. They then diverged to recognise distinct sets of substrates in the cell, 
thereby regulating distinct cellular responses.
1.2.2 Protein-tyrosine kinases
Protein tyrosine kinases are involved in m any signal tranasduction systems 
such as cell proliferation and differentiation (Hunter & Cooper 1985, Ullrich 
& Schlessinger 1990, Cooper 1990). These kinases can be divided into 
receptor-type tyrosine kinases (RTK), and non-receptor-type protein tyrosine 
kinases (NRPTK). The latter is the type of kinases involved in signalling by 
im m une receptors.
1.2.3 Receptor tyrosine Kinases
RTK are cell surface proteins that are receptors for ligands, such as the 
receptors for m any growth factors; a classical example is the insulin receptor 
(Kahn & W hite 1998). Insulin  b ind ing  regulates cellular grow th and 
m etabolism  through the activation of the integral tyrosine kinase in the 13- 
subunit of the insulin receptor (Kahn & W hite 1998). Insulin-stim ulated 
recep tor au tophospho ry la tion  activates the kinase lead ing  to tyrosyl 
phosphorylation of endogenous substrates (such as PLC-y and PI3-kinase) 
w hich play a role in signal transduction cascades by generating second 
m essengers (Kasuga et al 1983, Rosen et al 1993, White et al 1985, W ilden et al 
1990, Backer et al 1992)
1.2.4 Non-recep tor protein tyrosine kinases (NRPTKs)
NRPTK are intracellular protein tyrosine kinases that fall into two classes, 
src-fam ily pro tein  tyrosine kinases (PTKs), and syk and zap-70  PTKs 
(Taniguchi et al 1991, Burkhardt et al 1991).
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1.2.4.1 src-like kinases
src-like kinases (src, lyn, fyn, yes, hck, blk, Ick, abl, crk and nek) are widely 
d istribu ted  am ong haem atopoetic cells w ith some degree of cell type 
specificity. These kinases possess one src-homology region 2 (SH2) dom ain, 
one SH3 dom ain and a catalytic dom ain (reviewed in Mustelin & Burn 1993). 
These kinases are anchored at the interface of the plasm a m em brane by 
m yristoylation of the N-terminal glycine residue (Bolen et al 1992).
1.2.4.2 SIC family kinases in immune-receptor signalling
src family kinases act as signal transducers in association w ith cell surface 
receptors that lack an intracellular catalytic dom ain (Cooper 1990, Semba & 
Toyoshima 1990). This concept was originally established by the observation 
that the src-like kinase Ick is physically and functionally associated w ith the T- 
cell surface antigens CD4 and CD8 , receptors for major histocom patibility 
complex molecules (Veillette et al 1989, Barber et al 1989, Abraham  et al 1991). 
Associations of the interleukin 2 receptor p chain and T-cell antigen receptor 
w ith the src-like kinases Ick and fyn respectively, have also been reported 
(Hatakeyama 1991, Samelson 1990, Cooke 1991).
1.2.4.3 syk and zap-70 kinases
syk kinase is expressed in B and monocytic cells (Hutcherof et al 1991) and its 
prim ary structure is highly homologous to zap-70 which is expressed in T and 
NK cells (Chan et al 1991, 1992). Unlike the src-like kinases, syk and zap-70 
bear two SH2 dom ains and a catalytic dom ain, bu t no m yristoylation site 
(Tanguchi et al 1991, Chan et al 1992).
1.2.4.4 syk and zap-70 kinases in immune-receptor signalling
16
These kinases act in signal transduction by binding, presumably, to the ITAM 
motif of receptor subunits. Based on the analysis of association between zap- 
70 and the Ç chain through TCR stim ulation (Chan et al 1991, 1992), it is 
hypothesised that zap-70 binds phosphorylated tyrosine residues of the Ç 
chain via SH2 dom ains once the Ç chain has been phosphorylated, w hich 
occurs through a src-like kinase, after receptor stim ulation (Weiss 1993). 
However, in the case of syk activation, some discrepancy has been found: in B 
cells the syk kinase has been reported to associate with the BCR complex even 
in the absence of ligand (Hutchcroft et al 1992).
1.2.5 Protein déphosphorylation (role of phosphatases)
As m entioned in section 1.2.1, protein phosphorylation is a rapidly reversible 
reaction  tha t rep resen ts a general m echanism  for the regu la tion  of 
intracellular events. The role of protein phosphorylation and of PTKs in 
generating signals has already been discussed. However, dephosphorylation 
is ano ther very im portan t regulatory  factor in in tracellu lar signalling. 
M em brane-bound phosphatases have been show n to play two distinct 
regulatory roles in FTK-dependent signalling by imm une receptors. It has 
been proposed that PTKs, loosely associated with non-aggregated receptors, 
are p reven ted  from  signalling  by the presence of m em brane-bound  
phosphatases (Beaven & M etzger 1993). However, in some system s the 
opposite seems to happen (M ustelin et al 1992), creating some degree of 
controversy.
1.2.5.1 Role of protein phosphatases in immune-receptor signalling
CD45, a m em brane-bound phosphatase, has been show n to inhibit FcyR 
signalling w hen co-aggregated (Rankin et al 1993). In contrast, CD45 has been 
show n to be essential for TCR activity (reviewed in M ustelin & Burn 1993).
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In isolated T cell membranes and in vivo, both Ick and fyn can be activated by 
CD45-m ediated dephosphorylation (M ustelin et al 1989, 1992). In addition, 
fyn and Ick activities were m arkedly reduced in both CD45-negative cells and 
in norm al T cells trea ted  w ith  the tyrosine phospha tase  inh ib ito r, 
phenylarsine oxide (Biffen et al 1994). It has been proposed that the catalytic 
activity of fyn and Ick is activated by dephosphorylation (through CD45) and 
inh ib ited  by phosphory la tion  (through the cytosolic PTK, p50cs/c) of a 
negative regu la to ry  tyrosine residue (M ustelin & Burn 1993). Thus, 
phosphatases appear to either inhibit or enhance the activity of different PTKs 
and may, therefore, play a critical role in m odulating the resultant PTK- 
dependent signalling pathways. However, the physiological role that CD45, 
or other phosphatases, m ay play in Fc-receptor signalling has yet to be 
elucidated.
1.3 LIPID SIGNALLING
In response to the activation of cell surface receptors, the levels of free lipids 
increase 1.4-2-fold above control levels (Nishizuka 1992 & 1995, H annun 1994, 
Kolesnick 1994). These quantities greatly underestim ate the increase in the 
signalling pools, which are generally considered to contain little or no second 
m essenger in the absence of stimulus. Unfortunately, conventional assays 
cannot distinguish between the structural and signalling pools of these lipids 
and m easure stim ulated elevations over the entire cell.
Signal generation is followed by signal amplification, an observation that 
helps to explain how small transient signals generated at the cell surface can 
induce a w ide range of biological responses. A consensus is emerging that 
recognises the interaction of lipid second m essengers and protein  kinase
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cascades. In this regard, m any lipid second messengers have the ability to 
cross bilayers and connect compartm ents that are norm ally separated under 
resting conditions.
The initial and most im portant step in the generation of lipid or lipid derived 
second messenger is the hydrolysis of phospholipids by a group of enzymes 
called phospholipases, and also by the phosphorylation of lipids by lipid 
kinases.
1.3.1 Phospholipases C
The phosphoinositide-specific phospholipases C (PLCs) are enzym es that 
specifically hydrolyse phosphatidylinositol 4-5-bisphosphate (PIP2) to generate 
the second messengers diacylglycerol (DAG) and inositol-1-4-5-trisphosphate 
(IP3) (Lee & Rhee 1995). (Figure 3).
1.3.1.1 Classes of PLCs
Three different groups of PLCs have been identified: (3; y and ô (Lee & Rhee 
1995). All three PLC isoforms are single polypeptides containing two regions 
of high homology, designated X and Y, preceded by a plekstrin homology (PH) 
dom ain. In addition, PLC-y has m ultip le src hom ology region 2 (SH2) 
domains and a single SH3 (Lee & Rhee 1995). (Figure 4).
1.3.1.2 Mechanisms for PLC activation
Two mechanisms have been described for PLC activation: PLC-|3 activation is 
m ediated via heterotrimeric G proteins, in G-protein-coupled receptors. PLC- 
(3 activation occurs via GTP-bound a  subunits of the Gq class or via |3y 
subunits. G qa interacts w ith a region distal to the Y domain whereas the (3y 
subunits bind to an am ino-term inal segment, perhaps via the PH dom ain 
(Lee & Rhee 1995). On the other hand, PLC-y binds to receptor tyrosine
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kinases or receptor-associated tyrosine kinases via SH2  dom ains and is 
activated by phosphorylation. (Figure 5).
1.3.1.3 Role of diacylglycerol (DAG) and inositol-l-4-5-trisphosphate (IP3) in 
signal transduction
Diacylglycerol (DAG) acts as a second messenger by activating a num ber of the 
serine/ threonine protein kinases (PKCs) (Nishizuka 1992 & 1995); w hereas 
inositol-l-4-5-trisphosphate (IP3) binds to an IP3 receptor (IP3R) to mobilise 
intracellular stored calcium and to prom ote an influx of external calcium, 
perhaps working in conjunction with IP4 (Irvine 1990, 1991). (Figure 5).
1.3.1.4 Role of phosphatidylinositol transfer protein in PLC signalling
A major finding, in the lipid signalling pathw ays, is the recognition of the 
role of phosphatylinositol transfer protein (PITP) in signalling through either 
PLC-P or PLC-y (Thomas et al 1993, Kauffmann-Zeh et al 1995). A lthough 
PITP transfers phosphatidylinositol (PI) and not the substrate of PLC, PIP2, 
PITP was found to be necessary for sustained PLC signalling in reconstitution 
assays using streptolysin O perm eabilised cells. Presum ably, PITP allows 
refilling of the pool of PIP2 by presenting PI to PI4-kinase. It has also been 
suggested that PITP potentiates phospholipase D (PLD) activity by increasing 
the cellular content of PIP2 , which is a putative PLD cofactor (Liskovitch & 
Cantley 1995).
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Figure 3
Phosphatidylinositol-bisphosphate (PIP2) is hydrolysed by a 
PIP2 -specific phospholipase C to generate two second messengers.
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The two second messengers generated are:
inositol trisphosphate (IPg)
(i) Inositol trisphosphate (IP3 ) -a water soluble product released 
into the cytosol to mobilise intracellular stores of calcium.
(ii) Diacylglycerol (DAG)-a membrane anchored lipid second 
messenger which activates protein kinase C (PKC).
21
Figure 4
Phospholipases C
1. Genes: several purified. 16 amino acid sequences deduced from 
cDNA (14 mammalian plus 2 drosophila). 10 genes.
2. 3 groups: p, y, 5 -  overal similarity is low exept for two regions i.e.
X = 170 aa (60% homology) and Y = 260 aa (40%).
5 p isoforms identified. 4 mammalian, pi 150 kDa.
2 mammalian y isoforms -  y1 145 kDa.
4 mammalian 5 isoforms -  61 85 kDa.
3. Structure: all PLCs have an amino terminal 300 aa region before X 
domain, p and ô only only 50-70 aa between X and Y. y = 400 aa region 
between X and Y which contains the SH2 and SH3 domains.
All mammalian isoforms have a pleckstrin homology (PH) domain.
PLC-P
PH
CH IK X .
PLC-y
PH S H 2 S H 2  SH3
Y
PLC-Ô
PH
-  X y T I-
22
Figure S
Schematic representation of receptor-protein tyrosine kinase (RPTK)/ 
receptor-associaed protein tyrosine kinase, and by G-protein coupled 
receptor induced phospholipase C ( PLC ) activation and signal 
transduction.
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1.3.2 Phospholipase D
Phospholipase D (PLD) catalyses the hydrolysis of phospholipids, usually 
phosphatidylcholine, to generate phosphatidic acid plus the head group. 
Phosphatidic acid may act directly as a signalling molecule (Moolenaar et al 
1986, Lambeth et al 1994) or can be further metabolized to form diacylglycerol 
by phosphatidic acid phosphohydrolise (Perry et al 1993, Liscovitch & Cantley 
1995, Exton 1994). (Figure 6 ).
1.3.2.1 Classes of PLDs
Two biochemically distinguishable PLD activities have been characterised; 
one is dependent upon small GTPase Arf and upon PIP2 (Brown et al 1995, 
Singer et al 1995), and another is stim ulated by oleate (Okamura & Yamashita 
1994). Recently, a gene required for meiosis in Saccaromyces cerevisia (Rose 
et al 1996) was isolated and show n to have sequence hom ology to a castor 
bean PLD (Wang & Zheng 1994). The first cloned m am m alian homologe of 
the p lant PLD, hum an PLDl (hPLDl), is regulated by PIP2 , ARF, RhoA, and 
PKC (Hamm ond et al 1997, 1995). A rat PLDl (rPLDl) has also recently been 
cloned and caracterised (Park et al 1997) and shows sim ilar properties to 
hPLD l. Two splice variants of PLDl have been identified (Ham m ond et al 
1997), bu t no significant differences in activity or in vitro regulation of the 
two forms have been observed. A second isoform of PLD, PLD2, was recently 
cloned from mouse (mPLD2) (Colley et al 1997) and rat (rPLD2) (Kodaki & 
Yamashita 1997). Both rodent PLD2s require PIP2 for activity and, unlike 
hPLD, are constituvely active in the absence of other activating factors w hen 
PIP2  is present. More recently a hum an PLD2 (hPLD2) has been cloned and 
partially characterised (Lopez et al 1998). Unenexpectedly, hPLD2 is activated 
not only by PIP2  but also by ARF-1. Although the m agnitude of the activation 
of hPLD2 by ARF is smaller than of hPLDl. (Figure 7).
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1.3.2.2 Mechanisms for PLD activation
It has been suggested that PLD activation can occur through the action of 
PTKs, PKCs, and small GTPases. (Figure 8 ).
However the mechanisms of activation of PLD by PTKs remains unclear since 
most of the information has been obtained w ith the use of PTKs inhibitors, 
and it is not known whether PTK activation results in direct phosphorylation 
of PLD or w hether phosphorylation of other interm ediate proteins regulate 
PLD activation (reviewed in Liscovitch & Chafifa-Caspi 1996, and Natarajan et 
al 1996). (Figure 8 ).
Regulation of phospholipase D by PKC has been shown to require ATP (Lopez 
et al 1995, Kiss et al 1991). Furthermore, in a study by Conrade et al (1994), 
regulation  of a PtdCho-specific PLD activity by PKC was exam ined in 
m em branes from Chinese ham ster lung fibroblasts by using the purified 
conven tiona l isoenzym es a, (3 and y, and the recom binant 6 , e and Ç 
isoenzymes. Both PKC a  and PKC (3 (in that order) enhanced, while other 
isoforms failed to modify PLD-mediated PtdCho hydrolysis. Interestingly, in 
these m em branes stim ulation of PLD activity by PMA did not require ATP. 
Collectively, These findings appear to indicate that regulation of PLD activity 
by PKC can occur by both  phosphory lating  and non-phosphory lating  
mechanisms. (Figure 8 ).
PLD is activated by v-src and depends upon a GTPase cascade containing Ras 
and Ral (Jaing et al 1995a & 1995b). Ral constitutively associates w ith PLD 
through Ral's novel amino term inus, but Ral does not activate PLD alone 
(Jiang et al 1995b). A lthough it is not known w hether Ral-associated PLD 
depends upon Arf, as the A rf-dependent PLD does, the Ral-associated PLD 
activity does depend upon PIP2 (Jiang et al 1995b). Evidence also implicates 
Rho in PLD activation (Bowman et al 1993, Malcolm et al 1994). This growing
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evidence suggests that PLD activation depends upon a complex interplay of 
m ultiple small GTPases. (Figure 8 ).
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Figure 6
PLD hydrolysis of phosphatidylcholine and 
the generation of lipid second messengers
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Phospholypase D (PLD) hydrolyses phosphatidylcholine (PtdCholine) 
to generate phosphatidic acid (PA). PA can be further hydrolyse to 
generate lysophophatidic acid (lysoPA) via a cytosolic phospholipase A 
(PLA 2); or via a phosphatidyl- phosphohydrolase (PPH) to generate 
diacylglycerol (DAG), this latter step can be reversed via a DAG kinase.
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Figure 7
Phospholipases D
1. Genes: very few purified. One plant; one yeast; and one human. 
However, GenBank blast searches with the human gene sequence identify 
as many as 13 related sequences in eight prokaryotes and eukaryotes 
organisms.
2. Three different genes: human PLD (hPLD); yeast PLD (Spo14); plant 
PLD {Ricinus PLD) -  overal similarity is low exept for four regions (I; II;
III; IV).
hPLD 124 kDa (membrane associated, dependent on PIF^, PC specific) 
Spo14 195 kDa (membrane associated, dependent on PIF^, PC specific) 
Ricinus PLD 92 kDa.
3. Structure: within the four similar regions (I; II; III; IV), homology 
between the yeast and human enzymes is higher than with cognate 
secuences of the plant PLD.
hPLDI 
(1071 aa)
Spo 14 
(1683 aa)
Ricinus PLD 
(811 aa) III IV
28
Figure 8
Schematic representation of receptor-protein tyrosine kinase (RPTK), 
receptor-associaed protein tyrosine kinase, and by G-protein coupled 
receptor induced phospholipase D ( PLD ) activation and signal 
transduction.
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associated PTK RPTK
G-protein 
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1.3.2.3 Second messergers derived from PLD activity 
Phosphatidic acid (PA)
Phosphatidic acid (PA) has been implicated as a lipid second messenger in the 
regulation of protein kinases, GTPase-activating proteins, PI kinases, adenylyl 
cyclase and other signalling molecules (Foster 1993), however, direct effects of 
PA have not been clearly established and many effects are probably m ediated 
by the PA metabolites, DAG and lysophosphatidic acid (LPA) (Nishizuka 1992, 
M oolenaar 1995).
PLD has also been im plicated in regulating m em brane trafficking and 
vesicular transport (Brown et al 1993, Cockroft et al 1994, Kahn et al 1993), in 
w hich processes acidic phospholipids m ay facilitate m em brane budd ing  
a n d /o r  fusion (Randazzo & Kahn 1994). (Figure 9).
Lysophosphatidic acid (LPA)
Recently, second m essenger function has been ascribed to LPA, w hich is 
released from activated cells, especially platelets, and elicits diverse biological 
responses in different systems including platelet aggregation, cell growth and 
neurite retraction (Moolenaar 1995, J a link et al 1994). LPA may also play a 
role in inflammatory and proliferative responses to injury (Moolenaar 1995). 
(Figure 9).
Mechanism for lysophosphatidic acid action
LPA binds to a 38-40 kDa receptor which couples, via distinct G proteins, to 
m ultiple independent effector pathways. The a  subunit of Gi directly inhibits 
adenylyl cyclase, w hereas the Py dim er is thought to activate Ras via an 
interm ediary protein tyrosine kinase. The LPA receptor, via a mechanism 
involving Gq and stim ulation of PLC, also activates Rho, resulting  in 
stim ulation of focal adhesion kinase and phosphorylation and reorganisation 
of cytoskeletal proteins (Flordijk et al 1994).
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Figure 9.
Some signalling properties of phosphatidic acid and 
lysophosphatidic acid.
Many ofthe effects of phosphatidic acid and 
lysophosphatidic acid are very similar.
Extracellular signals
(cAMP ) |  
PI3-k, P I4-K~| I
Rho, FAK 
Stress Fibres
LysoPA
)
Tyr K activity
Ras, Raf 
MAPK
Phosphatidic acid (PA) and its metabolite, lysophosphatidic acid 
(lysoPA), have potent mitogenic effects in several cell lines. They 
stimulate the respiratory burst in neutrophils; activate phospholipase 
C gamma (PLCy); phosphoinositide 4-kinase (PI4-k); phosphoinositide 
3-kinase (PI3-k); tyrosine kinases (Tyr K); the Ras-Raf-m itogen 
activated protein kinase (MAPK) pathway; focal adhesion kinase (FAK); 
arachidonic acid (AA) production; calcium mobilisation; phospholipase 
D (PLD) activation; and decrease cyclic AMP (cAMP).
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Diacylglycerol (DAG)
A great num ber of receptor-signalling systems induce an increase in the mass 
of diacylglycerols (collectively diacylglycerol, alkyl-acylglycerol and alkenyl- 
acylglycerol; DRG), in particular sn-l,2-diacylglycerol (DAG), the physiological 
activator of protein kinase C (PKC) (Divecha & Irvine 1995). DAG can be 
generated by the action of PLC-catalysed hydrolysis of phosphatidylinositol 
4,5-bisphosphate, this DAG generation has been show n to be rap id  bu t 
transient (W right et al 1988, Cook et al 1990). However, a more sustained 
phase of DAG generation has been associated w ith  an increase in the 
activation of PLD-catalysed phosphatidylcholine hydrolysis, producing PA 
w hich can be converted to DAG by the action of phosphatid ic  acid 
phosphohydrolase. It has also been proposed that DAG can also be generated 
through a PC-PLC pathw ay, although the evidence for stim ulation of this 
pa thw ay  in m am m alian cells rem ains m ostly c ircum stantial (Cook & 
Wakelam 1992, Exton 1994). It has recently been demonstrated that the DAG 
and PA derived from PLC activation is predom inantly polyunsaturated while 
the lipids generated by PLD activation are saturated or m onosaturated (Pettitt 
et al 1997).
DAG generated through PLD: mixed feelings about signalling
The role of DAG generated through PLD as a second messenger, and indeed 
in activating PKCs is still controversial. It has been dem onstrated that PA, 
generated by the activation of PLD, can stimulate rho-m ediated actin stress 
fibre form ation in porcine aortic endothelial (PAE) cells (Cross et al 1996). 
This would suggest that, while PLD activation clearly results in an increase in 
DAG, it is not certain that this lipid plays a signalling role. Rather, it may be 
that the initial product, PA, functions as a messenger and that it is converted 
to DAG to attenuate the signal.
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The in vitro  and in v ivo  experiences
In vitro studies have dem onstrated that essentially all DAG species can 
activate PKC, although the in vivo evidence for PKC activation by PLD- 
derived DAG remains mixed. It has been shown there is no activation of PKC 
in IIC9 fibroblasts w hen stim ulated w ith a concentration of thrombin, which 
did not activate inositol lipid hydrolysis but did activate PLD (Leach et al 
1991). More recently it has been show n that PLD-derived DAG does not 
appear to regulate PKC activity in stimulated PAE cells (Pettitt et al 1997). On 
the other hand, it has been found that PKCe is activated under the same 
conditions (Ha & Exton 1993).
1.3.3 Phosphoinositide 3-kinases and the generation of lip id  second  
messengers
Phosphoinositide 3-kinases (PI3-kinases) catalyse the phosphorylation  of 
inositol phospholipids at the 3-position of the inositol ring (W hitman et al 
1988). The phospho lip ids p roduced  by the actions of these enzym es; 
PtdIns(3)P , P td Ins(3 ,4 )P2 (PIP2) and PtdIns(3 ,4 ,5 )P3 (PIP3 ), act as second 
m essengers which are increasingly im plicated in regulating a num ber of 
cellular responses. For example, PI3-kinase activity has been im plicated as 
being involved in insulin-induced glucose transport (Okada et al 1994), 
p latelet-derived  grow th factor- and insulin-induced actin rearrangem ent 
(W ymann & Arcaro 1994, Kotani et al 1994) and in the regulation of neuronal 
survival (Dudek et al 1997).
1.3.3.1 Classes of PI3-kinases
There are three classes of PI3-kinases which are determ ined by their in vitro 
substrate specificities. Class I PI3-kinases phosphorylate Ptdlns, PtdIns(4)P and 
P td Ins(4 ,5 )P2 - This class of enzymes can be further subdivided into class lA
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and class IB. Class lA PI3-kinases consist of pllO  catalytic subunits that are 
regulated by the SH2/SH3-dom ain containing p85 family of adaptor proteins 
and consist of the isoforms p llO a , pHOp, and pllO ô (Hiles et al 1992, H u et al 
1993, Vanhaesebroeck et al 1997). The p85 family of adaptor proteins (p55a, 
p55 PIK, p85a, and p85P) (Otsu et al 1991, Pons et al 1995, Inukai et al 1996 ) 
facilitate PI3-kinase interactions w ith other proteins through their SH2 and 
SH3 domains. Class IB consists of p i  10% an enzyme which associates w ith a 
plO l adaptor protein and is stimulated by G-protein Py subunits (Stephens et 
al 1994, Stoyanov et al 1995, Stephens et al 1997, Tang & Downes 1997). Class 
II PI3-kinases phosphorylate P tdlns and PtdIns(4)P but not P tdIns(4 ,5 )P2 
(M acD ougall et al 1996, Molz et at 1996) and class III PI3-kinases have a 
substrate specificity restricted to Ptdlns and are homologous to yeast Vps34p 
(vacuolar protein sorting defective) which is involved in the trafficking of 
proteins from the Golgi to the yeast vacuole (Hernan et al 1991, Stack & Emr 
1995, Volinia et al 1995).
Class lA  and IB are differentially activated
Previous studies have show n that receptors that are coupled to tyrosine 
kinases, such as insulin, exclusively activate class lA PI3-kinases through the 
p85 adaptor molecule (Hiles et al 1992, H u et al 1993, Vanhaesebroeck et al 
1997). In contrast, receptors that engage heterotrimeric G proteins, such as 
ATP, exclusively activate class IB PIB-kinases through the generation of py 
subunits (Stephens et al 1994, Stoyanov et al 1995, Stephens et al 1997, Tang & 
Downes 1997). No crosstalk between the coupling of these two receptor to PI3- 
kinases has been shown.
1.3.4 Sphingolipid-derived second messengers
H y d ro ly s is  of sp h in g o m y elin , ca ta ly sed  by sp h in g o m y elin ase , a 
sphingom yelin-specific  PLC, yields ceram ide and phosphory lcho line .
34
Cleavage of the amide-linked fatty acid from ceramide to form sphingosine is 
catalysed by ceramidases. Sphingosine can be m etabolised further, via a 
p a th w ay  involv ing  sphingosine kinase catalysed phospho ry la tion , to 
sphingosine 1-phosphate (SPP), and SPP can be cleaved to ethanolam ine 
phosphate  and trflns-2 -hexadecanal by a specific lyase located in the 
endoplasmic reticulum (reviewed in Spigel et al 1996). (Figure 10).
1.3.4.1 Ceramide as a second messenger
A num ber of direct targets for ceram ide action have now  been identified; 
including a ceram ide-activated pro tein  kinase (CAPK) (Liu et al 1994), a 
ceramide-activated protein phosphatase (CAPP) (Dobrowsky & H annun 1992), 
the putative guanine-nucleotide exchange factor Vav (Gulbins et al 1994) and 
the Ç isoform of protein kinase C (Lozano et al 1994, Muller et al 1995).
The best known ceramide second messenger function is derived from studies 
on TNFa induced inflamm ation and apoptosis. Ceramide appears to be a 
prim ary m ediator of both the inflamm atory and the apoptotic responses to 
TN Fa.
Ceramide and inflammation
W ith respect to the inflam m atory response, ceramide stim ulates CAPK to 
phosphorylate  Raf 1, enhancing Raf 1 activity. This initiates signalling 
th rough  the MAPK cascade (Yao et al 1995), and results in activation of 
cytosolic phospholipase A2 and release of arachidonic acid.
Ceramide and apoptosis
W ith regards to apoptosis, TNFa induces rapid hydrolysis of sphingom yelin 
to ceramide in all cells in which it initiates apoptosis. Ceramide also signals 
Fas-m ediated apoptosis (Cifone et al 1993, Gulbins et al 1995). Ceram ide- 
m ediated apoptosis extends beyond apoptosis induced by cytokine receptors: 
ionising rad ia tion  appears to directly  target m em branes, resu lting  in
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hydro lysis of sphingom yelin  to ceram ide w ith in  seconds (H aim ovitz- 
Friedm an et al 1994). This latter event may initiate an interphase form of 
apoptotic death.
1.3.4.2 Sphingosine and SPP as second messengers
Sphingosine and SPP were originally proposed as negative regulators of PKC 
(H annun & Bell 1989). How ever, m ore recently it has been show n that 
sphingosine and SPP play different roles in signalling. In this regard , 
sph ingosine  induced  a m itogenic effect that w as stereospecific  and 
independent of PKC inhibition in 3T3 fibroblasts (Zhang et al 1990, Olivera et 
al 1994).
Mitogenic effects of Sphingosine and SPP
Sphingosine and SPP may also regulate T-cell proliferation (Olivera & Spiegel 
1993). G row th inhibition by lSP-1/m yriocin, a potent im m unosuppressant 
which inhibits serine palm itoyltransferase and consequently sphingoid base 
synthesis, was reversed by exogenous sphingosine or SPP (Miyake et al 1995). 
Furthermore, certain growth factors, such as PDGF, induced a rapid, transient 
elevation in sphingosine and SPP levels in fibroblasts (Olivera & Spiegel 
1993) in arterial smooth muscle cells (Bornfeldt et al 1995) and in glom erular 
m esangial cells (Coroneos et al 1995). Furtherm ore a pharm acological 
inhibition of the generation of these sphingolipids reduced PDGF-induced 
cellular proliferation (Olivera & Spiegel 1993, Bornfeldt et al 1995, Coroneos et 
al 1995).
Sphingosine as inhibitor of cell growth
Although the mitogenc effects of sphingosine and SPP appear w idespread, in 
some cell types sphingosine inhibits cell growth, perhaps via PKC inhibition 
(H annun & Bell 1989). Sphingosine may even be an endogenous m ediator of
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apoptosis (Ohta et al 1995), although its acylation to produce ceramide in most 
systems confounds this issue.
Sphingosine and SPP in calcium mobilisation.
Sphingosine and SPP mobilise calcium from internal stores via an inositol- 
trisphosphate-independent pathw ay (Mattie et al 1994, Ghosh et al 1994). The 
response of calcium to SPP has m any hallmarks of a receptor-m ediated event, 
includ ing  rap id ity , reversibility , and specificity. As the endoplasm ic 
reticulum  contains the kinase which converts sphingosine to SPP, all the 
elements sufficient for regulated calcium signalling via these lipids appear to 
be to p o lo g ic a lly  com p a rt a m e n t a lise  d (G hosh  et al 1994). The 
electrophysiological and biophysical p roperties of a sph ingolip id-gated  
intracellular calcium -perm eable channel has previously been characterised 
(Kidman et al 1994).
A receptor for sphingolipid mediated-intracellular-calcium release.
The m olecular cloning and characterisation of a protein  that causes the 
induction of sphingosyl-phosphocholine-m ediated calcium release has been 
reported: this is know n as SCaMPER (for sphingolip id  calcium  release- 
m ediating protein of endoplasmic reticulum) (Mao et al 1996). The properties 
of SCaMPER are identical to those of the sphingolip id-gated  calcium- 
perm eable channel that was previously described (Kidman et al 1994, Mao et 
al 1996). These findings suggest that SCaMPER is a sphingolip id-gated 
calcium -perm eable channel and supports its role as a m ediator of this 
pathw ay for intracellular calcium signal transduction.
A cell surface receptor for SPP.
Although m any studies indicate an intracellular site of action of SPP, some of 
its biological effects when added exogenously, such as inhibition of m otility 
and invasiveness, m ay be due to extracellular effects on cell surface receptors 
(Yatomi et al 1995). SPP is stored in high concentrations in hum an platelets.
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is released upon activation by physiological stimuli, and may play a role in 
platelet aggregation (Yatomi et al 1995). C i /Go-coupled receptors m ay be 
directly or indirectly involved, as some responses to SPP are pertusis toxin 
sensitive. Furthermore, very recently it was shown that SPP is a ligand for 
the G-protein-couped orphan receptor EDG-1 ( Lee et al 1998).
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Figure 10
Sphingolipid-derived second messengers
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1.4 SIGNALING BY THE Ser/Thr PROTEIN KINASE C (PKC)
Serine/threonine protein kinases C (PKCs) are intracellular kinases involved 
in almost all intracellular signalling events.
1.4.1 Different PKCs
Protein kinases C (PKC) is a family of serine/threonine protein kinases which 
share a common requirem ent for phospholipid. PKC isoenzymes, depending 
on their structure and cofactor regulation, are divided into three groups (Hug 
& Sarre 1993, Dekker & Parker 1994): conventional (cPKC a; [11; p2; and y) 
which are calcium and DAG activated isoenzymes, novel (nPKC 5; e; q; and 6 ) 
w hich are calcium independent bu t DAG activated isoenzym es, and the 
atypical ones (aPKC Ç; Xh; and p) which do not require either calcium or 
diacylglycerol (Hug & Sarre 1993, Dekker & Parker 1994, N ishizuka 1988 & 
1989, Kazaniets et al 1993). (Figure 11).
1.4.2 Mechanisms for PKC activation
Recent investigations have show n that structural elements of PKC m ediate 
lipid activation (Newton 1995). The lipid binding moieties of cPKCs have 
long been known to reside in two conserved m odular domains (Cl and C2). 
Resolution of the crystal structure of the second cysteine-rich region of the C l 
dom ain of PKCy bound to phorbol ester revealed that the phorbol ester 
binding site is formed by P sheets, contained in the top half of the C l domain, 
that are pulled apart to form a cavity (Zhang et al 1995). Insertion of phorbol 
ester into this site does not alter the conformation of this dom ain but rather 
results in a surface that is continuously hydrophobic, perhaps allowing for 
efficient interactions w ith  m em branes. The lower half of the dom ain 
contains the m etal-b ind ing  sites and appears to be responsib le  for 
m aintaining the appropriate conformation of the domain. PKC isoenzymes
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that contain Cl regions but do not bind phorbol ester lack a particular 
conserved proline residue (Newton 1995).
Figure 11
Schematic representation of the primary structure of 
conventional, novel, and atypical protein kinase Cs
Protein kinase 0  isoenzymes are single polypeptides, comprised of an 
N-terminal regulatory region (20-40 kDa) and a C-terminal catalytic 
region. Four conserved domains (01-04) are found in most PKOs.
01 contains a Oys-rich motif that forms the diacylglycerol/phorbol 
ester binding site, this domain is immediately preceded by
an autoinhibitory pseudosubstrate sequence.
02 contains the recognition site for acidic lipids and, in some 
isoenzymes, the calcium-binding site.
03 contains the ATP-binding lobe of the kinase core.
04 contains the substrate-binding lobe of the kinase core.
The regulatory and catalytic halves are separated by a hinge region 
that becomes proteolytically labile when the enzyme is activated.
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1.5 SIGNALLING THROUGH FcyRI
H u m a n  FcyRI, a h igh-affin ity  IgC receptor, is an in teg ra l type  I 
transm em brane glycoprotein (Allen & Seed 1989) constitutively expressed on 
monocyte and m acrophage cell types. The cytoplasmic tail of FcyRI contains 
no obvious signalling m otif or hom ology w ith o ther im m une system  
receptors. Aggregation of FcyRI, however, results in signal transduction, seen 
as protein tyrosine phosphorylation events (Liao et al 1992, Scholl et al 1992, 
Rankin et al 1993, Lin et al 1994) and tyrosine kinase dependent calcium  
transients (Davis et al 1994, van de Winkel et al 1990). In myeloid cells, FcyRI 
is associated non-covalently w ith the y chain protein (Ernst et al 1993, Scholl 
& Geha 1993), which contains an IT AM necessary for activation of src-like 
and syk kinases (Reth 1989, Samuelson & Klausner 1992, Cambier 1995). 
(Figure 2).
One feature of monocytes and macrophages is the heterogeneity of response 
to im m une com plex challenge using  cells harvested  under d ifferen t 
conditions and different environments. Aggregation of Fey receptors lead to 
the tyrosine phosphory lation  of phospholipase Cyl (Liao et al 1992) and 
resulting  cytosolic calcium transients (Rankin et al 1993). Little is known, 
how ever, about the signal transduction  m echanism s underly ing  FcyRI 
signalling, or how  these m echanism s are m odified as blood m onocytes 
differentiate into tissue macrophages. Thus, to study early events in the FcyRI 
signalling pathw ay, we have used the hum an m onocyte cell line, U937 
(Harris & Ralph 1985), which constitutively expresses FcyRI and FcyRII and 
w hich allows controlled differentiation into a more m acrophage cell type by 
treatm ent w ith dibutyryl cAMP (dbcAMP) (Sheth et al 1988). Previous work 
has show n that the nature of calcium transients markedly changes as the cells 
become differentiated (Davis et al 1994). Thus, a single spike in calcium is
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observed in response to Fey receptor aggregation of cells treated  w ith  
interferon-y whereas calcium oscillations are generated in cells differentiated 
to a more macrophage state by dbcAMP (Floto et al 1995).
1.6 AIMS OF THE PRESENT STUDY
The aim s of th is s tudy  w ere to investigate  the signal tran sd u ctio n  
m echanism s underly ing  FcyRI signalling and how  these m echanism s are 
m odified as blood monocytes differentiate into tissue macrophages using the 
hum an monocyte cell line, U937.
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CHAPTER 2
MOLECULAR SWITCH BY FcyRI ANTIBODY RECEPTOR MOBILISES 
CALCIUM THROUGH TWO DISTINCT SIGNALLING PATHWAYS
2.1 ABSTRACT
Background: Aggregation of receptors for the Fc region of IgG activates a 
repertoire of responses that can lead to targeted cell killing via antibody 
directed cellular cytotoxicity (ADCC). The nature of the m yeloid cellular 
response to im m une complexes is highly variable and depends on the 
m aturation state of the cell.
Results: We show here that differentiation of a monocytic cell line, U937, to a 
more m acrophage phenotype results in an absolute and fundam ental switch 
in the nature of the phospholipid signalling pathw ay recruited following Fey 
receptor aggregation. In cytokine prim ed cells, FcyRI aggregation results in 
the activation of phospholipase D and sphingosine kinase w hereas no 
products of phospholipase C activation could be detected. In addition, release 
of stored calcium was secondary to phospholipase D and sphingosine kinase 
activation. In contrast, in cells differentiated to a more m acrophage type, 
aggregation of FcyRI resulted in activation of phospholipase C and neither 
sphingosine kinase nor phospholipase D was activated. M oreover, the 
resulting calcium transients were prolonged as calcium entry was stimulated. 
Thus, differentiation switches the nature of phospholipase recruitm ent by 
FcyRI and this switch dictates the type and duration of calcium transients and 
hence, provides a m olecular m echanism  for the distinct differentiation- 
dependent responses activated as cells m ature to a more macrophage-like cell.
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Conclusions: Our data demonstrates that the switch in signalling pathw ays is 
defined by a sw itch in accessory molecule recruitm ent by FcyRI as this 
receptor lacks an intrinsic tyrosine activation motif. As m any im m une 
receptors display ligand binding and signal transduction on separate chains 
(thereby opening the possibility of a sw itch in signal transduction) the 
mechanism defined here is therefore likely to have wide applications.
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2.2 INTRODUCTION
Binding of the constant region (Fc) of immunoglobulin G (IgG) molecules 
to its surface Im mune Recognition Receptor (FcyR) of leukocytes provides a 
pivotal link betw een the hum oral and cellular arms of the im m une system 
[see reviews 1-3]. On myeloid cells, aggregation of these receptors triggers a 
num ber of different effector functions including endocytosis of im m une 
complexes or phagocytosis of opsonised particles. Fey receptor aggregation 
activates a repertoire of responses including degranulation and release of 
proteases, activation of the respiratory burst and release of cytokines. These 
can ultim ately lead to targeted cell killing through antibody directed cellular 
cytotoxicity (ADCC) [4, 5] which is critically im portant for clearing virus 
infected cells and in cancer surveillance [6 ]. One feature of monocytes and 
m acrophages is the heterogeneity of responses to immune complex challenge 
using cells harvested under different conditions and different environm ents.
Three different classes of FcyR have been defined; FcyRI (CD64), FcyRII 
(CD32) and FcyRIII (CD16). Of these, the hum an high affinity receptor, FcyRI, 
is an integral type I m em brane glycoprotein [7] constitutively expressed on 
monocyte and macrophage cell types. The cytoplasmic tail of FcyRI contains 
no obvious signalling m otif or hom ology w ith o ther im m une system  
receptors. However, aggregation of FcyRI results in signal transduction as 
evidenced by protein tyrosine phosphorylation events [8 -1 1 ] and tyrosine 
kinase dependent calcium transients [12, 13]. In m yeloid cells, FcyRI is 
associated non-covalently  w ith  the y chain [14, 15] w hich contains an 
im m unoreceptor tyrosine activation motif (ITAM) necessary for activation of 
soluble tyrosine kinases [16-18]. The y chain, a 7 kDa protein  originally 
identified as a component of the high affinity IgE receptor (FceRI) in mast cells 
[19], is a member of a family of signal transducing molecules that includes the
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Ç chain of the T cell receptor [20]. As a result of the non-covalent association 
betw een FcyRI and the y chain, receptor aggregation results in clustering of 
the associated y chain IT AMs and thereby triggers tyrosine kinase recruitm ent 
and activation [21-23].
Activation of IgG-loaded receptors leads to the tyrosine phosphorylation of 
ph o sp h o lip ase  Cyl [8 ] and resulting  cytosolic calcium transients [10]. 
H ow ever, little  is know n about the signal transduction  m echanism s 
underlying FcyRI signalling or how they are modified as blood monocytes 
differentiate into tissue macrophages. Thus, to study early events in the FcyRI 
signalling pathw ay, we have used the hum an monocyte cell line, U937 [24], 
which constitutively expresses FcyRI and FcyRIIa and which allows controlled 
differentiation into a more m acrophage cell type by treatm ent w ith dibutyryl 
cAMP (dbcAMP) [25]. Previous work has shown the nature of the calcium 
transients m arkedly change as the cells become differentiated [12]. Thus, a 
single spike in calcium is observed in response to FcyR aggregation of cells 
treated w ith interferon-y whereas calcium oscillations are generated in cells 
differentiated to a more macrophage state by dbcAMP [26]. We now show that 
there is a fundam ental and absolute developmental switch in the particular 
phospholipase pathw ay recruited following Fey receptor aggregation during 
differentiation from a monocyte to a macrophage-like cell and that the types 
of calcium transients generated intracellularly are consequent on this switch 
in signalling pathway.
66
2.3 MATERIALS AND METHODS 
2.3.1 Materials and Cell Culture
U937 cells were cultured in RPMI1640 (Gibco) supplem ented w ith foetal 
calf serum  (10%), glutam ine (2 mM, penicillin (lOU/m l) and streptom ycin 
(lOjLLg/ml) at 37°C, 6 .8 % carbon dioxide in a water saturated atmosphere. The 
cells were treated w ith IFN-y (Bender Wein Ltd) (2 0 0 ng /m l) for 24 hours or 
dbcAMP (ImM) for 48 hours.
Antisense oligonucleotides were purchased from Oswell DNA Services 
(Southampton, UK). 24 mers were synthesised, capped at either end by the 
p h o sp h o th io ra te  linkages (first tw o and last tw o linkages), and  
correspondedto the reverse complement of the first 8 amino acids for either y  
chain or FcyRIIa. The sequences of the oligonucleotides were for y chain 5' 
GAG CAA GAC CAC TGC TGG AAT CAT 3', for FcyRIIa 5’ TCT GGG ACA 
TAG ATT CTG AGA CAT 3' and the jumbled control 5' CTG GTG GAA GAA 
GAG GAC GTC CAT 3'. Cells were incubated in lOpM oligonucleotide for 1 
hour p rio r to, and then for the duration  of culture w ith  either IFN-y or 
dbcAMP. A ddition of DOTAP (Boehringer-Mannheim) was found to have 
no influence on the effect of the antisense oligonucleotides.
2.3.2 Receptor aggregation for the biochemical assays
Cells w ere harvested by centrifugation (200g). For experim ents using 
ligand to aggregate the receptors, cells were incubated for 30mins on ice w ith 
IpM  hum an monomeric, polyclonal IgG (Serotec) to occupy the surface FcyRI. 
Excess unbound ligand was rem oved by dilution and centrifugation of the 
cells. Cells w ere resuspended and ligand occupied receptors w ere then 
aggregated by addition of 1:100 dilution of F(ab) goat anti-hum an IgG (Sigma)
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on ice (Figure 4). Cells were then w arm ed to 37°C for the times specified in 
the assays.
To aggregate specific Fey receptors, cells were incubated w ith specific 
monoclonal antibodies for 30 mins on ice (Figure 4). To aggregate FcyRI, cells 
were incubated w ith 1 pg of the monoclonal antibodies 22 and 32 w hich 
recognise separate epitopes on FcyRI away from the binding pocket. To 
aggregate specifically FcyRIIa, cells w ere incubated w ith  the m onoclonal 
antibody, 2el (Serotec) in the presence of 3pM hum an IgG4 (Serotec) to occupy 
the ligand binding pocket of FcyRI. After removal of excess antibody by 
dilution and centrifugation, the receptors were crosslinked by the addition of 
F(ab) goat anti-m ouse IgG F(ab) (1:50 dilution) (Sigma). Cells were then 
warm ed to 37°C for the times specified in the assays.
2.3.3 Measurement of Inositol Phosphates
Inositol phosphates were assayed essentially as described in H arnett and 
Harnett [39]. Briefly, U937 cells were labelled with myo-pH]-inositol (lpCi/10^ 
cells) for 16 hours at 37°C. To measure total accumulated InsP, cells (at 1- 
3x10^ cells/m l) were incubated for 10 mins in the presence of lOmM LiCl in 
RPMI 1640/lOmM HEPES/0.1% BSA (RHB) medium, pH7.4 prior to receptor 
crosslinking and lOmM LiCl was added to all solutions throughout [27, 28]. 
Following crosslinking of the receptors, the cells were extracted by a Bligh- 
Dyer phase separation and levels of [^H]inositol trisphosphate (InsPg) or total 
[^H]inositol phosphates (reaction m ixture containing 10 mM LiCl) w ere 
determ ined by liquid scintillation counting of fractions eluted follow ing 
Dowex (formate form) ion-exchange chrom atography of aliquots of the 
aqueous phase.
2.3.4 Measurement DAG Generation
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Mass DAG was m easured as described in Briscoe et al [27]. The lower 
organic phase of Bligh-Dyer extractions were dried in vacuo and the lipids 
so lub ilised  in  a T riton  X -lO O /P hosphatidy lserine  m ix ture. E coli 
diacylglycerol kinase (Calbiochem) was added to a final concentration of 5 
m Unit and the reaction started by addition of lOpl of 5mM ATP containing 
IpCi of p2p]-y-ATP m ade up in lOOmM Imidazole pH 6 .6 . After 30 min., the 
reaction  is stopped  by add ition  of 1ml of chloroform :m ethanol: HCl 
(150:300:2) and phases separated by addition of 300j l i 1 of chloroform and 400jxl 
of H 2O. Samples of the organic phase were then dried in vacuo, solubilised in 
40|uil of chloroform:methanol (19:1) and resolved on silica TLC plates (Merck, 
5714, 5x20cm 60p254)developed in chloroform: methanol:acetic acid (38:9:4.5). 
The PtdO H  band (relative to standards) was scraped and the associated 
radioactivity determ ined by liquid scintillation counting.
2.3.5 Measurement of Phospholipase D Activity
PLD activity was m easured by the transphosphatidylation assay [27, 28]. 
Briefly, U937 cells, were labelled (10^ cells/m l) w ith pH ]palm itic acid (5 
pC i/m l) in RPMI 1640 m edium  containing 5% (v/v) foetal calf serum  for 
16h. Following labelling, the cells were washed in ice cold RPMI 1640/lOmM  
HEPES/0.1%  BSA (RHB m edium ), resuspended at 2x10^ ce lls /m l and 
incubated at 37°C for 15 mins in RHB m edium  containing bu taiv l-o l (0.3% 
final). Specific Fc receptors were crosslinked as described above and, after the 
times indicated, cells were extracted by Bligh-Dyer phase separation. Samples 
of the low er organic phase were resolved on pre-run, heat activated TLC 
plates (20 x 20 cm. Silica gel 150A grooved plates, Whatman) developed in the 
organic phase of the solvent, ethyl acetate: 2,2,4 trimethylpentane: acetic acid: 
w ater (11:5:2:10). The [^H ]P tdB ut-containing silica ind ica ted  by the
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phosphatidylbutanol standard  was then scraped into scintillation fluid and 
counted.
2.3.6 Measurement of sphingosine kinase activity
Sphingosine kinase was assayed as described in Olivera et al, [40]. 
Reactions were term inated at the times specified in Figure 7 by addition of 
ice-cold PBS. After centrifugation, the cells were resuspended in ice-cold O.IM 
phosphate buffer (pH7.4) containing 20% glycerol, 1 mM m ercaptoethanol, 1 
mM  EDTA, ph o sp h a tase  inh ib ito rs (20 mM Z nC l2 , 1 mM sodium  
orthovanadate and 15 mM sodium  fluoride), protease inhibitors (10 p g /m l 
leupep tin , 10 p g /m l ap ro tin in  and 1 mM PMSF) and  0.5 mM  4- 
deoxypyridoxine. Cells were disrupted by freeze thawing and centrifuged at 
105,000g for 90 min at 4°C. Supernatants were assayed for sphingosine kinase 
activity using sphingosine (Sigma) and [y^^P]ATP (2jLiCi, 5mM). as specified in 
Olivera et al, [40]. After incubation, products were separated by TLC on silica 
gel G60 using chloroform :m ethanol:acetic acid: w ater (90:90:15:6) and 
visualised by auoradiography. The radioactive spots corresponding to 
sphingosine phosphate were scraped and counted in a scintillation counter.
2.3.7 Measurement of Cytosolic Calcium
Single cell measurement of changes in cytosolic calcium:
U937 cells treated w ith dbcAMP (ImM) or IFN-y (200ng m R l) w e re  
h a rv ested  and cells resu sp en d ed  in H EPES-buffered saline (HBS) 
supplem ented w ith Im M  CaCl2 . Cells were incubated sim ultaneously w ith 
prim ary antibody (either hum an hum an IgG (IpM) or the FcyRI specific mAh 
32 or FcyRIIa specific mAh 2el plus (IpM) hum an IgG4) and 5|iM Fluo3-AM 
(Molecular Probes) mixed w ith an equal volume of 25% w /v Pluronic F127 at 
room tem perature for 30 min. After centrifugation, cells were resuspended in
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HBS (Im M  Ca2+) at room tem perature and aliquots were settled on poly-L- 
lysine coated coverslips and placed in a perfusion chamber heated to 37°C. 
The perfusion  bath  was thoroughly  perfused w ith HBS (2mM Ca2+) to 
rem ove excess antibody and ensure complete solution change. For cells 
loaded with hum an IgG, receptors were then aggregated by addition of F(ab) 
fraction of goat anti-hum an IgG F(ab) antibody (1:50 dilution). For cells 
loaded w ith the FcyR specific mAbs, receptors were crosslinked w ith a F(ab) 
preparation of a goat antibody specific for mouse IgG F(ab). Scanning confocal 
imaging was achieved using a Zeiss inverted confocal microscope. Excitation 
light (488 nm) was provided by an argon laser and emitted light was detected 
at w avelengths above 515 nm. Laser attenuation , p inhole size and 
photom ultiplier brightness/contrast settings were m aintained constant for all 
experim ents. Frames were acquired every 3s (512 x 512 pixel) and pixels 
assigned intensity values (0-255). Transm itted visible light images were 
routinely taken before and after every experim ent to exclude artefactual 
changes in fluorescence caused by m ovem ent of cells in the focal plane. 
Results were adjusted for dye photobleach assessed in unstim ulated cells. 
Data analysis were carried out using M etam orph and Sigm aplot (Jandel 
Scientific Corp, USA) software. Results are expressed as the mean ±  standard 
error. Oscillations were defined as responses w ith two or more peaks 
separated by more than one data point.
M easurem ent of calcium concentrations in cell populations:
To m easure the release of calcium from intracellular stores, experiments 
w ere perform ed on cell populations in nom inally Ca2+ free HBS (at 37°C) 
using a Cairn Research Spectrophotom eter and fura-2 (Molecular Probes) 
loaded cells as described previously [12]. The backgound corrected 340/380 
ratio was calibrated using the m ethod of Grynkiewicz et al [41]. Following 
each experiment, cells were lysed by the addition of 50|iM digitonin in the
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presence of external 2  mM Ca2+ to give an Rmax value. Rmin was subsequently 
determ ined by the addition of 20mM EGTA (pH7.4) in the presence of 
equim olar concentration of Tris base.
2.3.8 N orthern analysis
Cells were treated with IFN-y or dbcAMP and harvested at set times. After 
centrifugation, the cells were lysed by addition of guanidinium  thiocyanate 
and the RNA w as extracted  using  the acidified phenol m ethod of 
C hom czynsky and Saachi [42]. The Equal am ounts of RNA w ere 
electrophoresed through 1 % agarose containing formaldehyde, transferred to 
N ytran m embranes (Amersham) and probed sequentially for mRNA to FcyRI 
[7], FcyRIIa [33] and y chain [19] using cDNAs for each labelled with ^^P by 
random  prim ing (HiPrime - Boehringer Mannheim). The blots were then 
probed w ith tRNA (gift from Dr R. White) labelled in the same way to allow 
normalisation. The hybridisation signal was visualised by placing against X 
ray film.
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2.4 RESULTS
2.4.1 Section 1: m obilisation of calcium undergoes a differentiation- 
dependent molecular switch
2.4.1.1 Differential generation of inositol phosphates following aggregation of 
Fey receptors on differentiated and cytokine treated cells.
To exam ine the m echanism  underly ing  the d ifferentiation-dependent 
change in calcium transients in U937 cells, experiments were perform ed to 
define Fey receptor coupling to lip id  signalling pathw ays that generate 
candidate  m essengers for eliciting calcium  release. Thus, as it is well 
established that aggregation of Fey receptors leads to the recruitm ent of 
tyrosine kinases and subsequent phosphorylation and presum ed activation of 
P td InsP 2"PLC [8 , 10, 11] w ith resultant generation of the calcium mobilising 
second messenger, InsPg, our first approach was to investigate coupling to this 
pathw ay. C rosslinking of Fey receptors on IFN-y treated  and dbcAMP 
differentiated U937 cells did indeed show differential coupling to PtdInsP2- 
PLC. A small but significant transient rise in InsPg was observed in cells 
differentiated w ith dbcAMP following receptor aggregation (Figure la). By 
contrast, no increase in InsPs could be detected following receptor aggregation 
by the same stimulus in cells treated w ith IFN-y (Figure la).
As the increase in measurable InsPg was small and transient even in cells 
d ifferentiated w ith  dbcAMP, total InsP accum ulation in the presence of 
lithium  chloride (lOmM) [27, 28] was m easured to ensure that any transient 
generation of InsP was not missed by sampling at specified time points. The 
results are shown in Figure lb . In dbcAMP differentiated cells, aggregation of 
Fey receptors initiated an increase in InsPs that was detectable at the first time 
po in t tested (5 min), and steadily increased in a linear fashion thereafter.
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Surprisingly, InsP s were not increased above control values in cells treated 
w ith IFN-y even 20 mins after receptor aggregation (Figure lb).
These data indicate that the ability of Fey receptors to couple to InsP 
generation following receptor aggregation in these cells depends on the 
differentiation state of the cell. In U937 cells differentiated w ith dbcAMP, Fey 
receptors are coupled to InsPg generation whereas, in IFN-y treated cells, they 
are not. Indeed, the failure to detect any InsPs accumulation in IFN-y treated 
cells suggests that the calcium spike previously docum ented in these cells is 
induced in an InsPs-independent m anner.
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Figure 2,1 Differential generation of inositol phosphates following ligand  
activation of Fey receptor in dbcAMP and IFN-y treated cells.
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a. InsPg levels in dbcAMP or IFN-y treated cells at set times (30 sec to 20 min) 
after Fey receptor aggregation. In dbcA M P-differentiated cells, InsPg 
concentrations were above control (samples w ith no aded cross-linking 
antibody) values at all time points after Fey receptor aggregation, although 
concen tra tions appeared  to oscillate. In IFN -y-treated cells, InsPs 
concentrations were never higher than control values at any time point. The 
data  show n are the m ean ±_ the s tan d ard  dev ia tion  of trip lica te  
m easurem ents and are representative of four different experiments.
b. Total accumulated InsPs following Fey receptor aggregation in dbcAMP- 
and IFN-y- treated cells. Cells were treated with lOmM lithium  chloride to 
prevent breakdow n of InsPs. Cells were harvested at 5 mins intervals after 
Fey receptor aggregation and assayed for InsPs concentration. The data shown 
are the m ean + the standard  deviation of triplicate m easurem ents and are 
representative of five separate experiments.
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2.4.1.2 Fey  receptor is coupled to DAG production in both differentiation
states
O ur first clue to the potential calcium-mobilising signalling pathw ay 
utilised in IFN-y treated cells was provided by experiments m easuring mass 
diacylglycerol (DAG) generation. Unexpectedly, in contrast to the InsPs 
m easurements, broadly similar levels of DAG were produced by Fey receptor 
aggregation in cells treated w ith IFN-y or cells differentiated w ith dbcAMP 
(Figure 2). As DAG can be generated by activation of the alternative 
phospholipases PtdCho-PLC and PtdCho-PLD (from phosphatid ic  acid 
(PtdOH) via phosphatidic acid phosphohydrolase) [28] in addition to that 
resulting from PtdlnsPz-PLC hydrolysis, we next investigated w hether either 
of these alternative pathways was responsible for the DAG generation. To do 
this, DAG was m easured in cells pretreated with butan-l-ol (0.3%) which traps 
phosphatidic acid (PtdOH), the immediate product of PtdCho-PLD, in a non- 
hydrolysable form as phosphatidyl butanol (PtdBut) [28]. A control for the 
specificity of this reaction is provided by the stereoisoform, butan-2 -ol which 
cannot act as an acceptor for the phosphatidyl-m oiety of PtdCho. In cells 
treated w ith IFN-y, Fey receptor-m ediated DAG production was com pletely 
blocked by bu tan-l-o l whereas, in cells differentiated w ith dbcAMP, DAG 
production was completely unaffected (Figure 2). Butan-2-ol had no effect on 
DAG production in either cell type (data not shown).
These results suggest that in dbcAMP differentiated cells DAG was, as 
expected from the InsP results, likely to be predom inantly  derived from 
P td InsP 2“PhC signalling. In contrast, in IFN-y treated cells DAG generation 
was entirely derived from coupling of Fey receptors to a PLD pathway.
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Figure 2.2 Fey receptor is coupled  to diacylglycerol p roduction  in  bo th
differentiation states.
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Relative DAG mass levels after aggregation of Fey receptor in dbcAMP- 
differentiated and IFN-y-primed cells. The effect of butan-l-ol (0.3%) on the 
levels of DAG mass before (Control) and after (X link) Fey receptor aggregation 
w as examined. The data show n are the mean ±  the standard  deviation of 
triplicate m easurem ents and are representative of four separate experiments.
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2.4.1.3 Fey receptors are coupled to PLD in IFN-y treated cells but not in 
dbcAMP differentiated cells
To confirm that Fey receptor signalling in IFN-y treated cells is indeed 
coupled to a PtdCho-PLD pathway, we investigated coupling in [^Hjpalmitate- 
labelled U937 cells using the transphosphatidy lation  assay [27]. These 
experim ents definitively showed that aggregation of Fey receptors in IFN-y 
treated cells stimulated activation of PtdCho-PLD, as evidenced by substantial 
generation of [^H]PtdBut in butan-l-ol (Figure 3), but not butan-2-ol (data not 
shown) treated cells over 30 min. By contrast, no accumulation of [% ]P tdB ut 
was detected in cells differentiated w ith dbcAMP (Figure 3). To ensure that 
differentiation w ith dbcAMP had not down-regulated PLD activity in these 
cells, the level of activity following stimulation with the phorbol ester, PMA 
(phorbol 12,13 m yristate acetate) was com pared in differentiated cells and 
those treated  w ith  IFN-y (Figure 3b). In both cell types, PMA (IpM ) 
stim ulated PLD essentially to an equivalent extent indicating that although 
Fey receptors are not coupled to PtdCho-PLD in dbcAMP-differentiated cells, 
one or more PtdCho-PLD activities are indeed expressed in these m acrophage­
like cells.
These results, therefore, categorically show differential coupling of the Fey 
receptors to major phospholipid  signalling pathw ays, P tdInsP2-PLC and 
PtdCho-PLD, at different stages of monocyte differentiation. Moreover, this 
switch in lipid signals is absolute.
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Figure 2.3 Fey receptor is coupled to PLD in IFN-y-treated cells but not in dbc- 
differentiated cells.
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M easurem ent of PLD activity in dbcAMP and IFN-y treated cells using the 
transphosphatidylation assay.
a. PLD activity was m easured as the accumulation of [^H]PtdBut in cells 
before (Control) and after (X link) aggregation of Fey receptors. The time for 
the accum ulation assay w as 30 min. Significant PLD activity w as only 
observed in IFN-y treated cells after Fey receptor aggregation
b. PLD activity in dbcAMP or IFN-y-treated cells following activation by 
phorbol ester, (PMA).
The data  show n are the m ean +_ the s tandard  deviation  of trip licate  
m easurem ents and are representative of six separate experiments.
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2.4.1.4 FcyRTmediated calcium transients in IFN-y treated cells are dependent 
on phospholipase D activation and sphingosine kinase
As no InsP3 accum ulation could be detected in IFN-y treated  cells 
following aggregation of FcyRI, alternative routes for calcium release were 
investigated. As a sphingoid  base has previously  been im plicated in 
m obilisation  of in tracellu lar calcium  stores [29-31], the differentiation- 
dependent coupling of FcyRI to sphingosine kinase was investigated in these 
cells. A prom pt two fold increase in sphingosine kinase activity was observed 
30 secs following receptor aggregation in these cells w hereas it w as not 
activated in dbcAMP differentiated cells.
A specific link betw een sphingosine kinase activation and PtdCho-PLD 
was dem onstrated by pretreating cells w ith 0.3% butan-l-ol which completely 
abolished the increase in sphingosine kinase activity observed after specific 
aggregation of FcyRI in IFN-y treated cells whereas butan-2-ol had no effect on 
sphingosine kinase activation (data not shown). This clearly dem onstrates 
that PtdCho-PLD activation is upstream  of sphingosine kinase; a finding that 
is consistent w ith the previous observation that phosphatid ic  acid, the 
im m m ediate product of PtdCho-PLD activation, can stim ulate sphingosine 
kinase in vitro [32].
The role of components of the novel activation pathw ay (PtdCho-PLD and 
sphingosine kinase) identified in IFN-y prim ed cells in m ediating the calcium 
transients was determ ined. Consistent w ith a role for sphingosine kinase, 
treatm ent of these cells w ith D-L-threo d ihydro-sphingosine (25 M) (DHS) 
com pletely abolished the release of calcium  from  stores in itia ted  by 
aggregating  FcyRI in IFN-y but not dbcAM P-treated cells. F u rth e rm o re , 
preincubation of IFN-y prim ed cells for 5 min with 0.3% butan-l-ol decreased 
the peak cytosolic calcium mobilisation from 217 ± 3 0  nM in the untreated 
cells to 99 4- 29 nM.
80
2.4.1.5 Summary for section 1
Taking all this data together, we have shown that im m une complexes 
trigger d ifferent phospho lip id  signalling pathw ays dependen t on the 
differentiation state of the cell. In dbcAMP differentiated cells, PtdInsP2-PLC 
is activated  and calcium m obilised th rough  the conventional pathw ay 
involving InsPs. However, in interferon-y primed cells, a novel pathw ay has 
been identified that involves sequential activation of PtdCho-PLD and 
sph ingosine  kinase and  m obilisa tion  of calcium  th ro u g h  an InsPs 
independent route. The im m ediate product of PtdCho-PLD, phosphatidic 
acid, has previously been shown to be an activator of sphingosine kinase in 
other systems [32] suggesting that phospholipase D may be directly upstream  
of sphingosine kinase. Moreover, the calcium transients were inhibited by 
bo th  DHS and bu tanol indicating that this pathw ay generates second 
m essengers able to release calcium from stores through a novel mechanism 
presum ably  involving a sphingoid  base acting on the recently cloned 
SCaMPER receptor [33] in the endoplasmic reticulum to effect calcium release 
from stores [29]. This novel pathw ay may, therefore, play an im portant role 
in the regulation of calcium in a wide range of biological responses.
2.4.2 Section 2: m echanism of the switch
2.4.2.1 The switch in phospholipid signalling pathways observed after 
differentiation is a function of the Fey receptor aggregated
The switch in the phospholipid signalling pathw ay recruited by immune 
complexes may result from the influence of differentiation on any one of the 
com ponents of the pathw ay. To investigate w hether the sw itch in 
p hospho lipase-ac tiva ted  signalling  is defined by the n a tu re  of the 
predom inant Fey receptor on the cell surface, monoclonal antibodies specific
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for either FcyRI or FcyRIIa were used to cross-link each receptor (see section
2 .2. 2  for m ore details). We com pared the results of cross-link ing  the 
individual receptors w ith those obtained by im m une-com plex activation in 
both IFN-y and dbcAM P-differentiated cells.
In dbcAMP differentiated cells, specific aggregation of either FcyRI or 
FcyRIIa gave similar results to those observed using hum an IgG, nam ely a 
m easurab le  rise of InsPs (Figure 4a,b) and DAG (Figure 4c,d); the 
accum ulation of the latter was unaffected by pretreating the cells w ith 0.3% 
butan-l-o l. In keeping w ith these results, no increase in PLD activity was 
m easured  after cross-linking either receptor in these differentiated cells 
(Figures 4e). To rule out the possibility that FcyRI signalling here sim ply 
reflected recru itm ent of FcyRIIa by the Fc region of either anti-FcyRI 
monoclonal antibodies used (antibodies 22 and 32), w hich are both m ouse 
IgGl subclass and can can be recognised at low affinity by FcyRIIa [34], the level 
of inositol phosphates was m easured in dbcAM P-differentiated cells in the 
presense of either whole molecule intact monoclonal antibodies 22 and 32 or 
a P(ab ' )2 preparation of the same antibodies. Polyclonal mouse IgG was used 
as an additional control. The intact anti-FcyRI antibodies and their F(ab ' )2 
fragm ents gave an identical accum ulation of inositol phosphates w hereas 
m ouse IgG l did not stimulate the generation of inositol phosphates (Figure 
4f). Thus, in dbcAMP differentiated cells, both FcyRI and FcyRIIa appear to be 
coupled to PtdInsP2-PLC and neither receptor is coupled to PtdCho-PLD. 
These results agree w ith those seen w hen Fey receptors are aggregated by 
im m une complexes in dbcAMP-treated cells.
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Legend for figure 2.4
Response of dbcAMP differentiated cells to specific crosslinking of FcyRI or
FcyRIIa using monoclonal antibodies.
a, b. Accumulated inositol phosphates at specified times after specific receptor 
cross-linking. The results are the mean + the standard deviation of triplicate 
m easurem ents are representative of four separate experiments.
c, d. DAG generation after specific receptor cross-linking for the indicated 
times and the effect of (Butanol) butan-l-ol on DAG production. The results 
are the m ean ±_ the standard  deviation of triplicate m easurem ents are 
representative of four separate experiments.
e. PLD activity after specific receptor crosslinking. The data show n are the 
m ean ±_ the stan d ard  d e v ia t io n  of trip licate  m easurem ents and are 
representative of five separate experiments.
f. Com parison of the ability of intact anti-FcyRI monoclonal antibodies and 
F (ab ' )2 preparations to induce inositol phosphate generation in dbcAMP- 
differentiated cells. In the presence of lOmM LiCl, cells w ere loaded w ith 
either no prim ary  antibody (Control), or equivalent concentrations of 
polyclonal m onomeric mouse IgG l (m lgG l), the F(ab ' )2 preparations of the 
FcyRI-specific monoclonal antibodies 22  and 32 (a-FcyRI (F(ab')2)/ intact whole 
molecule 22 and 32 (a-FcRI) or polyclonal monomeric hum an IgG l (IiIgGl). 
Following addition of the appropriate secondary antibodies and w arm ing of 
cells to 37°C for 20 m ins, total inositol phosphates were m easured. T he 
results are the m ean + the standard deviation of triplicate m easurem ents are 
representative of three separate experiments.
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Figure 2.4 Response of dbcAMP differentiated cells to specific crosslinking of
FcyRI or FcyRIIa using monoclonal antibodies.
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In contrast, in IFN-y treated  cells, com pletely d ifferent pa ttern s of 
signalling were obtained by cross-linking of specific Fey receptors. Only 
specific aggregation of FcyRI resulted in similar results to those for ligand 
activation, namely no detectable accumulation of inositol phosphates (Figure 
5a,b), a rise in DAG which was abolished by pretreating cells w ith 0.3% butan- 
l-o l (Figure 5c,d) and an increase in PLD activity (Figure 5e). By contrast, 
specific aggregation of FcyRIIa in IFN-y-treated cells using m onoclonal 
antibodies gave an identical pattern of responses to that observed for dbcAMP 
differentiated cells, nam ely an increase in inositol phosphates (Figure 5a,b) 
and butan-l-ol-insensitive DAG generation (Figure 5c,d) w ith no increase in 
PLD activity (Figure 5e). Thus, in IFN-y treated cells, FcyRI is coupled to 
PtdGho-PLD and FcyRIIa to PtdInsP2-PLC.
Taken together, these data indicate that FcyRIIa always signals through the 
activation of PtdInsP2“PLC regardless of the differentiation state of the cell. In 
contrast, FcyRI appears to sw itch its coupling to different phospholip id  
signalling pathw ays in a differentiation m anner. In dbcAM P-differentiated- 
cells, FcyRI is coupled to PtdInsP2-PLG and thereby adopts a signalling pattern 
that is identical to that observed for FcyRIIa. In IFN-y treated cells, FcyRI is 
independently  coupled to PtdCho-PLD and unlike FcyRIIa is not coupled to 
P tdInsP 2“PLC. This switch in coupling to phospholipid signalling pathw ays 
by FcyRI is absolute and is identical to that observed for ligand (hum an IgG) 
activation (Figures 1-3).
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Legend for figure 2.5
Response of IFN-y-primed cells to specific crosslinking of FcyRI or FcyRIIa 
using monoclonal antibodies.
a,b. Accum ulation of inositol phosphates at specified times after specific 
receptor cross-linking. The data show n are the m ean ±_ the s tandard  
deviation of triplicate m easurem ents and are representative of six separate 
experim ents.
c,d. DAG generation after specific receptor cross-linking for the indicated 
times and the effect of butan-l-ol (Butanol) on DAG production. The data 
shown are the mean ±  the standard deviation of triplicate m easurem ents and 
are representative of four separate experiments.
e. PLD activity after specific receptor cross-linking. The data shown are the 
m ean +. the standard  dev iation  of trip licate  m easurem ents and  are 
representative of four separate experiments.
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Figure 2.5 Response of IFN-y-primed cells to specific crosslinking of FcyRI or
FcyRIIa using monoclonal antibodies.
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2 .4 .2. 2  The FcyRI-dependent pathway in IFN-y treated cells is coupled to 
sphingosine kinase activation
As our studies had linked the activation of PtdCho-PLD with sphingosine 
kinase, the coupling of specific Fey receptors to sphingosine kinase activation 
and the effect of differentiation on its activation were examined using the 
monoclonal antibodies to aggregation each receptorin specifically. Consistent 
w ith the identified switch in phospholipid signalling pathw ays, sphingosine 
kinase activity was stimulated only following the specific aggregation of FcyRI 
in IFN-y prim ed cells (Figure 6 ). The sphingosine kinase activity did not rise 
above control values following aggregation of FcyRIIa in IFN-y -treated cells 
or following aggregation of either FcyRI or FcyRIIa in dbcAM P-differentiated 
cells (Figure 6 ). Thus, the receptor specificity of sphingosine kinase activation 
exactly parallels that observed for activation of PtdCho-PLD (Figure 4e and 5e).
This data therefore indicates that, in IFN-y-treated cells, FcyRI is coupled to 
a PtdCho-PLD and sphingosine kinase pathw ay whereas, in dbcAMP-treated 
cells, FcyRI is coupled to PtdInsP2-PLC and production of InsPs. In contrast, 
FcyRIIa is coupled to PtdInsP2-PLC and InsPg in both cell types.
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Figure 2.6 Sphingosine kinase activity is involved in the sinalling pathway 
triggered by FcyRI in IFN-y primed cells.
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Sphingosine kinase activity in cells treated with IFN-y or dbcAMP followed by 
specific receptor (FcyRI or FcyRIIa) cross-linking using monoclonal antibodies.
Controls are IFN-y-primed cells w ith no cross-linking antibody added. The 
data shown are the mean + the standard deviation of triplicate measurements 
and are representative of three separate experiments.
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2.4.2.S The switch in phospholipid signalling pathway is matched by a change 
in the nature of the calcium response
Differentiation of U937 cells w ith dbcAMP changes the nature of calcium 
transien t responses to Fey receptor aggregation stim ulsted  by im m une 
complexes. Thus, in dbcAMF-differentiated cells, about 50% of cells respond 
in the form of calcium oscillations [26] whereas in undifferentiated or IFN-y 
treated cells, the calcium response is in the form of a single spike. To 
determ ine w hether the differential calcium responses observed following 
m atu ration  reflect the change in the phospholip id  signalling pathw ays 
recru ited , we com pared the natu re  of calcium response resulting  from  
aggregation of either FcyRI or FcyRIIa using monoclonal antibodies w ith the 
response triggered by cross-linking w ith imm une complexes. In dbcAMP 
differentiated cells, about 50% of cells respond in the form  of calcium 
oscillations regardless of the nature of the Fey receptor aggregated (Figure 
7a,panels c-g,). In cells treated with IFN-y, the nature of aggregated receptor 
sw itched the nature  of the calcium response (Figure 7d-g); thus, specific 
aggregation of FcyRI resulted in a single spike of calcium (Figure 7e), identical 
to that observed in response to hum an IgG (Figure 7d), and pecific cross- 
linking of FcyRIIa gave calcium oscillations in 50% of the cells, identical to 
those observed in dbcAMP differentiated cells (Figure 7a-c,f,g). Thus, the 
failure to observe calcium oscillations following ligand activation in IFN-y 
treated cells is not a feature of their lack of the appropriate cellular machinery 
as, given the relevant trigger (FcyRIIa cross-linking), these cells are able to 
establish calcium oscillations. These data indicate that aggregation of FcyRIIa 
initiates calcium oscillations in U937 cells regardless of their differentiation 
status (Figures 7c,f,g). The finding that specific aggregation of FcyRI in the two 
differentiation states gives different calcium responses completely matches 
the sw itch observed differentiation-dependent sw itch in lipid signalling
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pathw ays. Thus, the d ifferentiation-dependent sw itch in the activated 
phospholipid pathw ay dictates the nature of the calcium transients.
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Legend for figure 2.7
Calcium responses in IFN-y and dbcAMP treated cells following Fey receptor 
aggregation by ligand or cross-linking of specific Fey receptors using 
monoclonal antibodies.
a-f. Changes in Fluo3 fluorescence as an indication of cytosolic calcium - 
representative traces from three cells (from different experiments) in either 
(a-c) dbcAM P-differentiated cells or (d-f) IFN-y -prim ed  cells, (a, d) Fey 
receptor aggregation triggered by cross-linking monomeric hum an IgG; (b, e) 
cross-linking of FcyRI using specific monoclonal antibodies 22 and 32; (c, f) 
cross-linking of FcyRIIa using specific m onoclonal antibody 2el on cells 
preloaded w ith hum an IgG4 to block the binding site of FcyRI (detailed in 
Materials and methods).
g. Statistical analysis of the proportion of cells responding in with calcium 
oscillations or a single spike of calcium under the conditions shown in (a-f). 
Each condition -  cross-linking using IgG (norm), anti-FcyRI antibodies (FcyRI) 
or anti-FcyRIIa antibodies (FcyRIIa) w as exam ined in four separa te  
experiments. The mean value and standard error is given for each condition 
- at least 2 0 0  individual cells were analysed.
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Figure 2.7 The switch in phospholipid signalling pathway is matched by a 
change in the nature of the calcium response.
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2.4.2.4 Changes in FcyRIIa and y  chain expression upon IFN-y and dbcAMP
treatment are identical
A ctivation of both phospholip id  pathw ays depended  on the in itial 
activation of tyrosine kinases: pretreatm ent of cells w ith the tyrosine kinase 
inhibitor genistein (0.37 mM) completely abolished the rise in PtdCho-PLD 
and sphingosine kinase following FcyRI aggregation in IFN-y treated cells 
(data not shown). To activate tyrosine kinases, FcyRI m ust recru it an 
accessory molecule as this receptor contains no IT AM in its cytoplasmic tail. 
We therefore investigated whether IFN-y and dbcAMP differentially induced 
the y chain and FcyRIIa, the two IT AM bearing molecules able to interact w ith 
FcyRI. Consistent w ith  previous reports [7], IFN-y resulted in a transient 
fifteen fold increase of FcyRI mRNA levels over basal levels (Figure 8 a). This 
transient rise in mRNA m arkedly precedes the increase in surface expression 
of FcyRI [7]. IFN-y also increases both surface FcyRIIa [12] and y chain protein 
[14] in U937 cells. Consistent w ith these previous observations for protein 
expression, IFN-y resulted in a transient increase of mRNA levels of both 
FcyRIIa and y chain (Figure 8 a). However, both these rises were much smaller 
(two-fold over basal levels) than that observed for FcyRI mRNA, although the 
time course of the response for all three transcripts was identical.
Treatm ent of cells w ith dbcAMP resulted in a steady decrease in the am ount 
of FcyRI mRNA such that after 48 hours levels had fallen to 50% starting 
levels (Figure 8b); however, as the protein on the cell surface appears to be 
stable, surface FcyRI remains readily detectable on these cells [12]. In contrast, 
levels of FcyRIIa mRNA rose steadily over time. These results of differential 
control of FcyRI and FcyRIIa expression are consistent w ith  the know n 
relative pattern of surface expression of the two receptors [12]. Surprisingly, y 
chain mRNA levels also rose during treatm ent of the cells w ith dbcAMP in 
an identical m anner to that observed for FcyRIIa (Figure 8b). Thus, the
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mRNAs encoding both ITAM-containing molecules behave in an identical 
fashion following cytokine treatm ent and differentiation. Regulation of the 
molecular switch in FcyRI signal transduction m ust be more complex than a 
mere change in the relative stoichiom etry of FcyRI to either of its accesory 
m olecules.
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Figure 2.8 Changes in FcyRIIa and y chain expression upon IFN-y and
dbcAMP treatment are identical.
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Levels of mRNA for FcyRI, FcyRIIa and the y chain.
a. U937 cells were treated with IFN-y and cells harvested at 0, 1, 3, 6, 12 and 24 
hours. Lqual amounts of total RNA from each time point were 
electrophoresed through a formaldehyde 1% agarose gel. After transfer on to 
Nylon membranes, specific transcripts for FcyRI, FcyRIIa and y chain were 
visualised usingthe relevant ^^P-Iabelled probes.
b. U 937 cells were treated with dbcAMP and cells harvested at 0, 1, 3, 6, 12 
and 48 hours. Total RNA extracted from these cells was handled as in (a). 
The positions of 28S and 18S RNAs are indicated.
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2.4,2.5 Mechanism of the molecular switch in FcyRI mediated signalling
following differentiation
The role of the two accessory molecules (FcyRIIa arid the y chain) in signal 
transduction  by FcyRI was next investigated by blocking the induction of 
expression using antisense oligonucleotides. In IFN-y treated cells, loading 
cells w ith antisense y chain completely abolished the increase in PtdCho-PLD 
activity observed following specific aggregation of FcyRI w ith m onoclonal 
an tibodies (Figure 9a). L oading cells w ith  an equ iva len t an tisense 
oligonucleotide to FcyRIIa had no influence at all on F cy R I-stim u la ted  
activation of PtdCho-PLD (Figure 9a). In IFN-y treated cells, we have shown 
that specific aggregation of FcyRIIa activates PtdlnsPz-PLC w ith generation of 
InsP (Figure 5a). Therefore, to check the specificity of these antisense 
oligonucleotides, their ability to interfere w ith FcyRIIa-mediated activation of 
PtdlnsPz-PLC was iiavestigated. The norm al increase in inositol phosphstes 
observed after specific aggregation of FcyRIIa was blocked in cells loaded with 
the oligonucleotide antisense to FcyRIIa (Figure 9b). The oligonucleotide 
antisense to the y chain had no influence on the ability of FcyRIIa to activate 
P tdInsP2"PLC (Figure 9b). These data therefore, definitively dem onstrate that 
FcyRI is coupled to PtdCho-PLD activation through the y chain in IFN-y 
-treated cells and that FcyRIIa plays no role in signal transduction for the high 
affinity receptor in these cytokine prim ed cells. In cells differentiated to 
m acrophage type using dbcAMP, FcyRI switches the nature of the activated 
intracellular signalling patw ay by switching the accessory molecule used for 
signal transduction. Thus, loading differentiated cells w ith antisense FcyRIIa 
completely abolished the accumulation of InsPs observed after aggregation of 
either FcyRIIa or FcyRI (Figure 9c). In contrast to the results in IFN-y treated 
cells, loading these differentiated cells w ith antisense y chain had no effect on 
FcyRI-m ediated signalling (Figure 9c). These data therefore, definitively
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dem onstrate that following differentiation FcyRI recruits FcyRIIa for signal 
transduction.
The antisense oligonucleotides act as reciprocal internal controls for each 
other as neither antisense oligonucleotide influenced the receptor activation 
of the alternative pathw ay (Figure 9a-c). Moreover, surface expression of total 
im m unoreactive Fc^RII was reduced by some 30% in cells treated w ith the 
oligonucleotide antisense to FcyRIIa (data not shown). As m onoclonal 
antibodies to FcyRII are unable to distinquish  between, the six potential 
isoform s of FcyRII, this observation  likely rep resen ts a considerable 
underestim ate  of the specific effect of the antisense oligonucleotide on 
FcyRIIa, the only IT AM bearing form of FcyRII. Finally, for both pathw ays, a 
standard  "jumbled" antisense control oligonucleotide was also assessed for 
nonspecific effects. Loading cells w ith this oligonucleotide did not influence 
the activation of either pathw ay (Figures 9d,e). Taken together, these data 
clearly dem onstrate that the differentiation-dependent sw itch in signalling 
pa thw ays activated  by aggregated  FcyRI results from a change in its 
recruitm ent of accessory molecules.
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Legend for figure 2.9
Loading of cells w ith antisense oligonucleotides dem onstrates that FcyRI is 
coupled to PtdCho-PLD through the recruitm ent of the y chain in IFN-y 
treated cells bu t is coupled to PtdInsP2-PLC through FcyRIIa in dbcAMP 
differentiated cells.
a,b U937 cells were loaded either w ith antisense y chain or antisense FcyRIIa 
prior to treatm ent w ith IFN-y overnight. Specific aggregation of FcyRI or 
FcyRIIa w as achieved using m onoclonal antibodies (see M aterials and 
m ethods for more details). PtdCho-PLD activity (a) and the accumulation of 
inositol phosphates 2 0  m in after receptor aggregation (b) were m easured.. 
The data  show n are the m ean ±_ s ta n d a rd  dev ia tio n  of trip lica te  
m easurem ents.
c. U937 cells were loaded with antisense y chain or antisense FcyRIIa prior to 
treatm ent for for 48 hours w ith dbcAMP (1 mM). The total accumulation of 
inosito l phosphates w as m easured  in cells 2 0  m in after the specific 
aggregation of FcyRI or FcyRIIa using monoclonal antibodies. The data shown 
are the mean + the standard deviation of triplicate measurements.
d. IFN-y prim ed U937 cells were loaded w ith a jum bled antisense control 
oligonucleotide and the effect on FcyRI coupling to PtdCho-PLD was assessed.
e. dbcAM P-differentiated U937 cells were loaded w ith the jum bled antisense 
control oligonucleotide and the effect on FcyRIIa coupling to PtdInsP2-PLC 
was assessed.
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Figure 2.9 Mechanism of the molecular switch in FcyRI mediated signalling
following differentiation.
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2.4.2.6 Summary for section 2
The notable findings from this study are, firstly, that the two Fey receptors 
(FcyRI and FcyRIIa) initiate fundam entally different phospholipid signalling 
pathw ays in IFN-y treated cells. Both pathw ays are present, intact and 
functional in IFN-y treated cells but the two Fey receptors are differentially 
and exclusively coupled. The second finding is that the phospholip id  
pa thw ay  activated by specific cross-linking of FcyRI in m onocytic and 
macrophage-like cells exactly mimics the differentiation-dependent switch in 
intracellular signalling observed for immune complex activation and results 
from a switch in the ability of this receptor to recruit different IT AM-bearing 
accessory molecules following differentiation.
2.5 CONCLUSIONS
We have shown that there is a fundam ental and absolute switch in the 
na tu re  of the in tracellu lar signalling  pathw ay  activated  by im m une 
complexes w hen a monocytic cell line differentiates to a more m acrophage­
like cell. Thus, in cells prim ed w ith IFN-y, the release of of intracellular 
calcium from stores is InsPg independent and is m ediated by the sequential 
activation of PtdCho-PLD and sphingosine kinase. This new ly identified 
signalling pathw ay presum ably involves a sphingoid base acting on the 
recently cloned SCaMPER receptor [34] in the endoplasmic reticulum to effect 
the release of calcium from stores [29]. In dbcAMP-differentiated cells, the 
same im m une complex challenge resulted in the activation of only PtdlnsP^- 
PLC; activation of the novel pathw ay involving PtdCho-PLD and sphingosine 
kinase could not be detected.
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The ability of FcyRI to switch signalling pathw ays reflects the fact that, unlike 
FcyRIIa, the cytoplasmic tail of FcyRI contains no known signalling or IT AM 
m otif bu t m ust recruit one of two accessory molecules. Therefore, unlike 
FcyRIIa, which through its intrinsic IT AM [33] demonstrates obligate coupling 
to PtdInsP2-PhC, FcyRI is able to switch recruitment between the y chain and 
FcyRIIa in a differentiation-dependent fashion and thereby couple to different 
in tracellu lar signalling pathw ays. In dbcAM P-differentiated cells, FcyRI 
recruits FcyRIIa whereas, in cytokine prim ed cells, FcyRI uses the y chain. The 
control of this switch does not rely on regulationof levels of y chain but rather 
appears to depend on the relative levels of FcyRI and FcyRIIa. The activation 
of different signalling pathways probably accounts for the different responses 
of m yeloid cells to challenge w ith im m une complexes. As m any im m une 
receptors have separate polypeptide chains for ligand binding and signal 
tran sd u c tio n  (allow ing a sim ilar sw itch in signalling  pathw ays) the 
mechanism defined here is likely to be widely used.
Implications for myeloid function  of the differential signalling by Fc 
Receptors
The finding that differentiation to a more m acrophage cell type causes 
U937 cells to switch the signalling pathw ays activated by Fey receptors such 
that pro longed calcium signals are generated agrees w ith  our previous 
finding that dbcAMP upregulates capacitative calcium entry [35, 36], which is 
required for refilling of the calcium stores. It is tem pting to speculate that the 
differentiation process prim es cells to produce a pro longed response to 
im m une complex activation by switching the nature of the second messenger 
to InsPs and inducing capacitative calcium entry to allow store filling, thereby 
m aintaining the calcium signal. Another likely im m ediate consequence of 
this sw itch in phospholipase  activation and calcium  signalling is the
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differential activation of protein kinase C isoforms, which are involved in a 
num ber of myeloid functions such as phagocytosis and endocytosis [37]. Such 
differential protein kinase C signalling may explain the finding that FcyRI- 
triggered phagocytosis can be inhibited by buffering cytoplasmic calcium [38]. 
Thus, this fundam ental and absolute molecular switch in the activation of 
phospholip id  signalling pathw ays following differentiation of cells to a 
macrophage cell type provides a method of precisely controlling the nature of 
the cellular response to immune complexes.
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CHAPTER 3
Fcyri-c o u p l i n g  t o  p h o s p h o l i p a s e  d  i n i t i a t e s  SPHIN GOSINE  
KINASE M EDIATED CALCIUM M OBILISATION AND VESICULAR  
TRAFFICKING
3.1 ABSTRACT
Aggregation of receptors specific for the constant region of im m unoglobulin 
G activates a repertoire of monocyte responses that can lead ultim ately to 
targeted  cell killing via antibody directed cellular cytotoxicity. The high 
affinity  receptor, FcyRI, contains no recognised signalling m otif in its 
cytoplasm ic tail bu t rather utilises the y chain of FcgRI as an accessory 
molecule to recruit tyrosine kinases for signal transduction. We show here 
that, in a hum an  m onocytic cell line p rim ed w ith  interferon-y , FcyRI 
mobilises intracellular calcium stores using a novel pathw ay that involves 
tyrosine kinase coupling to phospholipase D and resu ltan t dow nstream  
activa tion  of sph ingosine  kinase. M oreover, FcyRI is not coupled to 
phospholipase  C and hence, calcium  release from in tracellu lar stores 
occurred in the absence of any m easurable rise in inositol trisphosphate. 
Finally, as this novel activation pathw ay is also shown to be responsible for 
m ediating the vesicular trafficking of internalised im m une complexes for 
degradation, it is likely to play a key role in controlling intracellular events 
triggered by FcyRI.
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3.2 INTRODUCTION
The m acrophage-specific receptor (FcyRI) for the constant region (Fc) of 
im m unoglobulin G (IgG) plays a central role in the clearance of im m une 
complexes (1,2). FcyRI belongs to a family of receptors for IgG which are 
distinquished by the affinity for ligand. Whilst FcyRI is a high affinity IgG 
receptor, FcyRII and FcyRIII are both low affinity IgG receptors (reviewed in 
refs 1 and 2). A ggregation of FcyRI activates m acrophages to undergo a 
repertoire of responses that can ultim ately lead to cell killing through the 
process of antibody directed cellular cytotoxicity (ADCC); a critically im portant 
feature in the body's defence against virus infected cells and in cancer 
surveillance (3,4). Im m une complex aggregation of FcyRI initiates signal 
transduction events which include protein tyrosine phosphorylation (5,6) and 
tyrosine kinase dependent calcium transients (7,8). However, the cDNA for 
FcyRI predicts an integral type I glycoprotein in which, unlike FcyRIIa, the 
cytoplasmic tail contains no recognised signalling motifs (9). FcyRI has been 
show n to associate non-covalently w ith the signal transducing y chain (1 0 ) 
which contains an im m unoreceptor tyrosine activation motif (ITAM) (11,12) 
in its cytoplasmic tail and this association is thought to allow aggregated FcyRI 
to recru it and activate soluble tyrosine kinases (13). The y chain was 
originally identified in m ast cells as a component of the high affinity IgE 
receptor, FceRI, but has subsequently been found in m acrophages in the 
absence of the a chain of FceRI (14). Thus, although expressed in different cell 
types, the ligand recognition subunits (a chains) of FcyRI and FceRI are able to 
use the same signal transducing molecule. Recently, FceRI has been shown to 
mobilise calcium transients in a mast cell line through the activation of a 
novel pathw ay involving sphingosine kinase (15). How ever, the precise
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details of the signalling pathw ay and its relationship to tyrosine kinase 
activation are as yet unclear.
In this study, we dem onstrate that FcyRI mobilises calcium from intracellular 
stores by activating sphingosine kinase in the absence of phospholipase C 
activation and resultant generation of Inositol 1,4,5 triphosphate (InsPg) . We 
also show  that FcyRI-stim ulated activa tion  of sph ingosine  k inase  is 
dow nstream  of phospholipase D activation and both  these enzym es are 
dependen t on tyrosine kinase activation. M oreover, activation of this 
pa thw ay  is necessary and sufficient to account for intracellu lar calcium  
m obilisation after FcyRI aggregation in cytokine prim ed U937 cells and for 
efficient vesicu lar traffick ing  of in ternalised  im m une com plexes for 
degradation.
I l l
3.3 MATERIALS AND METHODS
3.3.1 Receptor aggregation
U937 cells, a hum an  m onocyte cell line (16), treated  w ith  200ng /m l 
in te rfe ron -y  for 18 hours were used for all experiments (8 , 17). For the 
biochemical assays,approximately 3 x 10^ cells were harvested and incubated 
w ith  IpM  hum an  m onom eric IgG (Serotec) to occupy surface FcyRI. 
U nbound IgG was removed by dilution and centrifugation of the cells. The 
cells were resuspended in ice cold Hepes buffered saline (HBS) and cross- 
linking antibody (goat anti-hum an IgG 1:100 dilution) was added. The cells 
were then w arm ed to 37°C and harvested at specified times for biochemical 
assay. Where the low affinity receptor was specifically aggregated using anti- 
FcyRIIa, the cells w ere loaded w ith the m onoclonal antibody 2el (Ipg) 
(Serotec) in the presence of saturating concentrations (3|iM) of hum an IgG4 
(to block binding of the Fc portion of 2el to FcyRI). After removal of excess 
antibody, anti-FcyRIIa was aggregated by addition of goat anti-mouse IgG F(ab) 
(1 :100  dilution).
3.3.2 Measurement of sphingosine kinase
Sphingosine kinase was assayed as described in reference 18. Briefly, reactions 
were term inated at the times specified in the figures by addition of ice-cold 
phosphate  buffered saline (PBS). After centrifugation, the cells w ere 
resuspended  in ice-cold O.IM phosphate buffer (pH7.4) containing 20% 
glycerol, ImM  mercaptoethanol, 1 mM EDTA, phosphatase inhibitors (20mM 
ZnClz, Im M  sodium  orthovanadate and 15mM sodium  fluoride), protease 
inhibitors (lO pg/m l leupeptin , lO pg/m l aprotinin and Im M  PMSF) and 
0.5mM 4-deoxypyridoxine. Cells were disrupted  by freeze thaw ing and
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centrifuged at 105,000g for 90 m in at 4°C. Supernatants were assayed for 
sphingosine kinase activity using sphingosine (Sigma) and [y^^PjATP (2pCi, 
5mM) as specified in Olivera et al, 1994 (18). After incubation, products were 
separated by TLC on silica gel G60 using chloroform:methanol:acetic acid: 
w ater (90:90:15:6) and visualised by autoradiography. The radioactive spots 
corresponding to sphingosine phosphate were scraped and counted in a 
scintillation counter.
3.3.3 Measurement of sphingosine -1-phosphate
Sphingosine-l-phosphate  concentrations w ere m easured  as described in 
reference 19. Briefly, cells were preincubated overnight (15h) in  m edia 
contain ing [^HJserine (20pC i/m l) to label cellular sphingolipids and free 
sphingosine pools. Following labelling, the cells were washed in ice cold RPMI 
1640/lOmM  HEPES/0.1% BSA (RHB m edium ), and resuspended in ice cold 
RHB m edium  containing O.lmM L-canaline and the pyridoxal phosphate  
analog 4-deoxypyridoxine (0.5mM) to inhibit the py ridoxal-dependen t 
sphingosine-l-phosphate lyase. Cells were then stimulated by the addition of 
crosslinking antibody and w arm ing to 37°C, the reactions term inated  at 
specified times. Cells were harvested by centrifugation, the lipid were extracted 
and analysed by TLC on silica gel G60 using chloroform :m ethanol:acetic 
acid:water (90:90:15:6). Standard sphingosine-l-phosphate was applied w ith the 
sam ples and the lip ids w ere visualised using iodine vapours. Bands 
corresponding to sphingosine-l-phosphate were excised from the plate and 
counted by liquid scintillation spectrometry. Results were calculated as per cent 
of the total radioactivity incorporated in the lipids. Data presented are the 
m ean ±  standard deviation of triplicate measurements and the results show n 
are representative of three different experiments.
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3.3.4 Measurement of inositol phosphate
Inositol phosphates were assayed essentially as described in reference 20. 
Briefly, U937 cells were labelled w ith myo-pH]-inositol (IpCi/lO ^ cells) for 16 
hours at 37°C. The cells were washed three times and resuspended (at 1-3x107 
cells/m l) in RPMI 1640/lOmM HEPES/0.1% BSA (RHB) medium, pH7.4 at 4°C. 
Following stim ulation, the cells were harvested, resuspended in lOOpl HBS, 
transferred  to glass triden t vials and extracted by add ition  of 0.94ml 
chloroform :m ethanol (1:2) on ice for 10 min. A Bligh-Dyer phase separation 
was achieved by addition of 0.31ml chloroform and 0.31ml water, vortexing 
and centrifugation at 270g for 5 min. Levels of [^H]inositol trisphosphate (InsP^) 
or total [^H]inositol phosphates (reaction mixture containing lOmM LiCl) were 
determ ined by liquid scintillation counting of fractions eluted following Dowex 
(formate form) ion-exchange chrom atography of aliquots of the aqueous phase. 
Results were calculated as per cent of the total radioactivity incorporated in the 
lipids. Data presented are the m ean ±. standard  deviation  of trip licate  
m easurem ents and the results show n are representative of three different 
experim ents.
3.3.5 Measurement of DAG generation
Mass DAG was m easured as described in reference 21. The lower organic 
phase of Bligh-Dyer extractions w ere dried  in vacuo and the lipids 
so lub ilised  in a T riton  X -lO O /P hosphatidylserine m ixture: Briefly, 
phosphatidylserine (30pl; supplied as 25mM stock from Lipid Products) is 
dried under nitrogen and then probe sonicated in 2.5ml of lOmM Imidazole 
buffer, p H 6 .6  containing 0.6% (w /v ) Triton X-lOO, until the solution is 
optically clear. Aliquots (50|l i 1) were added to the lipid samples which were 
then sonicated in a bath for 30 m inutes. Once sonicated, 20jxl of 250mM 
Imidazole buffer pH 6 .6  containing 250mM NaCl, 62.5mM MgCl2, 5mM EGTA
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and lOjLil of freshly prepared lOOmM DTT was added to the solubilised lipid.
E coli diacylglycerol kinase (Calbiochem) was added to a final concentration 
of 50m U nit/m l and the reaction started by addition of lOgl of 5mM ATP 
containing IpCi of p2p]-y-ATP m ade up in lOOmM Im idazole p H 6 .6 ; this 
results in a final ATP concentration of 0.5mM in a final reaction volum e of 
lOOjil. The tubes are incubated at 30^0 for 30 minutes. The reaction is stopped 
by add ition  of 1ml of chloroform :m ethanol: HCl (150:300:2). After 10 
m inutes, 300gl of chloroform and 400pl of H 2O are added. The tubes are 
vortexed and centrifuged at 270g for 5 m in to prom ote phase splitting and 
w ashed once w ith 1ml of a synthetic upper phase. The samples were then 
dried in vacuo, solubilised in 40pi of chloroform-.methanol (19:1) and 20pl 
spotted onto silica TLC plate (Merck, 5714, 5x20cm 6OF254). The plates were 
developed in chloroform :m ethanol:acetic acid (38:9:4.5) and radiolabelled 
bands were located by autoradiography or phosphorimaging. The PtdOH band 
(relative to standards) was scraped into scintillation vials, scintillant added 
and the associated radioactivity determined by liquid scintillation counting.
3.3.6 Measurement of Phospholipase D Activity
PLD activity was m easured by the transphosphatidylation assay (21). Briefly, 
U937 cells, were labelled (10^ cells/m l) with pH jpalm itic acid (5pCi/m l) in 
RPMI 1640 m edium  containing 5% (v/v) foetal calf serum for 16h. Following 
labelling, the cells were washed in ice cold RPMI 1640/lOmM HEPES/0.1% BSA 
(RHB m edium ), resuspended at 2x10^ cells/m l and incubated at 37°C for 15 
mins in RHB m edium  containing butan-l-ol (0.3% final). Specific Fc receptors 
were crosslinked as described above and, after the times indicated, cells were 
extracted by Bligh-Dyer phase separation. The lower organic phase was 
rem oved, dried  dow n under vacuum  (Jouan RC1022), and the sam ples 
redissolved in 25pl chloroform : m ethanol (19:1 v /v ) , containing 40pg
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unlabelled phosphatidylbutanol (Lipid Products, South Nutfield, Surrey, U.K.) 
as standard, and applied to pre-run, heat activated TLC plates (20 x 20 cm. Silica 
gel 150A grooved plates, Whatman). The plates were developed in the organic 
phase of the solvent, ethyl acetate: 2,2,4 trimethylpentane: acetic acid: w ater 
(11:5:2:10) for ap p ro x im ate ly  90 m ins and  the p o s itio n  of the  
phosphatidy lbu tanol p roduct detected using iodine vapour. [^H ]P tdB u t- 
containing silica indicated by the phosphatidylbutanol standard  was then 
scraped into scintillation fluid and counted. Results were calculated as per cent 
of the total radioactivity incorporated in the lipids. Data presented are the 
m ean ±  standard deviation of triplicate measurements and the results shown 
are representative of three different experiments.
3.3.7 Measurement of tyrosine phosphorylation by Western blot
U937 cells were loaded with hum an IgG and cross-linked as described earlier. 
After washing in PBS the cells were lysed w ith ice-cold RIPA lysis buffer 
containing Im M  PMSF, lOjag/ml CLAP (lOjag/ml each of chym ostatin, 
leupeptin, antipain and pepstatin), Im M  sodium  orthophosphate and Im M  
sodium  fluoride, for 30 min. Cellular debris was removed by centrifugation at
13,000 rpm  for 15 min and the cell lysates were incubated w ith an agarose- 
conjugated anti-phosphotyrosine monoclonal antibody (clone 4G 10; Upstate 
Biotechnology) at 4“C overnight. Phosphotyrosine pro teins w ere then  
harvested by centrifugation of the agarose beads and were then dissociated 
from the beads by boiling in sample buffer (22) containing 50 mM DTT for 15 
min. Sam ples w ere run  in a 10 % SDS-polyacrylamide gel (23). After 
electrophoresis, the proteins were transferred to a nitrocellulose m em brane 
(0.2pM pore size) as described (24). The presence of tyrosine-phosphorylated 
proteins was then detected by W estern blotting w ith a m onclonal anti-
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phosphotyrosine antibody (clone 4G10; Upstate Biotechnology). W esterns 
were developed using the ECL system (Amersham).
3.3.8 Measurement of cytosolic calcium
Cytosolic calcium was m easured in cell populations at 37°C using a Cairn 
Research Spectrophotometer as described previously (8 ). Cells were loaded 
w ith Fura2 and hum an monomeric IgG in HEPES buffered saline (HBS) 
supplem ented w ith Im M  Ca^+ to prevent depletion of calcium stores. After 
dilution and centrifugation to remove excess dye and antibody, the cells were 
resuspended in a small volume of HBS, Im M  Ca^+ to give a final density of 
10^ cells/lOOjLil. From this, cells were added to stirred cuvettes containing 
1.4ml of nom inally Ca^+ free HBS (at 37°C) in a Cairn Spectrophotom eter 
system (Cairn Research Ltd). Excitation wavelengths of 340, 360 and 380nm 
were provided by a filter wheel rotating at 35 Hz in the light path. Emitted 
light was filtered by a 485nm long pass filter and samples averaged to give a 
data point every 500ms. The backgound corrected 340/380 ratio was calibrated 
using the m ethod of Grynkiewicz et al 1985 (25). Following each experiment, 
cells were lysed by the addition of 50]iM digitonin in the presence of external 
2mM Ca^+ to give an Rmax value. Rmin was subsequently determ ined by the 
addition of 20mM EGTA (pH7.4) in the presence of equim olar concentration 
of Tris base.
3.3.9 Measurement of endocytosis and rate of trafficking for degradation
IFN-y treated cells were harvested and washed in phosphate buffered saline 
(PBS), 1% BSA. The cells were then loaded with ^'^^l-labelled IgG as described 
in reference 17. After rem oval of nonbound radiolabel by dilu tion and 
centrifugation, cross-linking antibody was added and the cells warm ed to 37°C 
for given times.
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E ndocytosis: The rate of endocytosis was assessed by m easuring the rate of 
internalisation of radiolabelled surface imm une complexes. At time zero, 
triplicate aliquots of cells were harvested into ice cold PBS (pH7.4) and this 
was counted in a Packard gamma counter to provide a m easure of the total 
counts bound to the cell surface. To measure the proportion of radiolabelled 
im m une complexes internalised after incubation at 37°C, any surface bound 
radiolabelled imm une complexes can be stripped from the cell by incubating 
the cells in ice-cold acidified PBS (pH2.0) (17). Radiolabelled im m une 
complexes that have been internalised rem ain trapped inside the cell and 
cannot be released by this acid w ash. Thus, to assess the rate of 
internalisation, aliquots of cells were transferred at given times into ice-cold 
acidified PBS (pH2.0) for 5 m inutes to strip off cell surface radiolabelled 
im m une complexes (17), the cells were then centrifuged and the pellets 
counted in a Packard gamm a counter to yield the counts that had  been 
internalised or cell associated counts. The cell associated counts for each time 
point were then expressed as the percentage of total counts bound at time zero 
to provide a measure of the rate of internalisation of the immune complexes. 
D e g ra d a tio n : After w arm ing the cells to 37“C for long time intervals, the 
proportion  of cell associated counts was observed to fall. To determ ine 
w hether this reduction in cell associated counts represented degradation of 
the im m une complexes, the supernatant following the cell incubation was 
examined for the presence of trichloroacetic acid soluble radiolabel indicating 
that the radiolabelled IgG had been degraded. Thus, cells were also harvested 
at the same time points to m easure the rate of degradation of the internalised 
counts. Cells were centrifuged, the supernatants harvested and trichloroacetic 
acid (TCA) was then added to these supernatants. After incubation on ice for 
60 mins, the samples were centrifuged at 12 ,0 0 0 g at 4°C and the supernatants 
w ere counted to provide a m easure of the TCA soluble counts in the
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supernatant. The results w ere expressed as percentage of the initial cell 
associated counts at time zero.
The resu lts show n are the m ean ±_ s tan d ard  dev ia tion  of trip lica te  
m easurem ents and are representative of three different experiments.
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3.4 RESULTS
3.4.1 Aggregation of FcyRI activates sphingosine kinase in a tyrosine kinase 
dependent manner
In interferon-y (IFNy) prim ed U937 cells, aggregation of FcyRI with surface 
bound  im m une complexes results in calcium transients in the form of a 
single spike (reference 8 and Figure lA). The FcyRI-associated accessory 
transducing molecule, y chain, has recently been reported to mobilise calcium 
via activation of sphingosine kinase w hen coupled to the high affinity IgE 
receptor, FceRI (15). Thus, to compare the nature of this FcyR I-calcium  
response to that of FceRI, the effect of D-L-f/zreo-dihydrosphingosine (DHS) 
on the release of calcium  from  in tracellu lar stores w as determ ined . 
P retreatm ent of cells w ith 25pM DHS completely abolished the FcyRI- 
m ediated rise in cytosolic calcium indicating that intracellular calcium stores 
are mobilised in these cells in a similar fashion to that observed for FceRI in 
m ast cells (15). The calcium stores were intact in cells treated w ith DHS as 
subsequent addition of thapsigargin (250nM) resulted in a prom pt increase in 
cytosolic calcium; thereby, dem onstrating that the failure to observe a rise in 
calcium following aggregation of FcyRI in cells pre-treated w ith DHS was not 
secondary to depletion of intracellular calcium stores.
As DHS acts as a competitive inhibitor of sphingosine kinase, the activity 
of this enzyme after FcyRI aggregation was next assessed. Aggregation of 
FcyRI stim ulated a prom pt increase in sphingosine kinase activity which was 
detectable w ithin 30secs (Figure IB). Sphingosine kinase activation by FcyRI 
aggregation in these cytokine prim ed cells was dependent on tyrosine kinase 
activation as treatm ent of the cells w ith genistein (0.37mM) com pletely 
abolished the response (Figure IB). Pretreatm ent w ith genistein at a lower 
concen tra tion  (O.lmM) also com pletely inh ib ited  FcyRI activation  of
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sphingosine kinase (Figure 1C) although concentrations below this only 
resulted in partial inhibition (Figure 1C).
In parallel w ith the activation of sphingosine kinase, FcyRI aggregation 
resu lted  in a p rom pt increase in the concentration of sph ingosine-l- 
phosphate in these cells (Figure ID). The concentration of sphingosine-l- 
phosphate peaked 30 seconds after receptor aggregation and, although levels 
fell gradually  thereafter, concentrations rem ained elevated above control 
values 5 mins after receptor aggregation. Pretreatment of cells w ith genistein 
(0.37mM) completely abolished the FcyRI-mediated increase in sphingosine-l- 
phosphate generation.
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Legend for figure 3.1
A. Cytosolic calcium concentrations in IFN-y treated U937 cells following 
aggregation of FcyRI. The arrow indicates the addition of either 25jLiM DHS 
(dashed line) or vehicle (solid line). Crosslinking antibody (XL) was added to 
the cuvette at 300 secs and thapsigargin at 475 secs. Thapsigargin (250nM) was 
added to assess the viability of the stores. Typical trace from 5 separate 
experim ents.
B. Activation of sphingosine kinase by FcyRI aggregation and the effect of 
tyrosine kinase inhibition. IgC-loaded FcyRI was aggregated by addition of 
crosslinking antibody (crosslink XL) and sphingosine kinase assayed in cell 
extracts at specified time points after aggregation. Results were compared to 
non-crosslinked controls (no crosslink control) and to cells pre-treated w ith 
genistein (0.37mM) for 30 mins prior to the addition of crosslinking antibody 
to inactivate tyrosine kinases (XL + genistein).
Results show n are the mean + S.D. for triplicate m easurem ents at each time 
point. The results shown are typical from three separate experiments
C. Effect of varying concentrations of genistein on sphingosine kinase 
activation by FcyRI aggregation. Sphingosine kinase activity was m easured in 
cells 30 secs after aggregating FcyRI in cells pre-treated for 30 mins w ith 
varying concentrations of genistein (0.01, 0.03, 0.1, 0.3, 1.0 mM) and compared 
to untreated control cells.
Results show n are the m ean ±  S.D. for triplicate m easurem ents at each 
concentration. The results shown are typical from three separate experiments
D. Increase in sphingosine-l-phosphate concentrations following FcyRI 
aggregation and effect of tyrosine kinse inhibition. Sphingosine-l-phosphate 
concentrations w ere m easured in cells following aggregation of FcyRI 
(crosslink XL) and com pared to non-crosslinked control cells (no crosslink 
control) and to cells pretreated w ith genistein (0.37mM) for 30 mins prior to 
addition of crosslinking antibody (XL + genistein).
Results shown are the mean + S.D. for triplicate measurements at each time 
point.The results shown are typical from three separate experiments
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Figure 3.1 M obilisation of intracellular calcium stores by FcyRI associated 
with activation of sphingosine kinase and appearance of sphingosine-l- 
phosphate.
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3.4.2 Aggregation of FcyRI activates phospholipase D and not phospholipase 
C in a tyrosine kinase dependent manner
As im m une complex aggregation of FcyRI has previously been reported to 
lead to tyrosine phosphorylation of phospholipase Cyl (5) w ith presum ed 
generation of InsPs and diacylglycerol (DAG), the role of this phospholipid 
signalling pathw ay in m ediating the cytosolic calcium response was also 
investigated. Surprisingly, no increase in InsPg could be detected (data not 
shown). As InsPs generation can be transient in nature, the accumulation of 
total inositol phosphates (InsPs) was m easured to ensure that any small 
transient InsPs signals did not go undetected. No accumulation of total InsPs 
over 20 m inutes could be detected in IFN-y prim ed U937 cells after 
aggregation of FcyRI (Figure 2A). PLC signalling was, however, functional in 
these cells as aggregation of a related immune receptor, the low affinity IgG 
recep to r (FcyRIIa), using  m onoclonal antibodies resu lted  in a easily 
m easurable accumulation of InsPg (data not shown) and total InsPs (Figure 
2A). Unlike FcyRI, the low affinity receptor possesses an integral, albeit 
unconventional ITAM in its cytoplasm ic tail: the tyrosine residues are 
separated by an unusually long intervening sequence (26). Taken together 
this data indicates that the high affinity receptor, FcyRI, mobilises calcium 
stores th rough  a novel pathw ay that, unlike the low affinity receptor 
(FcyRIIa), does not involve InsPg.
Interestingly, despite the lack of generation of InsPs over 20 mins, mass DAG 
concentrations were elevated following aggregation of FcyRI (Figure 2B). 
Thus, in an attem pt to delineate alternative lipid signalling pathw ays 
involved in m ediating the response to FcyRI, diacylglycerol (DAG) w as 
m easured in the presence of 0.3% butan-l-ol to block the generation of DAG 
derived from phosphatidic acid (PtdOH) resulting from phospholipase D
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(PLD) activation (21) . Under these conditions, the prim ary alcohol, bu tan-l- 
ol, traps the phosphatidyl-m oiety generated by PLD-mediated hydrolysis of 
phosphatidy lcholine  as phosphatidy lbu tano l (PtdBut): P tdB ut is no t a 
substra te  for the enzym e, phosphatid ic  acid phosphohydro lase, w hich 
converts PtdOH to DAG (21). FcyRI-coupled DAG was indeed shown to be 
derived from PtdOH generated by phospholipase D activation as pretreating 
cells w ith 0.3% butan-l-ol completely abolished the receptor stimulated rise in 
mass levels of DAG (Figure 2B).
Activation of phosphatidylcholine-specific phospholipase D (PtdCho-PLD) 
follow ing aggregation  of FcyRI w as dem onstra ted  by the defin itive 
tran sp h o sp h a tid y la tio n  assay (21). These experim en ts show ed th a t 
aggregation of Fey receptors in IFN-y prim ed, [^H jpalm itate-labelled cells 
stim ulated activation of PtdCho-PLD, as evidenced by substantial generation 
of [^H]PtdBut, in the presence of butan-l-ol, over a 30 min time course (Figure 
2C). H igher concentrations of butan-l-ol (1%) resulted in no further increase 
in m easured [^HjPtdBut compared to cells incubated w ith 0.3% butan-l-o l 
indicating that all the phosphatidyl m oiety generated by PtdCho-PLD is 
trapped at the lower concentration of prim ary alcohol. Lower concentrations 
of bu tan -l-o l (0.1%) resulted in less m easurable [^HjPtdBut. Thus, the 
optim al concentration of butan-l-ol to trap the phosphatidyl moiety is 0.3% 
(Figure 2D). The specificity of the measurement was confirmed using butan- 
2-ol which is unable to trap the phosphatidyl moiety generated by PtdCho- 
PLD. No [^H]PtdBut could be detected in cells preincubated w ith butan-2-ol 
even at 1% preincubation.
The increase in PtdCho-PLD activity following receptor aggregation was 
tyrosine kinase dependent as it was completely abolished by treating the cells
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w ith  genistein . M oreover, the concentration dependence of genistein- 
m ediated inhibition of PtdCho-PLD (Figure 2E) showed a similar profile to 
that obtained for sphingosine kinase coupling (Figure 1C).
Thus, FcyRI is coupled through tyrosine kinases to the activation of PtdCho- 
PLD and sphingosine kinase
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Legend for figure 3.2
A. Total InsPs accumulation over 20 mins following aggregation of Fey 
receptors. InsP accumulation over 20 mins was m easured following the 
aggregation of hum an monomeric IgG (FcRI XL) in IFN-y treated U937 cells in 
the presence of lithium  chloride (lOmM) and com pared to accum ulation 
following the specific aggregation of FcyRIIa (FcRIIa XL) in the cells treated in 
an identical way. Results show n are the m ean ±_ S.D. for triplicate 
m easurem ents at each time point. The results shown are typical from three 
separate experiments.
B. A ccum ulation of DAG over 20 m ins following aggregation of Fey 
receptors. DAG was m easured in cells 20mins after receptor crosslinking in 
cells preincubated w ith 0.3% butan-l-ol (XL + butan-l-ol) and compared to 
untreated cells (crosslink XL). The effect of butan-l-ol on basal levels was also 
m easured (Control and control + butan-l-ol). Results shown are the m ean ± 
S.D. for triplicate m easurements at each time point. The results shown are 
typical from three separate experiments.
C. Activation of PtdCho-PLD following aggregation of Fey receptors. The 
time course of accumulation of [^H]PtdBut was measured. The accumulation 
of pH ]PtdBut in cells following addition of crosslinking antibody (XL) was 
compared to cells loaded w ith monomeric IgG but the crosslinking antibody 
was om itted (No XL). Cells were harvested at 5, 10, 20 and 30 mins. Results 
shown are the mean + S.D. for triplicate measurements at each time point. 
The results shown are typical from three separate experiments.
D . Effect of varying concentrations of bu tan -l-o l and butan-2-ol on 
m easurem ent of pH]PtdBut. Cells were pre-incubated with either butan-l-ol 
(0.03, 0.2, 0.3 and 1.0%) or butan-2-ol over the same range and the total 
[3H]PtdBut. accumulation over 20 mins following addition of the crosslinking 
antibody was measured. Results shown are the mean ±  S.D. for triplicate 
m easurem ents at each time point.The results shown are typical from three 
separate experiments.
E. A ctivation of PtdCho-PLD follow ing aggregation of Fey re c e p to rs . 
Accumulation of [^FI]PtdBut was measured, in cells 20 mins after aggregation 
of FcyRI. The activity was compared to cells pretreated with genistein for 30 
mins and the effect of varying concentrations of genistein (0.01, 0.03, 0.1, 0.3,
1.0 mM) was measured. Results shown are the mean + S.D. for triplicate 
m easurements at each time point. The results shown are typical from three 
separate experiments.
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Figure 3.2 Phospholipase D and not phospholipase C is activated by 
aggregation of FcyRI in IFN-y primed cells.
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3.4.3 Activation of sphingosine kinase is doTvnstream of phospholipase D 
activation
To assess the relative rela tionsh ip  of activation of PtdCho-PLD  and  
sphingosine kinase, studies were initially undertaken to explore comparative 
kinetics of activation and use of selective inhibitors. However, comparison of 
the relative kinetics w as com plicated by the difference in the assay 
characteristics for m easuring sphingosine kinase and phospholipase D. Thus, 
sphingosine kinase is m easured as an in vitro kinetic kinase assay w hereas 
the assay for phospholipase  D relies on the accum ulation of a non- 
hydrolysable product. The difference in assay characteristics, therefore, 
p rec lu d ed  defin itive  early  com parative  tim e course analysis. The 
relationship  of phospholipase D and sphingosine kinase activation w as 
therefore addressed by examining selective inhibitors of the two enzymes.
To determ ine w hether sphingosine kinase activation w as upstream  or 
downstream  of phospholipase D, cells were pre-incubated with butan-l-ol or 
b u ta n -2 -o l  for 20 m ins before aggregation of FcyRI and the resu ltan t 
sphingosine kinase activity compared to that of control cells. Pretreating cells 
w ith butan-l-o l (0.3%) completely abolished the norm al sphingosine kinase 
response to FcyRI aggregation (Figure 3A). Consistent w ith these results, the 
rise in sphingosine-l-phosphate observed after aggregation of FcyRI was also 
blocked by pretreating cells w ith butan-l-ol (0.3%) (Figure 3B).
This data suggested that activation of sphingosine kinase is dependent on the 
activation of phospholipase D and generation of PtdOH. To assess this in 
detail, the effect on peak (30 secs after receptor aggregation) sphingosine 
kinase activity of preincubating cells w ith varying concentrations of bu tan-l- 
ol previously show n to influence phospholipase D was examined and these 
w ere com pared to the same concentrations of butan-2-ol w hich does not 
influence phospholipase D (Figure 2D). Peak activity of sphingosine kinase
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following FcyRI aggregation was abolished by incubating cells w ith either 
0.3% or 1.0% butan-l-ol but was completely unaffected by preincubation with 
butan-2-ol even at the highest concentration (Figure 3C). Incubation of cells 
w ith  a lower concentration of bu tan-l-o l (0.1%) partially  inhibited peak 
sphingosine kinase activity. Of interest, 0.1% butan-l-o l resulted in lower 
concen tra tions of [3FI]Ptd-But (Figure 2D) suggesting  tha t, at th is 
concentration, butan-l-ol is only able to trap a proportion of the phosphatidyl 
moiety generated by phospholipase D and that as a result some phosphatidic 
acid may be produced.
This data using bu tan-l-o l indicates that phospholipase D is upstream  of 
sphingosine kinase. Consistent w ith this observation, DHS, a competitive 
inhibitor of sphingosine kinase, had no effect whatsoever on phospholipase 
D activation at all concentrations examined even up to 100|iM (Figure 3D). 
The potency of DHS on sphingosine kinase was m easured directly; DHS at 
concentrations of 3 0 jliM  and above completely abolished the peak sphingosine 
kinase activity observed after FcyRI aggregation; lOpM DHS inhibited peak 
shingosine kinase activity by about 75% (Figure 3E).
Taken together, this data clearly indicates that activation of sphingosine 
kinase is secondary to activation of phospholipase D and generation of 
PtdOH.
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Legend for figure 3.3
A. Sphingosine kinase activity following FcyRI aggregation in cells treated 
w ith butan-l-ol. Cells were preincubated w ith 0.3% butan-l-ol and harvested 
at given times after aggregation of FcyRI for m easurem ent of sphingosine 
kinase activity. Results (XL + butan-l-ol) were com pared to control cells 
(crosslink XL). Results show n are the m ean +. S.D. for trip lica te  
m easurem ents at each time point. The results shown are typical from three 
separate experiments.
B. Sphingosine-l-phosphate  concentrations in cells follow ing receptor 
aggregation in cells treated with 0.3% butan-l-ol (XL+ butan-l-ol) compared to 
control untreated cells (crosslink XL). Results shown are the mean ±  S.D. for 
triplicate m easurem ents at each time point. The results show n are typical 
from three separate experiments.
C. Effect of varying concentrations of butan-l-o l or butan-2-ol on peak 
sphingosine kinase activity after FcyRI aggregation. Sphingosine kinase 
activity was m easured in cells 30 secs after aggregating FcyRI in cells p re­
treated for 30 mins w ith varying concentrations of butan-l-ol (0.03, 0.1, 0.3, 
1.0%) and com pared to cells incubated w ith butan-2-ol over the sam e 
concentration range. Results show n are the m ean ±_ S.D. for triplicate 
m easurem ents at each concentration. The results show n are typical from 
three separate experiments.
D. Effect of preincubating cells w ith varying concentrations of DHS on FcyRI- 
m ediated phospholipase D activation. PLD activity was m easured using the 
transphos-phatidy la tion  accum ulation assay (over 20 m inutes) in cells 
follow ing the aggregation of FcyRI in cells preincubated  w ith  vary ing  
concentrations of DHS (1, 3, 10, 30, lOOpM). Results shown are the m ean ±
S.D. for triplicate measurements at each concentration. The results shown are 
typical from three separate experiments.
E. Effect of preincubating cells with varying concentrations of DHS on FcyRI- 
m ediated sphingosine kinase activation. Sphingosine kinase activity was 
m easured in cells 30 secs after aggregating FcyRI in cells preincubated w ith 
varying concentrations of DHS (1, 3, 10, 30, lOOjiM). Results show n are the 
m ean ±  S.D. for triplicate m easurem ents at each concentration. The results 
shown are typical from three separate experiments.
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Figure 3.3 Sphingosine kinase activation is downstream of PtdCho-PLD 
activation.
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3.4.4 Tyrosine phosphorylation is triggered promptly by aggregation of FcyRI 
and is upstream of both phospholipase D and sphingosine kinase
Tyrosine phosphorylation events were m onitored in these cytokine prim ed 
U937 cells after aggregation of FcyRI by im m unoprecip ita ting  tyrosine 
phosphorylated  proteins w ith a monoclonal antibody to phosphotyrosine. 
Consistent w ith other reports (5-7, 27, 28), addition of cross-linking antibody 
to form surface im m une complexes resulted in the prom pt appearance of a 
large num ber of tyrosine phosphorylated proteins. Preincubating cells w ith 
either bu tan-l-o l (0.3%) or DHS (25|iM) did not influence the pa ttern  of 
tyrosine phosphorylation (Figure 4), results consistent w ith our findings that 
both PtdCho-PLD (Figure 2C) and sphingosine kinase (Figure 1C) activation 
are downstream  of tyrosine kinase activation.
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Figure 3.4 Tyrosine phosphorylation occurs promptly after aggregation of 
FcyRI and is unaffected by inhibitors of phospholipase D and sphingosine 
kinase.
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A. Western blot analysis of tyrosine phosphorylated proteins at given times 
after formation of surface immune complexes. Lane 1, cells loaded with 
monomeric IgG but no cross-linking antibody. Lane 2, cells loaded with 
monomeric IgG harvested immediately after addition of crosslinking  
antibody. Lane 3, cells harvested 1 minute after addition of crosslinking 
antibody. Lane 4, cells harvested 2 minutes after addition of crosslinking 
antibody and Lane 5, cells harvested 5 mins after addition of crosslinking 
antibody.
B. Tyrosine phosphorylation patterns in cells 2 mins after formation of 
immune complexes in cells treated with butan-l-ol (0.3%) (Lane 3) or DHS 
(25y,M) (Lane 4) compared to control cells (Lane 2). Lane 1, cells loaded with 
monomeric IgG but no crosslinking antibody.
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3.4.5 Activation of phospholipase D is necessary for both mobilisation of 
intracellular calcium  and for trafficking of im m une com plexes for 
degradation
Release of intracellu lar stores of calcium by aggregation of FcyRI w as 
significantly inhibited by pretreating the cells w ith 0.3% bu tan-l-o l (Figure 
5A); thus, p rov id ing  fu rther suppo rt for the role of this pa thw ay  in 
m obilising calcium  and the concept tha t FtdCho-PLD is upstream  of 
sph ingosine kinase. The possib ility  tha t b u tan -l-o l affected calcium  
m obilisation th rough  non-specific effects was ru led  out as subsequent 
addition of thapsigargin (250nM) resulted in a prom pt response in cytosolic 
calcium . In addition , bu tan-l-o l had no effect on the InsP g-depen  d e n t 
m obilisation of calcium following aggregation of the related low affinity 
receptor, FcyRIIa (Figure 5A). The difference in release of calcium after 
thapsigarg in  is not likely to be significant following m anual injection as 
undertaken here. Although the speed of calcium release by thapsigargin can 
be influenced by a num ber of intracellular factors such as the am ount of 
calcium in the stores, it is well recognised that there is considerable variability 
betw een runs for thapsigargin  m ediated calcium release and the largest 
influence is the rate of addition of thapsigargin and its mixing in the cuvette 
(29, 30).
As observed previously  (17), in ternalisation  of surface bound  im m une 
complexes is very rapid in IFN-y treated U937 cells. The cell-associated counts 
plateau betw een 15 and 30 mins. However, over prolonged incubations, the 
internalised cell-associated counts were found to dim inish gradually in the 
control cells such that, by 120 mins, approximately 50% of the cell associated 
counts had been lost (Figure 5B). This reduction was entirely matched by the 
appearance of counts in the culture m edia of the cells and these counts were 
not precipitable by trichloroacetic acid (TCA) (Figure 5B). The rate of
135
appearance of these TCA soluble counts in media is an indication of the rate 
of lysosomal degradation of the radiolabelled immune complexes (31) and is, 
therefore, a sensitive m easure of the rate of intracellular trafficking of 
internalised immune complexes from endosomes to lysosomes.
Pretreatm ent of cells w ith  bu tan-l-o l (0.3%) to inhibit PtdO H  generation 
appeared to reduce to a small extent the initial phase of endocytosis (Peak % 
counts internalised control cells 9 3 + 3  %; butan-l-ol treated cells 77 + 2 % ). 
Nonspecific effects of the alcohol were eliminated as butan-2-ol (0.3%) had no 
effect on the rate of endocytosis (Peak % counts internalised butan-2-ol treated 
cells 90 ±_ 3%). Following longer time intervals after in ternalisation of 
im m une complexes, the am ount of radiolabel trapped  inside the cells 
gradually decreased in the untreated cells and in cells treated w ith butan-2-ol 
(0.3%) such that about 50% of the initial internalised radiolabel had been lost 
from the cells after two hours incubation. This loss of cell associated counts 
was entirely matched by the appearance in the cell supernatant of radiolabel 
in a form that was soluble in TCA. Thus, after 2 hours, 47 + 2 % of the initial 
counts in the control cells appear as TCA soluble counts w ith in  the 
supernatan t; this is a m easure of trafficking of im m une complexes for 
lysosomal degradation (31). Treatment of cells w ith butan-l-o l significantly 
inhibited trafficking of immune complexes for degradation. Thus, the rate of 
loss of cell associated (internalised) counts was significantly slowed in cells 
treated  w ith  bu tan -l-o l (after 2 hours incubation % counts rem aining 
internalised - control cells 43 + 5 %; butan-l-ol treated cells 63 ±  3 %). In 
addition, the rate of appearance of TCA soluble counts in the m edia over 
prolonged incubations was significantly slower for cells pretreated w ith 0.3% 
butan-l-ol compared to the control untreated cells or cells treated with butan- 
2-ol (Figure 5B). Thus, following 120 mins of incubation, only 19 + 0.5% of 
counts appeared as TCA soluble counts in the m edia of cells treated w ith
136
butan-l-ol in contrast to approximately 45 ±  1% for the control cells and 40 ±
0.4 % for cells treated w ith butan-2-ol.
C onsistent w ith  the biochem ical data  defining the signalling pathw ay, 
inhibition of sphingosine kinase w ith DHS (25pM) also significantly inhibited 
trafficking of im m une complexes for lysosomal degradation (Figures 5B). 
T hus, ac tiva tion  of th is in trace llu la r signalling  p a th w ay  invo lv ing  
phospholipase D and sphingosine kinase is required for the appropria te  
trafficking of internalised immune complexes along the degradative pathw ay.
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Legend for figure 3.5
A. B utan-l-ol 0.3% inhibits the release of in tracellular calcium  stores 
initiated by FcyRI but has no influence on calcium release initiated by FcyRIIa. 
Cytosolic calcium  concentrations w ere m easured  in cell popu la tions 
prew arm ed to 37°C following the aggregationof the Fc receptors.
Upper panel: calcium release in cells following the aggregation (XL) of FcyRI 
in cells pre-treated w ith  0.3% bu tan -l-o l (dotted line) was com pared to 
untreated control cells (solid line). Thapsigargin (250nM) (TG) was added at 
the end of the experiment to ensure that calcium stores were intact. Typical 
trace from 5 separate experiments.
Lower panel: calcium release in cells following the specific aggregation (XL) 
of FcyRIIa in cells pre-treated with 0.3% butan-l-ol (dotted line) was compared 
to untreated control cells (solid line). Thapsigargin (250nM) (TG) was added 
at the end of the experiment to ensure that calcium stores were intact. Typical 
trace from 5 separate experiments.
B. Trafficking of immune complexes for degradation.
The rate of appearance in the culture m edium  of radiolabel as TCA soluble 
counts was m easured in control cells and compared to cells preicubated with 
butan-l-o l (0.3%), butan-2-ol (0.3%) or DHS (25|xM). Results shown for each 
time poin t are the counts in the incubation supernatant soluble in TCA 
expressed as a percentage of the total counts bound at time zero (17).
Results shown are the mean ±  S.D. for triplicate measurements at each time 
point. The results shown are typical from two separate experiments.
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Figure 3.5 Functional consequences of PtdCho-PLD and sphingosine kinase 
activation.
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3.5 DISCUSSION
Taken together, this data indicates that FcyRI in cytokine prim ed U937 cells is 
coupled through tyrosine kinase activation to a novel pathw ay responsible 
both for mobilising calcium transients through an InsPs-independent route 
and for trafficking internalised im m une complexes for degradation. This 
novel pathw ay involves the activation of PtdCho-PLD, in the absence of 
m easurable activation of phospholipase C, and this is upstream  of activation 
of sphingosine kinase which generates sphingosine-l-phosphate.
Sphingosine -1-phosphate has been proposed previously to play a role in 
m obilising calcium from intracellular stores (32, 33, 34). H ow ever, this 
proposal has proved highly controversial due to the presence of extracellular 
G protein coupled receptors for sphingosine-l-phosphate (35, 36) which are 
able to mobilise calcium through conventional InsPs recep to r-dependen t 
pathw ays. The recent cloning of the SCaMPER receptor (37) provides 
additional evidence that sphingoid derivatives are able to engage intracellular 
receptors and effect calcium release from stores independently  of InsPg 
generation. The data presented here provides evidence for specific imm une 
receptor triggering of this pathw ay in myeloid cells. Thus, aggregation of 
FcyRI resulted in the rapid activation of sphingosine kinase and consequent 
cellular increases in sphingosine-1 -phosphate concentrations. In these same 
cells, neither product of PLC activation could be detected; no accumulation of 
total InsPs could be m easured even in the presence of lithium  chloride to 
preven t breakdow n. M oreover, the observed increase in DAG could be 
completely blocked by pretreatm ent of cells with butanol indicating PtdCho- 
PLD rather than PLC activation as the source of the DAG. In contrast, 
aggregation of an alternative im m une receptor, FcyRIIa, on these cells, 
resu lted  in increases in both  PLC-dependent DAG and InsP generation
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indicating that this pathw ay is intact and functional in these cells and the 
assays used were potentially able to detect any such receptor triggered changes. 
Taken together, the data presented here suggests that the high affinity 
receptor, FcyRI, mobilises intracellular calcium through this sphingosine 
k inase-dependen t, InsPg-independent pathw ay. In this respect FcyRI is 
behaving like the high affinity IgE receptor, FceRI, in m ast cells (15). Of 
interest, both these receptors use the same signal transducing molecule (y 
chain) (10) to recruit soluble tyrosine kinases to m ediate cellular activation. 
H ow ever, the m echanism  of coupling of tyrosine kinases to sphingosine 
kinase activation following FceRI aggregation in mast cells was, however, 
unclear (15). Here, we dem onstrate that PtdCho-PLD is activated following 
aggregation of FcyRI in myeloid cells and that sphingosine kinase activation is 
dependent on PtdCho-PLD activation. The immediate product of PtdCho- 
PLD is phosphatidic acid and this is subsequently converted to DAG through 
the action of phosphatidic acid phosphohydrolase. Previous studies have 
shown that sphingosine kinase is activated by phosphatidic acid (38) and not 
by DAG (38) ; a product of both phospholipase D and phospholipase C. Our 
finding that sphingosine kinase is downstream  of PtdCho-PLD is, therefore, 
consistent w ith this in vitro work. Moreover, both components of this novel 
FcyRI-coupled in tracellu lar signalling pathw ay involving the sequential 
activation of PtdCho-PLD and sphingosine kinase depend on tyrosine kinase 
activation. This finding  is consistent w ith previous in vitro s tud ies  
demonstrating that v-Src can activate PLD (39).
Aggregation of FcyRI in myeloid cells triggers a num ber of effector functions. 
The novel intracellular signalling pathw ay dem onstrated here appears to be 
functionally interactive/associated w ith these. Thus, previous studies have 
im plica ted  phosphatid ic  acid in m odula ting  n eu tro p h il function, in 
particular by influencing the respiratory burst/N A D PH  oxidase cascade (40)
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In this current study  reported here, inhibiting this pathw ay at either the 
PtdCho-PLD and sphingosine kinase levels reduced or abolished the ability of 
this receptor to mobilise calcium from intracellular stores. In addition, 
inhibition of PtdCho-PLD significantly slowed the rate of trafficking of 
in te rnalised  im m une com plexes for degradation . Of in terest, ADP- 
ribosylation factor plays a major role in regulating vesicular trafficking and 
this small molecular weight G protein has also been dem onstrated to regulate 
phospholipase D activity (41). The finding that FcyRI is coupled to the release 
of intracellular calcium stores and vesicular trafficking via a novel pathw ay 
which does not use InsPg has profound implications for the developm ent of 
strategies for therapeutic intervention against differential myeloid responses 
to im m une complexes.
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CHAPTER 4
DIFFERENTIATION DEPENDENT SWITCH IN PICC ISOENZYME 
ACTIVATION BY FcyRI THE HUMAN HIGH AFFINITY RECEPTOR FOR 
IMMUNOGLOBULIN G
4.1 ABSTRACT
Aggregation of receptors for the constant region (Fc) of im m unoglobulin G on 
m yeloid cells results in endocytosis or phagocytosis and cellular activation. 
Previous w ork has shown, using the cell line U937, that the high affinity 
receptor, FcyRI, activates alternate intracellular signalling pathw ays depending 
on the cell differentiation state which results in a marked change in the nature 
of calcium transients w ithin the cell. Here, we show that protein kinase C is 
activated in both IFN-y prim ed and dbcAMP differentiated cells bu t that the 
nature of the particular isoenzymes recruited differ. Thus, in IFN-y prim ed 
U937 cells, FcyRI aggregation results in an increase of PKG activity which is 
essentially  calcium  independen t resulting  from the translocation to the 
m em brane of the novel PKCs, ô and 8, together w ith the atypical PKG 
However, in cells differentiated to a more m acrophage phenotype, all PKG 
enzym e activity after receptor aggregation is calcium dependent. Gonsistent 
w ith this finding, the isoenzymes translocated to the nuclear-free m em brane 
fraction are the conventional PKCs a, p, and y; results consistent w ith our 
previous finding that FcyRI couples to phospholipase C in such dbcAMP- 
differentiated cells. Thus, the nature of PKG isoenzyme activated following 
FcyRI aggregation is defined by differentiation. The calcium dependence of the
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PKC isoenzym e is consistent w ith  the du ra tion  of calcium  transien ts 
previously reported in the two differentiation states.
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4.2 INTRODUCTION
Binding of the constant region (Fc) of imm unoglobulin G (IgG) to cell surface 
receptors (FcyR) on leukocytes provides a pivotal link betw een the hum oral 
and cellular arms of the im m une system (see reviews 1-3). Three different 
classes of Fey receptors have been defined; FcyRI (CD64), FcyRII (GD32) and 
FcyRIII (CD16) (see reviews 4-6). Of these, the hum an high affinity receptor, 
FcyRI, is an integral type I membrane glycoprotein (7) constitutively expressed 
on monocyte and macrophage cell types. On myeloid cells, aggregation of these 
receptors triggers a num ber of different effector functions including endocytosis 
of im m une complexes or phagocytosis of opsonised particles. Fey receptor 
aggregation activates a repertoire of responses including degranulation and 
release of proteases, activation of the respiratory burst and release of cytokines. 
These can ultim ately lead to targeted cell killing through antibody directed 
cellular cytotoxicity (ADCC) (8, 9) which is critically im portant for clearing virus 
infected cells and in cancer surveillance (10).
One feature of monocytes and macrophages is the heterogeneity of response to 
im m une complex challenge using cells harvested under different conditions 
and different environm ents. Little is know n about the signal transduction 
m echanism s underlying this or how they are modified as blood monocytes 
differentiate into tissue macrophages. Thus, to study early events in the FcyRI 
signalling pathw ay, we have used the hum an monocyte cell line, U937 (11), 
which constitutively expresses FcyRI and FcyRII and which allows controlled 
differentiation into a more macrophage cell type by treatm ent w ith dibutyryl 
cAMP (dbcAMF) (12). Previous work has shown that the nature of calcium 
transients m arkedly change as the cells become differentiated (13). Thus, a 
single spike in calcium is observed in response to Fey receptor aggregation of 
cells treated w ith interferon-y whereas calcium oscillations are generated in 
cells differentiated to a more macrophage state by dbcAMP (14). This switch in
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calcium signalling patterns is dictated by a switch in the intracellular signalling 
pathw ays activated by FcyRI in the two differentiation states (15). Thus, the 
calcium spike in IFN-y treated cells results from the sequential activation of 
phosphatidylcholine phospholipase D (PtdCho-PLD) and sphingosine kinase 
(15, 16) whereas the calcium oscillations observed in dbcAMP differentiated 
cells are associated w ith activation of phosphatidylinositol 4,5 bisphosphate 
phospholipase C (PtdInsP2-PLC) and subsequent generation of inositol 1,4,5 
trisphosphate (InsP3). Both activation pathways generate diacylglycerol (17, 18) 
and thereby can activate protein kinase C (PKC) (18, 19) and this kinase has been 
shown to play an im portant role in mediating Fey receptor functions (20-23). 
PKC isoform s, depending  on their structure and cofactor regulation, are 
divided into three groups (24, 25): conventional (PKC a; (31; pll; and y) which are 
calcium and diacylglycerol activated isoenzymes, novel (PKC Ô; £; q; |i and 6) 
which are calcium independent but diacylglycerol activated isoenzymes, and 
the atypical ones (PKC Ç; Xtx ) w hich do not require either calcium or 
diacylglycerol (24-28). Here, we show that the nature of the PKC isoenzymes 
activated by immune complexes differ in the two differentiation states. Thus, 
calcium  dependent typical PKCs (a, p, and y) were activated in dbcAMP 
differentiated cells whereas the calcium independent, novel PKCs, d and e, and 
the atypical isoenzyme z were activated in the cells prim ed w ith IFN-y.
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4.3 MATERIALS AND METHODS 
4.3.1 Cell culture.
U937 cells were cultured in a hum idified atm osphere at 37°C, 6.8% CO2 in 
RPMI 1640 m edium  (Gibco) supplem ented w ith foetal calf serum  (10%), 
glutam ine (2 mM), penicillin (10 U ml"^) and streptomycin (10 mg m l“ )^. The 
cells were treated w ith IFN-y (a gift from Bender Wein Ltd) (100 ng /m l) for 24 
hours or dbcAMP (ImM) for 48 hours.
4.3.2 Analysis of PKC isoform expression.
U937 cells (10^ cells), either IFN-y prim ed or differentiated with dbcAMP, were 
harvested by centrifugation at 200g for 5 m in and the cell pellet solubilised in 1 
ml of lysis buffer (50 mM Tris, 150 mM sodium  chloride, 2% NP40, 0.25% 
sodium  deoxicholate, ImM  EGTA, 1 mM PMSF, lOmM sodium  orthovanadate, 
lO jig /m l chym ostatin, lO pg/m l leupeptin, lO pg/m l antipain and 1 0 |ig /m l 
pepstatin). Cell lysates were frozen in liquid nitrogen, then thaw ed and 
hom ogenised (15-20 strokes) on ice in a pre-cooled Dounce homogeniser. The 
cell lysates were centrifuged at 20,000 g for 15 m inutes at 4"C and the 
supernatants containing total solubilised cellular protein was harvested and 
stored at -20°C. The am ount of protein in supernatants was quantified using 
Bradford (BIO-RAD, UK) assay.
4.3.3 Aggregation of FcyRI.
Cells were harvested by centrifugation (200g for 5 min). After resuspension, the 
cells w ere incubated for 30 m in on ice w ith IpM  h u m an  m onom eric , 
polyclonal IgG (Serotec) to occupy surface FcyRI. Excess unbound ligand was 
rem oved by dilution and centrifugation. Cells were resuspended and ligand 
occupied receptors were then aggregated by addition of 1:50 dilution of F(ab)
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goat anti-hum an IgG (Sigma) on ice. Cells were then w arm ed to 37“C for the 
times specified in the assays.
4.3.4 Cell Fractionation.
Following receptor cross-linking, cells were harvested at the specified times and 
subcellular fractions were prepared by a modification of m ethods previously 
described (29-31). Briefly, cells were harvested and resuspended in cold nuclear 
preparation buffer (lOmM Tris-HCl, pH  7.4, 2mM magnesium chloride, 0.14M 
sodium  chloride, 2% NP40, 0.25% sodium  deoxycholate, Im M  EGTA, Im M  
PMSF, lOmM sodium  o rthovanadate , lO q g /m l chym ostatin , 1 0 ( ig /m l 
leupeptin , lO pg/m l antipain and 10 |ig /m l pepstatin). Cells were frozen in 
liquid nitrogen, then thaw ed under running hot water, the nuclei released by 
15-20 strokes of a pre-cooled Dounce homogeniser and centrifuged at 15,000g for 
5 min. In order to examine the integrity of the nuclear m em brane, the pellet 
was resuspended in 20jig/m l of propidium  iodide and viewed by fluorescence 
microscopy. The supernatant was centrifuged at 100,000g and 4°C for 30 min, 
the pellet containing the m em brane fraction resuspended in 200pl of the 
nuclear p repara tion  buffer and stored  at -20°C. The cytosol fraction, 
represented by the high speed supernatant, was also stored at -20°C. The 
am ount of protein recovered in each fraction was quantified using the Bradford 
reagent system.
4.3.5 Gel Electrophoresis and Western Blots.
Proteins (50|ig of whole cell lysate or 20pg of the m em brane fraction), were 
resolved on 10% polyacrylamide gels (SDS-PAGE) under denaturing condition. 
The resolved proteins were transferred to nitrocellulose m em branes. The 
m em branes were blocked by incubating overnight in PBS 5% non-fat milk, 
0.1% Tween 20 buffer at 4°C. The mem brane then was w ashed in PBS, 0.1%
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Tween 20 and incubated individually  w ith m ouse m onoclonal antibodies 
specific for each of hum an PKC isoforms (Transduction Laboratories) at 
dilutions as recommended by the manufacturer, in 5% non-fat m ilk/PBS/0.1%  
Tween 20 at room tem perature for 4 hours. We have previously characterised 
the specificity of these PKC isoform specific antibodies (31). Following washing 
of the m em branes, bands were visualised  using ECL W estern Blotting 
Detection System (Amersham International, Amersham, UK).
4.3.6 PKC enzyme activity assay.
PKC assays were carried out using the Biotrak Protein Kinase C enzyme assay 
system (Amersham, UK). Briefly, the system is based upon the PKC catalysed 
transfer of the y-phosphate group of adenosine-5'-triphosphate to a peptide 
substrate specific for PKC. U937 cells treated with IFN-y or differentiated w ith 
dbcAM P w ere stim ulated  by FcyRI aggregation at the indicated tim es. 
Following stimulation proteins from whole cell lysates or fractionated, nuclear- 
free m em brane sam ples, w ere p a rtia lly  pu rified  by DEAF cellu lose 
chrom atography (W hatm an DE52). PKC enzym e activity, from partially  
purified  sam ples, was m easured from whole cell lysate, or fractionated, 
nuclear-free, m em brane sam ples in the presence of 1.5 mM calcium , or 
substituting calcium with 1.5 mM EGTA containing buffer.
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4.4 RESULTS
4.4.1 Aggregation of FcyRI activates PKC in both IFN-y primed and dbcAMP 
differentiated U937 cells.
The kinetics of activation of PKC was measured in cells prim ed with IFN-y and 
compared to that observed for cells differentiated by dbcAMP. Resting PKC 
activity was identical in the two cell types and aggregation of FcyRI resulted in a 
prom pt increase in PKC activity. Thus, 30 secs after receptor aggregation, PKC 
activity had doubled in both cell types (Figure lA). In IFN-y treated cells, this 
initial rapid rise in PKC activity was followed by a sustained steady increase 
which reached a plateau w ithin 20 m inutes and was m aintained 45 m inutes 
after receptor aggregation (Figure. IB). In contrast, in dbcAMP differentiated 
cells, PKC activity increased very rapidly, such that peak PKC was achieved 2.5 
m inutes after receptor aggregation and this activity was then m aintained over 
the subsequent 45 minutes (Figure. IB). Although the time to reach plateau of 
PKC activity differed for IFN-y prim ed and dbcAMP differentiated cells, the 
plateau levels eventually reached in both cell types was very similar.
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Figure 4.1 PKC activity after Fey receptor aggregation in IFN-y-primed or
dbc AMP-differentiated U937 cells.
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A. PKC activity following FcyRI aggregation, (short, up to 5 min, time course) 
in dbcAMP differentiated (dbcAMP) and IFN-y prim ed (IFN-y) U937 cells. The 
data are the mean ±  the standard deviation of triplicate measurements for each 
time point and are representative of four separate experiments.
B. PKC activity following FcyRI aggregation (long, up to 45 min, time course) in 
dbcAMP differentiated (dbcAMP) and IFN-y prim ed (IFN-y) U937 cells. The 
data are the mean + the standard deviation of triplicate m easurem ents for each 
time point and are representative of four separate experiments.
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4.4.2 FcyRI aggregation results in calcium dependent or independent PKC 
enzyme activity depending on cell differentiation.
Previous w ork has show n that the nature of calcium transients generated 
following FcyRI aggregation m arkedly change following differentiation of the 
cells (12, 13). Since calcium is an im portant co-factor for PKC activity, we next 
investigated the calcium dependence of the observed PKC activity.
In IFN-y prim ed cells, the increase in PKC activity over the first 20 m inutes 
after receptor aggregation was unaffected by the withdrawal of calcium from the 
assay (Figure 2A). At the later time points (30 mins and 45 mins), addition of 
calcium resulted in a small increase in m easured PKC activity. This data 
indicates that over the first 20 m inutes after receptor aggregation, calcium 
independent novel or atypical PKCs account for the vast majority of the PKC 
activation observed in these cells. The calcium dependent classical PKCs only 
contribute to the total PKC activation in the later stages following receptor 
aggregation and even here they are only a minor component.
In contrast in dbcAMP differentiated cells, w ithdraw al of calcium from the 
assay completely abolished any increase in measurable PKC activity at all time 
points. Thus, in these cells, aggregation of FcyRI results in the activation of 
calcium dependent, typical PKCs and there is little contribution of calcium 
independent novel or atypical PKCs (Figure 2B).
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Figure 4.2 Calcium dependence of PKC activity after Fey receptor aggregation in 
IFN-y-primed or dbcAMP-differentiated U937 cells.
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A. PKC activity following FcyRI aggregation in IFN-y prim ed U937 cells in the 
presence of 1.5 mM calcium (IFN +Ca2) or substituting calcium w ith 1.5 mM 
EGTA (IFN -Ca2) in the assay buffer. The data are the m ean + the stardard  
d ev ia tio n  of trip lica te  m easu rem en ts for each tim e p o in t and  are 
representative of three separate experiments.
B. PKC activity following FcyRI aggregation in dbcAMP differentiated U937 
cells in the presence of 1,5 mM calcium (dbcAMP +Ca2) or substituting calcium 
w ith 1.5 mM EGTA (dbcAMP -Ca2) in the assay buffer. The data are the mean 
±  the stardard deviation of triplicate measurements for each time point and are 
representative of three separate experiments.
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4.4.3 FcyRI aggregation results in PKC translocation to membranes.
PKC activation is associated with its translocation to the plasma mem brane (24, 
25, 32). PKC activity in the nuclear-free m em brane fraction was therefore 
m easured together w ith the calcium dependence of this activity in IFN-y 
prim ed and dbcAMP differentiated cells following aggregation of FcyRI. In IFN- 
y treated cells, mem brane associated PKC activity increased very rapidly after 
receptor aggregation. An increase was observed within the first 15 seconds and 
reached m axim al activity at 2 m inutes; thereafter being sustained for 45 
m inutes (Figure 3A). W ithdrawal of calcium from this assay had no effect on 
the PKC activity indicating that the translocated PKCs were predom inantly  
calcium  independent. In contrast, in dbcAMP differentiated cells, all the 
m em brane associated PKC activity was dependent on the presence of calcium 
in the assay indicating that the PKCs translocated to the m em brane are the 
conventional calcium dependent PKCs. In these cells, receptor aggregation also 
resulted in a very rapid increase in PKC activity in the m em brane fraction. 
However, in contrast to the cells prim ed with IFN-y, this mem brane associated 
PKC activity peaked 2.5 minutes after receptor aggregation and then fell rapidly 
to achieve a new plateau level of activity that was m aintained over the 
subsequent 45 minutes (Figure 3B).
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Figure 4.3 PKC activity translocated to the nuclear-free membrane fraction and 
its calcium dependence after Fey receptor aggregation in IFN-y-primed or 
dbc AMP-differentiated U937 cells.
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A, PKC activity following FcyRI aggregation in IFN-y prim ed U937 cells in the 
nuclear-free m em brane fraction and in the presence of 1.5 mM calcium (IFN 
+Ca2) or substituting calcium w ith 1.5 mM EGTA (IFN -Ca2) in the assay 
buffer. The data  are the m ean ±_ the standard  dev iation  of trip licate  
m easurem ents for each time point and are representative of three separate 
experim ents.
B. PKC activity following FcyRI aggregation in dbcAMP differentiated U937 
cells in the nuclear-free m em brane fraction and in the presence of 1.5 mM 
calcium (dbcAMP +Ca2) or substituting calcium with 1.5 mM EGTA (dbcAMP 
-Ca2) in the assay buffer. The data are the mean ±  the standard deviation of 
triplicate m easurem ents for each time point and are representative of three 
separate experiments.
158
4.4.4 PKC isoenzyme expression is regulated by differentiation.
Several PKC isoenzymes, from the three defined groups, have been shown 
to be expressed in monocytes and macrophages (21, 33). However, changes 
following differentiation are still unclear. The findings reported here indicate 
that calcium independent PKCs are preferentially activated in IFN~y treated 
cells compared to dbcAMP differentiated cells where calcium dependent PKCs 
are activated. To determ ine w hether this change in isoenzyme recruitm ent 
following FcyRI aggregation reflected a change in the relative expression of the 
various PKCs, cell lysates were probed with monoclonal antibodies specific for 
each enzyme for cells prim ed w ith IFN-y or differentiated w ith dbcAMP and 
the patterns compared to that for untreated, resting cells.
W estern blot analysis showed that in untreated U937 cells PKC a, p, y, 8, e, 0, ji, 
ilX, and Ç, are all expressed to varying degrees (Figure 4 lane 1). Treatm ent of 
the cells w ith IFN-y resulted in an increase in PKC 8, £, |X, xlX, and 0. PKC a , 
and Ç rem ained unchanged and a reduction  in expression of p, and y 
isoenzymes was observed (Figure 4 lane 2). In contrast dbcAMP differentiation 
resulted in upregulation of PKC a, P, and y, and downregulation of PKC 8, £, 
ilX, and Ç. PKC p and 0 remained unchanged by dbcAMP treatm ent of U937 
cells (Figure 4 lane 3).
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Figure 4.4 Analysis of the different PKC isoenzymes expressed in: U937 cells; 
IFN-y-primed U937 cells; and dbcAMP-differentiated U937 cells.
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Cells were cultured in their normal growth media (untreated), or in media 
containing IFN-y (100 ny/ml) for 24 hr (IFN-y), or in media containing dbcAMP 
(ImM) for 48 hr (dbcAMP). Samples from cell lysates were subjected to 
SDS/PAGE and Western blotted. The blots were incubated individually with 
mouse monoclonal antibodies specific for each of human PKC isoenzymes (a, 
P, y, 5, e, 0, i/X, p, Q.  Bands were visualised by ECL (Amersham).
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4.4.5 Differentiation-dependent differential translocation of PKC isoenzymes to 
the membrane fraction following FcyRI cross-linking.
To determ ine whether aggregation of FcyRI results in differential activation of 
p a rtic u la r  isoenzym es in IFN-y p rim ed  cells com pared  to dbcAM P 
differentiation, specific translocation of individual PKC was investigated. In 
IFN-y prim ed cells, the novel PKCs ô and e and atypical Ç isoenzym es were 
translocated to the membrane fraction following FcyRI cross-linking. However, 
all of the conventional PKC a  appeared to be m em brane bound  in non­
stim ulated  IFN-y-primed cells and thus translocation could not be assessed 
(Figure 5A). In contrast, in dbcAMP differentiated cells, only the conventional 
PKCs a, p, y were translocated to the membrane fraction in response to FcyRI 
cross-linking.
The novel PKC p , which contains a putative transm em brane dom ain, is as 
expected, mem brane bound in both IFN-y prim ed and dbcAMP differentiated 
cells even in the absence of receptor aggregation and thus translocation could 
not be assessed (Figure 5B). No other PKC isoenzymes could be detected in the 
nuclear-free m em brane fraction.
161
Figure 4.5 Protein analysis of the different PKC isoenzymes translocated to 
the nuclear-free membrane fraction following FcyRI aggregation in IFN-y 
primed and dbcAMP differentiated U937 cells.
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A. Western blots analysis of the different PKC isoenzymes translocated to the 
nuclear-free membrane fraction of IFN-y primed U937 cells following FcyRI 
aggregation time course. The blots were incubated individually with mouse 
monoclonal antibodies specific for each of human PKC isoenzymes (a, (5, y, 5, 
e, 0, 1/ X, |i, Q. PKC isoenzymes found to translocate ô, e, Ç. PKCs a  and is 
membrane bound throughout the experiment.
B. Western blots analysis of the different PKC isoenzymes translocated to the 
nuclear-free membrane fraction of dbcAMP differentiated U937 cells 
follow ing FcyRI aggregation time course. The blots were incubated 
individually with mouse monoclonal antibodies specific for each of human 
PKC isoenzym es (a, (3, y, ô, e, 0, i/ X, ji, Q. PKC isoenzymes found to 
translocate a, |3, y. PKC p is membrane bound throughout the experiment.
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4.5 DISCUSSION
Endocytosis of imm une complexes by FcyRI has been shown here to cause a 
prom pt and sustained activation of PKC in both IFN-y prim ed U937 cells and 
cells differentiated to a more macrophage phenotype by dbcAMP. However, 
the precise nature of the PKCs activated by receptor aggregation differs. 
Calcium independent PKC isoenzymes were activated in IFN-y prim ed cells 
whereas, following differentiation, calcium dependent PKCs were the major 
activated  form. A lthough IFN-y and dbcAMP m odified the relative 
expression levels of the various PKC isoenzymes, all the major species were 
still present in lysates of both cell types and thus, the changes in expression 
cannot account for the fundam ental sw itch in PKC isoenzym e activation 
following receptor aggregation. This observation implies that FcyRI is able to 
recruit and specifically activate different isoenzym es depending  on the 
differentiation state of the cell and likely results from the switch in signalling 
pathw ays activated by FcyRI following differentiation. This switch dictates the 
duration  of calcium transients in these cells and it is notew orthy that the 
calcium dependence of the PKCs activated by FcyRI reflects this change. 
Previous w ork has show n that, in these two differentiation states, FcyRI is 
coupled to the activation of distinct intracellular signalling pathways. FcyRI is 
able to switch between these two activation pathways as its cytoplasmic tail 
contains no signalling motif but, rather, the receptor m ust recruit an accessory 
molecule to activate tyrosine kinases. Thus, in IFN-y prim ed cells, FcyRI acts 
through the y chain and is coupled to the activation of PtdCho-PLD and 
sphingosine kinase. In these cells, changes in cytosolic calcium are transient 
as, following release from stores, calcium levels peak w ithin 1 m in and then 
fall to basal levels. Consistent w ith this, the PKC isoenzymes activated are
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calcium independent and the predom inant PKCs translocated to m em branes 
are the isoenzymes ô, e and Ç.
Novel PKCs are activated by diacylglycerol which is generated in this pathw ay 
by phosphatidic acid-phosphohydrolase (PPH) converting phosphatidic acid, 
the im m ediate p roduct of PtdCho-PLD, to diacylglycerol. How ever, the 
diacylglycerol species produced by this pathway differs from that generated by 
PtdInsP2“PLC and recent evidence suggests that the diacylglycerol produced by 
PtdCho-PLD and PPH is not able to activate PKC (34). Atypical PKCs are not 
activated by either calcium or diacylglycerol. However, phosphatidic acid 
itself has been show n to activate specifically PKC Ç; thus, p rovid ing  a 
potential link betw een the novel intracellular signalling pathw ay we have 
previously defined in IFN-y prim ed U937 cells following FcyRI aggregation 
and the pattern of PKC activation observed. Our recent work has shown that 
aggregation of FcyRI also activates PI3-kinase in IFN-y treated cells (35) and 
that PI3-kinase is upstream  of phospholipase D activation. This finding 
provides an explanation for the observations reported here as both novel and 
atypical PKCs are activated by second messengers generated by PI3-kinase (36- 
39).
In IFN-y prim ed cells, FcyRI recruits the y chain to act as its accessory molecule 
for signal transduction (40, 41, 15). The y chain acts as a signal transducing 
accessory molecule for a num ber of receptors including the high affinity IgE 
receptor, FceRI in mast cells (42). In cells expressing FceRI, endocytosis of this 
receptor has been correlated w ith threonine phosphorylation of the y chain 
and this phosphorylation was attributed specifically to PKC Ô activation (43). 
Of interest, PKC ô was physically associated with the FceRI receptor complex 
in particular w ith the p chain of the receptor complex. A lthough sim ilar 
phosphory la tion  of threonine residues of the y chain has been show n 
following aggregation of FcyRI (44), PKC 5 im m unoreactivity could not be
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dem onstrated in FcyRI im m unoprecipitates either before or after receptor 
aggregation by imm une complexes (data not shown). This may result from 
the lack of expression of the FceRI - b chain in myeloid cells.
In contrast to IFN-y prim ed cells, differentiation of U937 cells by dbcAMP to a 
more macrophage phenotype results in a switch in the intracellular signalling 
pathw ays activated following FcyRI aggregation (15). Thus, PtdInsP2 PTC and 
not PtdCho-PLD is activated w ith the subsequent generation of diacylglycerol 
and InsPg. Associated with this, the calcium transients are prolonged as store 
dum ping is followed by activation of I c R A C  and significant calcium entry (45, 
46). Consistent w ith this, the PKCs activated are the conventional type being 
calcium  dependen t and , specifically, the isoenzym es a, p and y are 
translocated to m em branes. The sw itch observed in activation pathw ay 
results from a sw itch in the accessory molecule used by FcyRI as in the 
dbcAMP differentiated cells, signalling by FcyRI appears to be m ediated by 
FcyRIIa (15).
Activation of PKC is well established as essential in m ediating phagocytosis in 
myeloid cells (20-23). The switch in calcium dependence of the activated PKC 
isoenzymes in the two cell types provides an explanation for the observation 
that phagocytosis m ediated by FcyRI is calcium independen t w hereas 
phagocytosis mediated by FcyRII is calcium dependent (20). In dbcAMP, FcyRII 
is used as the signal transducing molecule (15). In these cells, only calcium 
dependent PKCs are activated. Buffering of intracellular calcium w ould 
therefore abolish PKC activation and thereby prevent phagocytosis. In IFN-y 
prim ed cells, FcyRI uses the y chain for signal transduction and, under these 
circum stances, calcium  independen t PKCs are activated . Buffering 
intracellular calcium will therefore have no effect on PKC activation.
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CHAPTER 5
AGGREGATION OF THE HUMAN HIGH AFFINITY IMMUNOGLOBULIN 
G RECEPTOR (FcyRI) ACTIVATES BOTH TYROSINE KINASE AND G- 
PROTEIN COUPLED PHOSPHOINOSITIDE 3-KINASE ISOFORMS
5.1 ABSTRACT
Phosphoinositide 3-kinases (PI3-kinases) play an im portan t role in the 
generation of lipid second messengers and the transduction of a m yriad of 
biological responses. Distinct isoforms have been shown to be exclusively 
activated either by tyrosine kinase coupled- or G-protein-coupled receptors. 
We show here, however, that certain non-classical receptors can couple to 
both tyrosine kinase- and G-protein-dependent isoforms of PI3-kinase: thus, 
aggregation of FcyRI, the hum an high affinity IgG receptor, on monocytes 
unusually  leads to activation of both these types of PI3-kinase. Following 
aggregation of FcyRI, PIP3 levels rise rapidly in IFN-y prim ed cells reaching a 
peak w ithin 30 secs. M oreover, and in contrast to the situation observed 
follow ing stim ulation of these cells w ith  either insulin  or ATP, w hich 
exclusively activate the tyrosine kinase- and G-protein-coupled forms of PI3- 
kinase, respectively, PIP3 levels remain elevated even 2  mins after receptor 
aggregation. We show here that whilst the initial peak results from transient 
activation of the p85-dependent p llO  isoform of PI-3kinase, presum ably 
through recruitm ent of tyrosine kinases by the y chain, the later sustained rise 
of PIP3 results from activation of the G-protein Py sub unit-sensitive isoform, 
p llO y . This is the first evidence that receptors which lack an intrinsic 
signalling motif, such as FcyRI, can recruit both tyrosine kinase and G- 
p ro tein -coup led  in tracellu lar signalling m olecules and thereby in itiate  
cellular responses.
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5.2 INTRODUCTION
Fc receptors (FcyRs) specific for IgG are expressed on the surface of m any 
different cell types of the im m une system  and play an im portant role in 
linking the cellular and hum oral arms of the imm une response (1-3). On 
m yeloid cells aggregation of FcyRs leads to a num ber of cellular responses 
includ ing  the in ternalisation  of im m une complexes by endocytosis or 
opsonised particles through phagocytosis, de granulation and the release of 
proteases, activation of the respiratory burst, and the release of cytokines. 
These processes can lead to targeted cell killing through antibody directed 
cellular cytotoxicity (ADCC) (4, 5) which is im portant for the clearance of 
virus infected cells and in cancer surveillance (6 ).
Three classes of FcyRs have been identified and cloned in m am m als (FcyRI, 
FcyRII and FcyRIII), each of which has a variety of isoforms w ith differing 
affinities for IgG and tissue distributions (1, 2). FcyRI is the hum an high 
affinity receptor (7) and although its cytoplasmic tail contains no obvious 
signalling motif, FcyRI has been shown to associate physically with the ITAM- 
containing y chain (8 , 9) and FcyRI cross-linking results in signal transduction 
as evidenced by tyrosine phosphorylation events (10-13) and tyrosine kinase 
dependent calcium transients (14, 15).
Phosphoinositide 3-kinases (PI3-kinases) catalyse the phosphorylation  of 
inositol phospholip ids at the 3-position of the inositol ring (16). The 
phospho lip ids p roduced  by the actions of these enzym es; PtdIns(3)P, 
PtdIns(3 ,4 )P2 (PIP2) and PtdIns(3 ,4 ,5 )P3 (PIP3), act as second messengers which 
are increasingly implicated in regulating a num ber of cellular responses. For 
example, PI3-kinase activity has been implicated as being involved in insulin- 
induced glucose transport (17), platelet-derived growth factor- and insulin- 
induced actin rearrangem ent (18, 19) and in the regulation of neuronal 
survival (2 0 ).
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There are three classes of PIS-kinases which are determ ined by their in vitro 
substrate specificities. Class I PI3-kinases phosphorylate Ptdlns, PtdIns(4)P and 
P td Ins(4 ,5 )P2 - This class of enzymes can be further subdivided into class lA 
and class IB. Class lA PI3-kinases consist of pllO  catalytic subunits that are 
regulated by the SH2/SH3-dom ain containing p85 family of adaptor proteins 
and consist of the isoforms p llO a, pllOp, and p ll0 5  (21-23). The p85 family of 
adaptor proteins (24-26 ) facilitate PI3-kinase interactions w ith other proteins 
through their SH2 and SH3 domains. Class IB consists of pllOy, an enzyme 
which associates w ith a plO l adaptor protein and is stimulated by G-protein Py 
subunits (27-30). Class II PI3-kinases phosphorylate Ptdlns and PtdIns(4)P but 
not PtdIns(4 ,5 )P2 (31, 32) and class III PI3-kinases have a substrate specificity 
restricted to Ptdlns and are hom ologous to yeast Vps34p (vacuolar protein 
sorting defective) which is involved in the trafficking of proteins from the 
Golgi to the yeast vacuole (33-35).
Previous studies have show n that receptors that are coupled to tyrosine 
kinases, such as insulin, exclusively activate class lA PI3-kinases through the 
p85 adaptor molecule. In contrast, receptors that engage heterotrim eric G 
proteins, such as ATP, exclusively activate class IB PI3-kinases through the 
generation of Py subunits. No crosstalk between the coupling of these two 
receptor to PI3-kinases has been shown. We report here the first example of a 
single receptor, FcyRI, which has the capacity to activate both class lA and class 
IB PI3-kinases.
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5.3 MATERIALS AND METHODS 
5.3.1 Materials
H um an IgG and sheep-anti-hum an IgG (y chain specific) were obtained from 
Serotec. Potassium  oxalate, and all phospho lip ids w ere from  Sigma. 
[32p]orthophosphate (HCl free) was obtained from Amersham. W ortm annin, 
lavendustin A and tyrphostins A23 and A25 were obtained from Calbiochem 
and genistein  w as from  Sigma. Cells w ere treated  w ith  inh ib ito rs at 
concentrations specified for 30 minutes at 37°C prior to receptor aggregation or 
stim ulation.
A ntisense o ligonucleotides w ere purchased  from Oswell DNA Services 
(Southam pton, UK). Anti-pllO y oligonucleotides corresponded to the first 8 
(24 mer) or 10 (30 mer) amino acids of pllOy. The sequences of these 
oligonucleotides were
5' CTGTTTATAGTTCTCCAGCTCCAT 3' and 
5' CACGGGCTGTTTATAGTTCTCCAGCTCCAT 3'.
A control oligonucleotide (24 mer) of random  sequence was also m ade, the 
sequence of which was 
5' CTGGTGGAAGAAGAGGACGTCCAT 3'.
The 24 mers were capped at either end by phosphothiorate linkages (first two 
and last two linkages) w hereas each linkage of the 30 m er consisted of a 
phosphothiorate. Cells were incubated w ith 10 )iM of oligonucleotide for one 
hour prior to, and then for the duration of culture with IFN-y.
5.3.2 Cell culture
U937 cells were cultured in RPMI 1640 (Gibco) supplemented w ith 10% fetal calf 
serum  (FCS), 2 mM glutam ine, 10 u n its /m l penicillin and 10 m g /m l of 
streptom ycin at 37°C, 6 .8 % carbon dioxide in a w ater saturated atm osphere.
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U937:Ap85 cells (a generous gift from L. Stephens, Barbraham  Institu te , 
Cambridge, UK) were similarly cultured, but in addition were cultured in the 
presence of 0.6 m g /m l G418 and 0.1 m g /m l hygrom ycin B (both from 
Calbiochem). Expression of Ap85 was induced with 15 mM IPTG, 5 nM PMA 
and 100 pM zinc chloride for 10 hours. All cells were prim ed with 200 n g /m l of 
I F N - y  (a k ind  gift from  Bender W ein Ltd) for 24 hours p rio r to 
experim entation.
5.3.3 FcyRI cross-linking
Cells were harvested by centrifugation and then incubated at 4°C w ith 1 pM 
hum an m onomeric IgG (Serotec) to occupy surface FcyRI. Excess unbound 
ligand was rem oved by dilution and centrifugation of the cells. Cells were 
resuspended in ice cold RPMI 1640/10 mM HEPES/0.1% BSA (RHB) and cross- 
linking antibody (goat anti-hum an IgG; 1:50 dilution) was added. Cells were 
then w arm ed to 37°C for the times specified in the assays.
5.3.4 Insulin and ATP stimulation
Cells were harvested by centrifugation, resuspended in ice cold RHB, and 
incubated w ith  either 10 p g /m l insulin or 100 pM  ATP. Cells were then 
w arm ed to 37°C for the times specified in the assays.
5.3.5 Pertussis Toxin activation and Culture
Pertussis toxin (90 pg /m l) was activated by incubation in 25 mM DTT for 30 
m in at 37°C. The concentration was then adjusted to 60 p g /m l w ith 75 mM 
Tris-HCl, pH  7.5 containing 1 m g /m l BSA. Pertussis toxin was then incubated 
overnight w ith cells at a final concentration of 1 p g /m l (36).
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5.3.6 Measurement of Phosphoinositide 3-kinase activity
U937 cells (2x10^ cells/m l) were treated w ith IFN-y as described and harvested 
by centrifugation. Cells w ere then w ashed in phosphate free RPMI and 
resuspended in phosphate free RPMI containing 10% dialysed FCS. Cells were 
labelled with 500 pC i/m l [^2p]pQ^ for 90 min at 37°C. After labelling, cells were 
w ashed in ice cold RHB. Cells were stimulated with either insulin or ATP, or 
FcyRI cross-linked, and the reactions stopped at specified times w ith ice-cold 
PBS. Cells were perm eabilised w ith m ethanol and the lipids extracted w ith 
chloroform. Aliquots from the organic phase were used to analyse total label 
incorporation w hilst duplicate aliquots were dried dow n under vacuum , 
resuspended in chloroform: m ethanol (19:1), PIP2 (10 pg /m l) standard added 
and spotted onto a silica TLC G60 plate (20 x 20 cm x 250 pm  ; W hatm an) 
p re c o a te d  w ith  p o ta s s iu m  o xa la te . P la te s  w ere  d e v e lo p e d  in 
ch loroform / acetone/ m ethano l/ acetic a c id /w a te r (80:30:26:24:14) and the 
standards visualised w ith iodine vapours. Radiolabelled bands were located by 
autoradiography or phosphorim aging, and the PIP3 band was scraped into 
scintillation vials, scintillant added and the associated radioactivity determ ined 
by liq u id  sc in tilla tion  counting . Q uan tifica tion  of labelled  P IP 3 by 
phosphorim aging or scintillation counting always yielded the same ratio of 
PIP3 generation.
5.3.7 Western blot
U937:Ap85 cells were induced to express Ap85 as described earlier. N on­
induced  or induced cells (1 0 ^) w ere harvested  by centrifugation  and 
solubilised in sample buffer (37) containing 50 mM DTT. Samples were boiled 
for 15 m inutes and run  in a 10 % SDS-polyacrylamide gel (38). After 
electrophoresis, the proteins were transferred to a nitrocellulose m em brane 
(0.2 pM  pore size) as described (39). The blots w ere tested  for the
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overexpression of Ap85 by W estern blotting w ith a polyclonal anti-p85a 
antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA). W estern blots were 
developed using the ECL system (Amersham).
5.3.8 Immunoprécipitation
For im m unoprécipitations, cells were lysed w ith ice-cold RIPA lysis buffer 
containing 1 mM PMSF, Ip g /m l CLAP (Ip g /m l each chymostatin, leupeptin, 
antipain and pepstatin) 1 mM sodium  orthophosphate and 1 mM sodium  
fluoride, for 30 min. Cellular debris was removed by centrifugation at 13,000 
rpm  for 15 min, and the cell lysates were precleared with protein A-agarose. 
Cell lysates were either incubated w ith 10 pg  anti-p llO  y (Santa C ruz 
Biotechnology, Inc, Santa Cruz, CA) followed by 10 pg protein A-agarose 
(Santa Cruz Biotechnology) or 10 pg of anti-p85-PI3 kinase conjugated to 10 pg 
of p ro te in  A -agarose (U pstate  b iotechnology. Lake P lacid, NY) to 
im m unoprecipitate p85 and pllOy.
For the studies of tyrosine phosphorylation of p85, IFN-y-treated cells were 
loaded with hum an IgG and cross linked as described . Cells were harvested at 
specified times, lysed and p85 im m unoprecipitated from the cell lysates by 
incubating 500 pi cell lysate w ith 10 pg anti-PI3 k inase/p ro te in  A-agarose 
overnight. Proteins were harvested by centrifugation of the agarose beads and 
dissociated from the beads by boiling in sample buffer (37) containing 50 mM 
DTT for 15 m inutes and run in a 10 % SDS-polyacrylamide gel (38). After 
electrophoresis, the proteins were transferred to a nitrocellulose m em brane 
(0.2 pM pore size) as described (39). The presence of tyrosine phosphorylated 
proteins was then detected by W estern blotting w ith  a m onclonal anti- 
phosphotyrosine antibody (clone 4G 10; Upstate Biotechnology). W esterns 
were developed using the ECL system (Amersham).
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For the quantitation  of the effect of antisense oligonucleotides on pllO y 
levels, cells were incubated with the relevant oligonucleotides as described. 
Cells w ere harvested, lysed and pllO y im m unoprecipitated from  the cell 
lysates. Proteins were harvested and subjected to SDS-PAGE electrophoresis 
as above. Blots were probed for the presence of pllO g and visualised by 
p ro b in g  w ith  rad io labe lled  donkey anti-goat. Specific bands
corresponding to pllO y were quantified using a phosphorim ager (Fuji, FUJIX 
BAS 1000).
5.4 RESULTS
5.4.1 Cross-linking FcyRI stimulates phosphoinositide 3-kinase activity
Following the formation of surface immune complexes in interferon-y (IFN- 
y ) prim ed U937 cells, the cellular levels of phosphatidylinositol 3, 4, 5- 
triphosphate  (PIP3) rose rapidly reaching a peak 30 seconds after receptor 
aggregation (Figure lA). After this initial peak, PIP3 levels were reduced but 
rem ained elevated about 2 -fold above control (non-cross-linked cells) up to 
two m inutes after cross-linking (Figure lA). This 2 fold stim ulation above 
basal levels was sustained and rem ained elevated 15 m inutes after receptor 
cross-linking (data not shown). All of this stimulated increase in PIP3 levels 
could be abolished by treating the cells before receptor aggregation w ith the 
PI3-kinase specific inhibitor wortm annin (50 nM) (Figure lA).
Previous studies have show n that insulin and ATP stim ulate distinct PI3- 
kinases in U937 cells (40, 27); insulin being coupled to the p85-dependent PI3- 
kinase whereas ATP activates the G-protein py subunit stim ulated PI3-kinase. 
The response observed for FcyRI aggregation was, therefore com pared in 
these same cells to that observed for insulin and ATP. The sustained rise in 
PIP3 observed after FcyRI aggregation was not observed for either insulin or
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ATP. Thus, insulin stim ulated a rapid, transient increase of PIP3 w hich 
quickly retu rned  alm ost to basal levels w ithin two m inutes of receptor 
stim ulation (Figure IB). The time course for PIP3 levels following ATP 
stim ulation were similar to that for insulin although the reduction after the 
peak w as less rap id  than  that observed for insulin  but, unlike FcyRI 
aggregation, levels reached basal w ithin two minutes.
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Figure 5.1 PI3 kinase is activated by FcyRI aggregation in IFN-y U937 cells.
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The time course of activation differs from that observed for either tyrosine 
kinase or G protein stimulated PI3-kinase.
A. PIP3 production in IFN-y prim ed U937 cells following aggregation of FcyRI 
(XL), C oncentrations were com pared to cells in w hich no crosslinking 
antibody (No XL) was added and in cells treated w ith 50nM w ortm annin 
(Wrt). The data show n are the mean ±  the standard deveation of triplicate 
m easurem ents for each tim e point and are derived from three separate 
experim ents.
B. PIP3 concentrations in IFN-y prim ed U937 cells following stim ulation of 
tyrosine kinase activated PI3-kinase w ith insulin (10 p g /m l) or G protein  
activated PI3-kinase w ith ATP (IGOpM). The data shown are the mean ±  the 
standard  deveation of triplicate m easurem ents for each time point and are 
derived from three separate experiments.
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5.4.2 FcyRI cross-linking stimulates tyrosine kinase-dependent PI3-kinase 
activities
As FcyRI has been show n to signal through the recruitm ent of non-receptor 
tyrosine kinases (41,42), the relationship of PI3-kinase to tyrosine kinase 
activa tion  w as investigated . The p85 subun it w as rap id ly  ty rosine  
phosphorylated after FcyRI aggregation as phosphotyrosine could be detected 
w ith in  30 secs of ad d in g  cross-linking antibody  to the cells. This 
phosphorylation was attenuated in cells pretreated with O.lmM genistein and 
was abolished in cells treated with 0.37mM genistein (Figure 2A).
The effect of inhibiting tyrosine kinases on PI3-kinase activation was 
m easured. Pre-incubation of cells for 30 m inutes w ith genistein (0.37 mM) 
completely blocked the increase of PIP3 after receptor aggregation (Figure 2B). 
C onsistent w ith  the phosphotyrosine data, the low er concentration  of 
genistein (O.lmM) did not abolish activity but reduced peak PI3 kinase activity 
by 6 8 + 4  %. Three other tyrosine kinase inhibitors (2pM lavendustinA , 160 
pM tyrophostin A23 or 28 pM tyrphostin A25) all inhibited peak PI3 kinase 
activity (Figure 2C).
This data indicates that all of the increase in PI3-kinase activity following 
FcyRI aggregation is downstream  of the activation of tyrosine kinases.
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Legend for figure 5.2
A. W estern  b lo t of im m unoprec ip ita tes of p85 p robed  w ith  anti- 
phosphotyrosine antibody. Cells were harvested before aggregation of FcyRI 
and 30 sec, 1 m in and 2 m in after aggregation of the receptor. p85 was 
im m unoprecipitated from cell lysates and the Western probed for presence of 
phosphotyrosine (upper panel). U ntreated cells were com pared to cells 
pretreated with either 0.1 mM genistein or 0.37 mM genistein. The blot was 
then stripped and probed w ith anti-p85 (lower panel).
B PIP3 production was m easured in cells pretreated with genistein (0.37mM) 
for 30 m ins prior to aggregation of FcyRI (XL + Gen) and com pared to 
untreated cells (XL). The data shown are the mean + the standard deviation 
of triplicate m easurem ents for each time point and are derived from three 
separate experiments.
C Peak PIP3 production (30 secs) was measured in cells pretreated for 30 mins 
w ith various tyrosine kinase inhibitors and compared to control levels (XL 
control). Genistein was used at two concentrations - 0.37 mM and 0.1 mM; 
Lavendustin A - 2 pM, Tyrphostin A23 - 160 pM and Tyrphostin A25 - 28 pM. 
The data  show n are the m ean ±_ the standard  deviation  of trip licate  
m easurem ents for each time poin t and are derived from five separate 
experim ents.
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Figure 5.2 Inhibition of tyrosine kinase activity blocks FcyRI-stimulated PI3 
kinase activity.
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5.4.3 FcyRI cross-linking stimulates p85-dependent and -independent PI3- 
kinase activities
To investigate  w hether the PI3-kinase activity detected  upon  FcyRI 
stimulation was due to the activation of a p85 dependent PI3-kinase, the type 
usually associated w ith tyrosine kinase activation, a U937 cell line was used 
which had been stably transfected w ith an IPTG inducible dom inant negative 
form of p85 (U937:Ap85). This dom inant negative protein lacks the binding 
site for the p i  10 catalytic subunit of PI3-kinase and so w hen over-expressed 
w ill oblate p85 m ediated PI3-kinase associations w ith  other signalling 
components (40).
First, the kinetics of PIP3 production was compared betw een the w ild type 
U937 cells and the non-induced U937:Ap85 cells. This showed that in both 
cell types the tem poral pattern  of stim ulation of PIP3 levels in the cells was 
identical. Thus, peak levels were observed at 30 seconds but values in both 
cell types remained elevated over 2 m inutes (Figure 3). However, following 
over-expression  of Ap85, the p a tte rn  of PI3-kinase stim u la tion  w as 
significantly altered (Figure 3). In U937:Ap85 cells induced to express Ap85, 
the peak level of PIP3 was delayed; significant stimulation was only detectable 
after one m inute (Figure 3). However, two minutes after receptor aggregation 
sim ilar levels of PIP3 levels were m easured for both Ap85-expressing and 
wild-type cells (Figure 3). Overall, the amount of PIP3 generated after receptor 
aggregation  w as reduced  and this reduced level of PI3-kinase w as 
com m ensurate w ith the loss of the early, rapid peak of PI3-kinase activity 
observed in p85-functional cells.
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Figure 5.3 Expression of a dominant negative form of p85, Ap85, abolishes 
only the early peak of PIP3 observed after FcyRI aggregation.
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The time course of FcyRI stim ulated PIP3 concentrations were m easured in 
cells induced to express the dom inant negative form of p85 (Ap85 + IPTG XL) 
and compared to the same transformed cells not induced to express (Ap85 (no 
induced) XL) and wild type U937 cells (U937 XL). The data shown are the 
m ean ±  the standard  deviation of triplicate m easurem ents for each time 
point and are derived from three separate experiments.
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The correct functioning of the dom inant negative Ap85 protein was shown in 
two ways. First, over-expression of the truncated Ap85 was verified by 
W estern blot analysis which showed the truncated form of p85 only following 
induction w ith IPTG (Figure 4A). The functional dom inant negative role for 
this truncated p85 was verified by assaying PI3-kinase activity following 
stim ulation of the cells by insulin or ATP. In keeping w ith  the know n 
requirem ent of insulin for p85 to couple to PI3-kinase, induction of the 
dom inant negative Ap85 in these cells completely abolished the expected rise 
in PIP3 after insulin treatm ent (Figure 4B). In contrast, the response to ATP 
was entirely unaffected by the presence of the truncated p85 (Figure 4C). This 
finding is consistent w ith the fact that insulin exclusively stim ulates p85 
m ediated PI3-kinase in response to tyrosine phosphorylation events whereas 
ATP exclusively stim ulates pllO y, the G-protein py stim ula ted  (p85- 
independent) PI3 -kinase isoform. The data also clearly supports previous 
observations on the exclusive coupling of these two types of receptors to 
distinct PI3-kinase isoforms.
Taken together, these results suggest that FcyRI aggregation stimulates both a 
p85-dependent PI3-kinase and a p85-independent PI3-kinase. The tem poral 
relationship of the response in the Ap85 cells suggests that the p85-dependent 
activity is responsible for the rapid and transient peak of PI3-kinase activity 
and the p85-independent activity is responsible for the delayed activity 
observed two m inutes after cross-linking.
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Legend for figure 5.4
A. W estern blot analysis of cells induced to overexpress Ap85 com pared to 
non-induced cells. Whole cell extracts were run in a 10 % SDS-polyacrylamide 
gel, proteins were then transferred to nitrocellulose and blotted with an anti- 
p85 polyclonal antibody as described in M aterials and M ethods. Lanes 
correspond to: 1. IFN-y prim ed U937 cells; 2. IFN-y prim ed U937:Ap85 cells 
non-induced for the expression of Ap85; 3. IFN-y prim ed U937:Ap85 cells 
induced to over-express Ap85; - Lanes 4 and 5. Loading of twice am ount of 
pro tein  com pared to lanes 1-3 (lane 4. IFN-y prim ed U937 cells; 5. IFN-y 
prim ed U937:Ap85 cells non-induced for the expression of Ap85); Lanes 6 and 
7. Loading of four times am ount of protein compared to lanes 1-3 (lane 6 . 
IFN-g prim ed U937 cells; 7. IFN-y prim ed U937:Ap85 cells non-induced for the 
expression of Ap85).
Bands corresponding to wild-type constitutive p85 and Ap85 are indicated.
B. PI3-kinase coupled to tyrosine kinase activation was inhibited in cells 
expressing the dom inant negative, Ap85.
Production of PIP3 in induced (Ap85 + IPTG + Ins), uninduced cells (Ap85 (no 
induced) Ins) and wild type cells (U937 Ins) following treatm ent w ith insulin 
(10 pg /m l). The data show n are the m ean ±  the standard  deviation of 
triplicate m easurem ents for each time point and are derived from four 
separate experiments.
C. A ctivation of G pro tein  coupled PI3-kinase was unaffected by the 
expression of the dom inant negative p85.
Production of PIP3 in induced (Ap85 + IPTG + ATP), uninduced cells (Ap85 
(no induced) ATP) and wild type cells (U937 ATP) following treatm ent w ith 
ATP (10 pM). The data shown are the m ean + the standard  deviation of 
triplicate m easurem ents for each time point and are derived from four 
separate experiments.
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Figure 5.4 Verification that Ap85 is expressed and functionally active.
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5.4.4 FcyRI cross-linking activates pllOy, a G-protein (3y subunit dependent 
PI3-kinase
Since it appeared that aggregation of FcyRI stim ulated both p85-dependent 
and -independen t activities, we next investigated w hether the p85- 
independent activity could be due to the stim ulation of the G-protein py 
subun it dependent PI3-kinase, pllOy. This enzyme has previously been 
purified and cloned from U937 cells (27, 28) and pig neutrophils (29, 30). To do 
this anti-sense oligonucleotides were designed com plem entary to the N -  
term inal encoding region of pllO y mRNA to knock out the expression of this 
enzyme. Two oligonucleotides were designed; a 30-mer w hich included a 
phosphoth iorate  group at each linkage, and a 24-mer w hich only had  
p h ospho th io ra te  links at e ither end. Both of these o ligonucleotides 
significantly inhibited ATP stim ulated PI3-kinase activity in U937 cells, an 
activity known to be attributed to pllO y (Figure 5A; 43, 27). In cells loaded 
w ith the short oligonucleotide, peak ATP stimulated PI3 kinase activity was 
reduced to 52 ±  6 % of control whereas, in cells loaded with the 30-mer, peak 
kinase activity was reduced to 25 ±  2  % of control. Consistent w ith this 
observation, the level of pllO y was reduced by equivalent am ounts in cells 
p re trea ted  w ith  the antisense oligonucleotides (cells treated  w ith  short 
oligonucleotide 57 % of control; cells treated with 30-mer 28 % of control). In 
contrast, a control oligonucleotide of random  DNA sequence had no effect on 
ATP stim ulated PI3-kinase activity (Figure 5A). The longer of the two pllO y 
antisense oligonucleotides was found to be the slightly more effective of the 
two oligonucleotides, probably due to it being more resistant to nuclease 
attack. N either oligonucleotide influenced the rise in PIP3 observed after 
insulin  stim ulation (Figure 5B) findings consistent w ith the fact that the 
insulin receptor couples exclusively to the p85-dependent PI3-kinase.
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T rea tm en t of the IFN-y p rim ed  U937cells w ith  p llO y  an ti-sen se  
oligonucleotides altered the pattern  of PI3-kinase stim ulated activity after 
FcyRI aggregation (Figure 5C). The initial rapid increase in PIP3 levels 
p rev iously  observed 30 seconds after receptor aggregation  rem ained  
unaltered. However, in m arked contrast to control oligonucleotide treated 
and un trea ted  cells, PIP3 levels had returned to basal levels w ithin one 
minute; kinetics reminiscent of the exclusive coupling of the insulin receptor 
to the p85 system. Indeed, these results essentially are the inverse of those 
obtained w ith the Ap85 expressing cells where the initial peak of activation 
was lost but stimulation remained elevated after one m inute (Figure 3).
Taken together these results indicate that FcgRI cross-linking results in initial 
activation of a p85-dependent PI3-kinase which lasts less than one m inute, 
and this is followed by the stimulation of a G-protein bg subunit dependent 
PI3-kinase (pllOg). This latter activity was found to be insensitive to pertussis 
toxin (Figure 5D) and so was unlikely to have been activated by G-proteins of 
the Gi type.
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Legend for figure 5.5
A. Treatm ent of cells w ith either antisense oligonucleotide to pllO y (ATP 
short and ATP long) significantly reduced PIP3 following stim ulation w ith 
ATP (lOOfiM) (control ATP). A control jumbled oligonucleotide had no effect 
on ATP stim ulated PIP3 levels (ATP oligo control). The data shown are the 
m ean +. the standard  deviation of triplicate m easurem ents for each time 
point and are derived from three separate experiments.
B. Treatm ent of cells w ith either antisense oligonucleotide to pllO y (Ins 
short and Ins long) had no influence on the PIP3 concentrations achieved 
after stim ulaton w ith insulin (10 pg/m l). A control jumbled oligonucleotide 
had no effect on insulin stim ulated PIP3 levels (Ins oligo control). The data 
shown are the mean ±  the standard deviation of triplicate m easurem ents for 
each time point and are derived from three separate experiments.
C  The initial peak in PIP3 observed 30 secs following FcyRI aggregation was 
unaffected in cells treated w ith the pllO y antisense oligonucleotides. The 
delayed sustained rise in PIP3 observed 2 mins after FcyRI aggregation (XL) 
was abolished by treating cells w ith this antisense oligonucleotide (XL short 
and XL long). The control jum bled oligonucleotide had no effect on any 
aspect of PIP3 levels after FcyRI aggregation (XL oligo cont). The data shown 
are the m ean ±  the standard  deviation of triplicate m easurem ents for each 
time point and are derived from three separate experiments.
D. Treatment of cells w ith pertussus toxin (XL FT) had no influence on PIP3 
concentrations observed after FcyRI aggregation (XL). The data shown are the 
m ean ±_ the standard  deviation of triplicate m easurem ents for each time 
point and are derived from three separate experiments.
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Figure 5.5 Treatment of cells with an antisense oligonucleotide to pllOy 
selectively abolishes ATP stimulated PI3-kinase and inhibits the delayed PI3- 
kinase activity after FcyRI aggregation.
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5.5 DISCUSSION
We show for the first time, in this paper, that ligation of a single receptor can 
induce coupling to two distinct classes of PI-3Kinase: levels of PIP3 rise very 
rapidly after aggregation of FcyRI in IFN-y primed U937 cells due to the rapid 
and transien t activation of a p85-dependent PI3-kinase. In contrast, the 
sustained elevation of PIP3 observed following receptor aggregation appears to 
result from a delayed, longer lasting, but ultimately smaller p85-independent 
PI3-kinase activity. This latter activity was shown to be due to the activation of 
p llO y, a G-protein py subunit-sensitive form of PI3-kinase (29, 28). This is the 
first demonstration of a single receptor stimulating both tyrosine kinase and G- 
protein regulated PI3-kinases.
Activation of PI3-kinase appears necessary to m ediate some of the effector 
functions for Fc receptors. Thus, inhibition of PI3-kinase w ith w ortm annin 
inhibits antibody-dependent phagocytosis in U937 cells and COS cells (44, 45). It 
is interesting to note that although w ortm annin inhibits Fc receptor m ediated 
phagocytosis in U937 cells, it will not block endocytosis of immune complexes 
in these cells (data not shown). Previous studies have show n that PI3-kinase 
activ ity  is increased  in im m unoprecip ita tes using  anti-p85 and anti- 
phosphotyrosine antibodies in U937 cells following aggregation of FcyRI and 
FcyRII. This activation seemed to be secondary to tyrosine phosphorylation. 
Consistent w ith this, the data presented in this paper showed that the tyrosine 
kinase inhibitor, genistein, was able to block completely PI3-kinase activation 
(Figure 2). Sim ilarly inhibition of tyrosine kinases w ith  genistein  has 
previously been shown to inhibit FcyRI-mediated phagocytosis in transiently 
transfected COS cells, but not FcyRI-mediated endocytosis in the same cells and 
in U937 cells (41, 46). Taken together, these results are consistent and suggest 
that PI3-kinase activation as a result of tyrosine phosphorylation events is
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essential for FcyRI-mediated phagocytosis, bu t that endocytosis of im m une 
complexes by FcyRI is independent of these signalling events.
The question relating to how FcyRI couples to both a p85-dependent and a G- 
protein subunit sensitive PI3-kinase remains to be answered. FcyRI contains no 
known signalling motif but has to recruit an accessory signalling molecule. In 
IFN-y treated U937 cells, FcyRI recruits the y chain which contains a cytoplasmic 
im m unoreceptor tyrosine activation m otif (ITAM) (8 , 9). It therefore seems 
likely that the p85-dependent PI3-kinase activity is a result of a direct 
interaction betw een the SH2 dom ain of p85 and the IT AM of the y chain, 
probably after tyrosine phosphorylation of the IT AM by a Src-type kinase or Syk 
(For review see 47). Indeed, the p85 regulatory subunit of PI3-kinase has been 
shown to bind with phosphopep tides of the y chain IT AMs (48) but there is also 
evidence to suggest that p85 can directly interact with phosphorylated Syk via a 
YxxM motif on the Syk protein. It has been proposed for FceRI signalling that 
Lyn becomes activated upon receptor clustering and tyrosine phophorylates the 
IT AMs of the y chain, in itiating the recruitm ent of Syk through its SF32 
dom ain. Phosphorylated Syk can then activate other dow nstream  signalling 
molecules including PI3-kinase (49). Recent studies have show n that Lyn is 
associated w ith both FcyRI and the y chain independently of receptor cross- 
linking and that the level of the phosphorylation of this Src-type kinase 
increases upon receptor cross-linking (42). These studies also showed that Syk 
associates w ith the y chain following FcyRI aggregation and the resultan t 
phosphorylation of the g chain. The p85 regulatory subunit of PI3-kinase has 
been shown to bind with phosphopeptides of the y chain IT AMs (48). Therefore 
it is probable that the p85-dependent PI3-kinase activity is recruited as a result 
of FcyRI recruiting the y chain and subsequent tyrosine kinases, notably Lyn and 
Syk.
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H ow FcyRI m ight recruit a heterotrim eric G-protein is less clear. The results 
presented here show that all PI3-kinase activity stim ulated following FcyRI 
aggregation was abolished by pre-treating cells w ith genistein (Figure 2). This 
suggests that the activation of pllOy also occurs downstream of the activation of 
tyrosine kinases. It is possible that mem bers of the Tec family of tyrosine 
kinases, for example Tec, Itk or Btk, could play a role in the activation of pllO y 
via a heterotrimeric G-protein since this family of enzymes all contain SH2 and 
PH domains. It is feasible that the SH2 dom ain of a Tec-type tyrosine kinase 
could associate w ith the y chain (or a tyrosine phosphorylated protein such as 
Syk) and recruit a heterotrim eric G-protein whilst at the plasm a m em brane. 
This G-protein could then activate pllOy via its |3y subunits.
In conclusion we have shown in the present paper that two distinct PI3-kinase 
isoforms are activated following FcgRI aggregation in IFN-y prim ed U937 cells; 
both p85-regulated and G-protein py subunit-sensitive PI3-kinase isoforms are 
activated. This is the first evidence to suggest that receptors such as FcyRI, 
w hich do not have an intrinsic signalling motif, can recruit both  tyrosine 
kinase and G -protein-coupled in tracellular signalling m olecules to initiate 
distinct cellular responses. It has yet to be elucidated as to how FcyRI is able to 
recruit these different regulatory molecules and w hether there are distinct 
physiological roles for the two PI3-kinases and their products.
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CHAPTER 6
GENERAL DISCUSSION
6.1 FcyRs ARE IMPORTANT SIGNAL GENERATING MOLECULES
FcyRs act as trigger molecules for inflam m atory, cytolytic, endocytic and 
phagocytic activities of immune effector cells.
There are some common features in the signalling pathw ays initiated by Fc 
receptor aggregation. These common characteristics include the tyrosine 
phosphorylation of proteins (Scholl et al 1992, Liao et al 1992, Rankin et al 
1993, Lin et al 1994), followed by rise in intracellular calcium levels (Rankin et 
al 1993). In the case of FcyRI, it has been show n that im m une-com plex 
aggregation of this receptor give rise tyrosine phosphorylation of proteins 
(including PLCyl) (Liao et al 1992), and rise in intracellular calcium levels 
(Rankin et al 1993). How ever, the signalling events that occur betw een 
pro tein  tyrosine phosphorylation and the rise in intracellular calcium is 
poorly understood. This lack of knowledge is due, at least partly, to the fact 
that the signalling pathw ays derived from monocytes and m acrophages 
harvested under different condition are very heterogeneous in nature. In 
order to overcome this problem we have used the hum an monocytic cell line 
U937 (Harris & Ralph 1985). This cell line allows controlled differentiation 
w ith dbcAMP from monocyte phenotype to a more m acrophage phenotype 
(Sheth et al 1988). Hence, they are widely used as a model to study, and better 
u n d ers tan d , the cellular events that m ay be happen ing  w hen blood 
monocytes differentiate into tissue macrophages.
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6.2 DIFFERENTIAL SIGNALLING PATHWAYS INITIATED BY Fey 
RECEPTORS
6,2.1 Novel pathway in IFN-y primed cells
As PLCyl has been show n to be tyrosine phosphorylated following Fey 
receptor aggregation (Liao et al 1992), activation of PLC was m easured in U937 
cells fo llow ing form ation  of surface im m une com plexes. In cells 
differentiated w ith dbcAMP to a more macrophage phenotype, a prom pt and 
transient rise in InsPg was observed after imm une complex aggregation of 
FcyR. However in cells prim ed with interferon-y, no increase in InsPg could 
be detected. Since InsPg is transient by nature, it was possible that the InsPg 
peak had  been missed as a result of sam pling time. Lithium chloride was 
therefore used to assay total InsP accumulation over time. Lithium chloride 
prevents breakdow n of InsP and can be a valuable tool in situations as here 
w here there is concern that InsPg production is transient (Plevin et al 1991, 
Briscoe et al 1994). However, no accumulation of InsP could be detected in 
IFN-y prim ed cells. This data suggests that PLC is not activated by imm une 
complexes in these cells. This finding raises two issues. First, it is at variance 
with the reported tyrosine phosphorylation of PLCyl. Second, it implies that 
the calcium  transien ts observed in the cells arise th rough  an InsPg 
independent route.
Tyrosine phosphorylation is w idely accepted as a m arker of activation. 
However, there are a num ber of examples where proteins are phosphorylated 
bu t no increase in activity can be observed. A classical example is PLCy. It has 
been  show n that phosphory lation  of Tyr-783 in PLCy is essential for 
stim ulation of enzymatic activity in NHI-3T3 cells stim ulated w ith PDGF 
(Kim et al 1991). Yet in m any cases, the tyrosine phosphorylation of PLCy
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does not correlate w ith enzymatic activity; certain extracellular signals lead to 
weak tyrosine phosphorylation of PLCy and strong production of InsPg, while 
other signals cause strong tyrosine phosphorylation of PLCy but only very 
low levels of InsPg are p roduced  (Ree & Bae 1997). Thus, tyrosine 
phosphory la tion  per se cannot solely be used as a m easure of enzym atic 
activation.
Cytosolic calcium concentration rise from two m echanism s; release of 
calcium from intracellular stores and entry of calcium from outside the cell. 
In IFN-y prim ed cells, the rise in cytosolic calcium observed after formation of 
surface im m une complexes, is transient in nature, typically lasting 1 -2  
m inutes. Studies using manganese quench of Fur a 2 or extracellular EGTA to 
chelate calcium in these IFN-y prim ed cells have indicated that calcium entry 
con tribu tes very  little  to the overall changes in cytosolic calcium  
concentrations. In im m une cells, InsPg is considered the major second 
messenger involved in release of calcium from stores (Liao et al 1992, Rankin 
et al 1993). InsPg binds to the InsPg receptor and initiates calcium release 
(Irvine 1990, 1991). However, the data presented in this thesis implies that in 
these cytokine prim ed U937 cells, calcium release from intracellular stores is 
m ediated through an alternative mechanism. Work perform ed as part of this 
thesis has identified a novel pathw ay capable of calcium release through an 
InsPg independent route.
In The absence of a measurable increase of InsP in IFN-y prim ed U937 cells, an 
alternative activation pathw ay needed to be defined. Our first clue resulted 
from m easurem ent of DAG. An equivalent increase in DAG was observed in 
both IFN-y prim ed cells and in dbcAMP differentiated cells. At first sight, this 
was surprising as no PLC activation was detected in IFN-y treated cells and
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DAG is generally considered the p roduct of PLCyl hydrolysis of PIP2 
(Cockcroft & Thomas 1992, Lee & Rhee 1995). However, DAG can also arise 
following the activation of PLD, which produces phosphatidic acid. This is 
subsequently hydrolysed by the action of phosphatidic acid phosphohydrolase 
to produce DAG (Exton 1994, Liscovitch & Cantley 1995, Hueng & Postle 1995). 
A lthough the stereoisoform of the two species of DAG differs (Pettitt et al 
1997, H odgkin et al 1998), the assay used cannot distinguish betw een them. 
The fact that the DAG arose as a result of PLD activation was confirmed by the 
use of butan-l-ol. As mentioned above, PLD generation of DAG is a two step 
reaction; first PLD breaks down phosphatidyl choline to generate phosphatidic 
acid and choline, then via the action of phosphatidyl-phosphohydrolase 
(PPH) phosphatidic acid is converted to DAG. In this reaction water acts a 
donor to the enzyme. However, prim ary short chain alcohols are m uch 
better donors than water, and, in the presence of such an alcohol, PLD will 
produce a phosphatidyl-alcohol, which is metabolised m uch more slowly 
than phosphatidic acid, and no DAG is produced (Hueng & Postle 1995, Pettitt 
et al 1997, Hodgkin et al 1998).
Phosphatidic acid is the imm ediate product of PLD activation and there is 
increasing evidence that this molecule may act as a second messenger. The 
m ost convincing evidence that phosphatid ic acid has second m essenger 
functions comes from the dem onstration that PLD activation is an essential 
step in the stim ulation of actin stress-fibre assembly, following activation of 
LPA receptors in PAE cells (Cross et al 1996). No other phospholipase is 
know n to be activated in this situation. Furthermore, w hen bu tan-l-o l is 
present (causing generation of phosphatidy 1-butanol rather than phosphatidic 
acid), LPA -stim ulated phosphatid ic  acid accum ulation and stress-fibre
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form ation are both inhibited. Exogenous phosphatidic acid induces stress- 
fibre formation even in alcohol-treated cells (Cross et al 1996).
The DAG product of PLD-PPH activity is a different stereoisoform to that of 
PLCyl. There is considerably debate as to whether this DAG species is able to 
activate conventional isoforms of protein kinase C (Pettitt et al 1997, H odgkin 
et al 1998). W hen m easured by an assay that measures overall PKC activity, 
DAG derived from PLD did not seem to influence PKC activity in IIC9 
fibroblasts. However, it was later suggested that this DAG is able to stimulate 
the atypical PKCg (Leach et al 1991, Ha & Exton 1993). H ow ever, this 
conclusion is questionable since both PLD and PLC could have been activated 
in these cells. In LPA-stim ulated PAE cells, in w hich PLD is the only 
phospholipase known to be activated and only PLD-derived DAG is formed, 
LPA ne ither stim u la ted  to tal PKC activity nor enhanced  m em brane 
translocation of any PKC isoform. At least in PAE cells, PLD-derived DAG 
does not seem to activate PKC (Pettitt et al 1997).
Sphingosine kinase (SK) was activated follow ing form ation of surface 
im m une complexes in IFN-y treated U937 cells. This sphingosine kinase 
activation was definitely dem onstrated to be downstream  of PLD activation. 
This finding correlates w ith in vitro studies where sphingosine kinase has 
been show n to be activated by phosphatid ic  acid (Olivera et al 1996). 
Sphingosine kinase yields sphingosine-l-phosphate as its product and assay of 
IFN-y prim ed U937 cells detected this product after receptor aggregation. The 
role of sphingosine-l-phosphate (S-l-P) in causing calcium release from stores 
is controversial (Ghosh et al 1990, Mattie et al 1994, Wu et al 1995, Postma et al 
1996). A num ber of reports have show n calcium transients w hen S-l-P is 
applied to cells. However, S-l-P receptors are found in the plasma membrane
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(Wu et al 1995, Postma et al 1996, Lee et al 1998). These are classical G protein 
coupled receptors and are able to activate PLC thereby possibly releasing 
calcium through the InsPg receptor. However, a direct role for sphingosine 
products has been strengthened by the recent cloning of the SCaMPER 
receptor (Mao et al 1996). The w ork described in this thesis p rov ides 
additional support for this novel mechanism of calcium release. Treatm ent 
of cells w ith bu tan-l-o ld  to block the product of PLD activity, or DHS to 
inh ib it sphingosine kinase resu lted  in dim inished or oblated calcium  
transients in response to receptor activation.
Activation of PLD and SK was dependent on tyrosine kinase activation as 
genistein, an inhibitor of tyrosine kinases, blocked PLD and SK activation in a 
concentration dependent m anner. There are three forms of PLD which differ 
in their activation mechanisms. Two of these have been cloned (Hamm ond 
et al 1997, Kotaki & Yamashita 1997, Colley et aï 1997). It is unclear from the 
w ork presented here which form of PLD is activated in this pathw ay although 
w ork is continuing to investigate this. However, PI3-kinase activation was 
dem onstrated in IFN-y prim ed cells and this activation was tyrosine kinase 
dependent. Subsequent studies using  w ortm annin  and LY290043 have 
show n that PI3-kinase lies upstream  of PLD activation. W ortm annin is 
know n to act on other enzym es at high concentrations (Bonser et al 1991, 
Cross et al 1995). Indeed, w ortm annin (lOOmM) is capable of inhibiting PLD 
activ ity  d irectly  (Bonser et al 1991). H ow ever, the concentration  of 
w ortm ann in  (50nM) used to determ inate the relationship of PI3-kinase 
activation to PLD activation was below this threshold and was dem onstrated 
to have no direct effect on PLD activity following stim ulation by phorbol 
esters.
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M easurem ent of PI3-kinase activity in IFN-y prim ed cells revealed a very 
unusual profile; activation was very prolonged, lasting for at least 15 m inutes 
after imm une complex aggregation of FcyRI. Two isoforms of the Class I PI3- 
kinase exist and have been defined in U937 cells (Hiles et al 1992, H u et al 
1993, Vanhaesebroeck et al 1997). One is activated by tyrosine kinases through 
the binding of the adaptor protein p85 to phosphorylated SH2 domains. The 
other is activated by Py subunits of heterotrimeric G proteins (Stoyanov et al 
1995, Stephens et al 1997). Insulin, which acts through tyrosine kinases, and 
ATP, w hich acts th rough  a seven transm em brane dom ain receptor, are 
classically used to define these two enzymes. In this study, both the tyrosine 
kinase dependent form of PI3-kinase and the Py dependent form of PI3-kinase 
were found to be activated by Fey receptor aggregation in IFN-y prim ed U937 
cells. The initial peak was p85 dependent whereas the delayed rise was 
dependent on the Py activated form of the enzym e. The m echanism s 
underlying this dual activation remains to be resolved, but may well relate to 
the unusual second m essengers generated in these cells. The findings 
reported here for IFN-y prim ed cells contrast with prelim inary studies in 
dbcAMP differentiated cells where PLCyl activation is solely dependent on 
the p85 (tyrosine kinase) dependent form of PI3-kinase. Direct m easurem ent 
of PI3-kinase has shown that all the PI3-kinase activation can be explained as 
the p85, tyrosine kinase dependent form. In these cells, no py activation form 
of PI3-kinase could be detected.
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6.3 DIFFERENTIATION DEPENDENT SWITCH IN SIGNALLING  
PATHWAYS BY FcyRI
The w ork presen ted  in this thesis has show n that im m une complexes 
activate distinct pathw ays depending on the differentiation status of U937 
calls. Thus, in dbcAMP differentiated cells, immune complexes activate PLC 
whereas in IFN-y prim ed cells a novel pathw ay is activated that induces the 
sequential activation of PI3-kinase, PLD and sphingosine kinase. These two 
pathw ays result in differing calcium transients. In dbcAMP differentiated 
cells, calcium oscillations are generated and cell population studies indicate 
that calcium store release is followed by stimulation of calcium entry (Davis, 
Sage & Allen) through the activation of Icrac (Floto, Mahaut-Smith, Allen & 
Som asundram). In IFN-y prim ed cells, a single spike in calcium is observed 
and store dum ping is not associated with significant entry of calcium.
A differentiation dependent induction or suppression of the two pathw ays 
was unlikely as both pathw ays were demonstrated to be present in both cell 
types. Thus, PLC could be activated, using a different receptor, in IFN-y 
prim ed cells and PLD activity could be measured, following stimulation w ith 
phorbol esters, in dbcAMP differentiated cells. An alternative explanation for 
the differentiation dependent switch in signalling pathw ays was therefore 
needed. The work presented in this thesis demonstrated that in IFN-y prim ed 
cells, FcyRI recruits the y chain for signal transduction whereas in dbcAMP 
d iffe ren tia ted  cells, FcyRI recru its FcyRIIa for signal tran sd u c tio n . 
F u rtherm ore , the y chain appears to be coupled to the novel signal 
transduction pathw ay whereas FcyRIIa is coupled to PLC activation.
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Tyrosine kinase activation is the initial event in both pathways. To activate 
tyrosine kinases; receptors either possess intrinsic kinase activity (e.g. NGFR, 
EGFR etc.) or a dom ain (in their cytosolic region) capable of recruiting 
cytosolic kinases. In cells of the immune system such domain is called IT AM 
(Im m une-receptor Tyrosine A ctivatory Motif) ( Reth 1989, Sam uelson & 
K lausner 1992, Gambler 1995). The tyrosine residues of the IT AM are 
phosphorylated by Src-like kinases and these then act as high affinity sites for 
Syk kinase. Both the y chain and FcyRIIa possess IT AMs although they differ 
substantially (Gambler 1995). In particular, the IT AM of FcyRIIa is unusually 
long as the intervening sequence betw een the tyrosine residues is 14 amino 
acids and not the typical 10 amino acids. It seems likely that the nature of the 
IT AM dictates the nature of the Src-like tyrosine kinase activated and that this 
in tu rn  determ ine the signalling pathw ay initiated by im m une complexes. 
The ability of FcyRI to switch signalling pathways reflects the fact that this 
receptor does not itself contain an IT AM in its cytoplasmic tail, bu t m ust 
recruit an accessory molecule for signal transduction. Thus, the ligand 
recognition dom ain and effector dom ain of the receptor complex are on 
separate polypeptide chains. This then allows the receptor to recruit alternate 
accessory molecules. Here, we have shown that this occurs for FcyRI and that 
the accessory molecule dictates the signalling cascade initiated by FcyRI. This 
has profound implications. First, it provides an explanation for the well- 
know n heterogeneity of the response of monocytes and m acrophages to 
imm une complexes. Second, many receptors of the immune system display a 
similar organisation as the ligand recognition domain and effector dom ain lie 
on different polypeptide chains. It thus seems likely that other receptors may 
also employ a similar switch in signal transduction.
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6.3.1 Consequences of the switch
The switch in signal activation pathw ay together w ith the associated change 
in calcium transients is likely to have profound effects on the nature of cell 
activation. In this thesis, the nature of the PKC isoforms activated by 
im m une complexes was found to differ between the two cell types. Thus, in 
dbcAMP differentiated cells where calcium signals are prolonged, the calcium 
dependent PKC isoforms (a,p,y) are activated. In IFN-y prim ed cells, where 
the calcium response is transient, the atypical isoforms (ô,£) and the novel (Q 
are activated. PKC activation  is necessary to m ediate phagocytosis 
(Zhelesnyak & Brown 1992, Zheng et al 1995, Karimi et al 1995). The results 
presented here provide an explanation for the finding that FcyRIIa m ediated 
phagocytosis is calcium dependent whereas FcyRI m ediated phagocytosis is 
calcium independent (Edberg et al 1995, Waite 1997).
Mechanisms of PKC activation in IFN-y prim ed cells. If the stereoisoform of 
the DAG produced  th rough  PLD activation is inactive, then w hat is 
stim ulating PKCs ?. Potential activators in this system could be phosphatidic 
acid, the prim ary product of PLD activity, which has been implicated in the 
activation of some of the PKC isoforms (Ohgushi et al 1997). A nother 
potential candidate is PIP3 , the product of the Class I PI3-kinases, which has 
been show n to activate several iso forms of PKC (Toker et al 1993, Toker & 
Cantley 1997), the best example being the activation of PKC Ç (Nakanishi et al 
1994, Standaert et al 1997).
Calcium transients are know n to influence the transcription factors, NFAT 
and NFkB (Crabtree & Clipstone 1994, Rao 1994, Baeurle & Henkel 1994, 
D olm etsch et al 1997). Recent reports have shown that the frequency of
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calcium oscillations influences transcription factor activation (Li et al 1998, 
Dolm etsch et al 1998). The switch in signal transduction pathw ays w ith the 
consequen t sw itch in  calcium  transien ts  therefore  likely influences 
transcription factor recruitm ent and activation.
The w ork described in this thesis provides a possible m echanism  to explain 
the differential activation of these two transcription factors. One signalling 
pathw ay (PLC) is linked to the generation of calcium oscillations whereas the 
other signalling pathw ay is linked to a single spike in calcium transients. The 
same receptor is capable of initiating the different calcium transients as it able 
to switch intracellular signalling pathw ays that dictate the calcium transients. 
The switch in signalling pathw ays is itself determ ined by the nature of the 
accessory molecule recruited by FcyRI.
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